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AITC - allyl isothiocyanate 
AMI - amitriptyline 
ARD - ankyrin repeat domain 
BCA - bicinchonic acid 
CaM - calmodulin 
CaMKII - Ca2+ calmodulin-dependent 
kinase II 
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CapZ - capsazepine 
CGRP - calcitonin gene related peptide 
CNS - central nervous system 
DMEM - Dulbecco’s Modified Eagle 
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EC100 - maximum effective concentration 
EC50 - half maximal effective 
concentration 
Emax - maximal response of efficacy 
HEPES - 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
I-RTX - iodoresiniferatoxin 
M2+ - divalent metal cation 
NADA - N-arachidonoyl dopamine 
NGF - nerve growth factor 
PBMC - peripheral blood mononuclear cell 
PIP2 - phosphatidylinositol-4,5-
bisphosphate  
PKA - protein kinase A 
PKC - protein kinase C 
PNS - peripheral nervous system 
RTX - resiniferatoxin 
RuRed - ruthenium red 
R4W2 - hexapeptide RRRRWW-NH2 
S.D. - standard deviation(s) 
TG - trigeminal ganglion 
TGs - trigeminal ganglia 
TM - transmembrane / transmembrane 
segment 
TRPV1 - transient receptor potential 
vanilloid 1 
VGCC - voltage-gated calcium channel 
12-HPETE - 12-hydroperoxy-
eicosatetraenoic acid 
2-APB - 2-aminoethoxydiphenyl borate 
 
Introduction and literature survey 
1 
1. Introduction 
 
The goal of pharmaceutical research is to find solutions for intervention into disease- or 
pain-causing processes through the specific and effective manipulation of the target. 
Throughout history, mankind has strived to find ways to cure diseases or relieve pain. From 
chewing on willow bark to modern pharmaceuticals, the history of painkillers is long and 
filled with many technological advances. The development of small-molecule therapeutic 
agents for the treatment and prevention of diseases has also played a critical role in the 
practice of medicine for many years. Over the past half-century, a progression of drug 
discovery has been observed. Still, there were many diseases for which there were no 
effective therapeutic interventions. Thanks to the rapid advancements, synthetic organic 
chemistry offered the promise that, if a drug could be envisioned, it could be made. The rapid 
development of biology, providing more detailed information at the molecular level, had the 
possibility to catch up with synthetic chemistry. 
Developing the therapeutic agents of the future will clearly involve the same basic science 
disciplines that have always been at the core of drug discovery: structural biology to provide 
information about the target biomacromolecules; chemistry to design and synthesize the drug 
candidates; and pharmacology to determine the effects of the interaction between drug and 
target. 
The discovery of novel opportunities for therapeutic interventions requires a better 
understanding of the target, in our case, the structure-function relationship of the TRPV1 ion 
channel. 
 
2. Literature survey 
2. 1. Transient receptor potential channels 
 
The first TRP channel was discovered in 1969 by Cosens and Manning, who isolated a 
mutant photoreceptor from Drosophila melanogaster which caused the specimen to become 
temporally blind upon exposure to bright light [4, 5]. TRP channels are one of the largest 
families of ion channels. The mammalian TRP superfamily, consisting of 28 TRP cation 
channels, can be subdivided into six subfamilies: the TRPC (“Canonical”), TRPV 
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(“Vanilloid”), TRPM (“Melastatin”), TRPP (“Polycystin”), TRPML (“MucoLipin”) and 
TRPA (“Ankyrin”) groups [6, 7] (Figure 1). All TRP channels are tetramers assembled with 
fourfold symmetry from the individual subunits containing six putative transmembrane 
segments (TMs). The 
region between the fifth 
and the sixth TMs, 
including a putative pore 
loop, forms the ion 
permeation pathway [8]. 
The amino and carboxyl 
(N- and C-) termini are 
located intracellularly 
and vary vastly in length 
and amino acid sequence. 
These cytoplasmic regions 
contain diverse well-
recognized domains and 
motifs that are likely to 
be involved in channel 
assembly, activation and regulation through protein-protein and/or protein-ligand interactions. 
Most TRP channels are cation-selective, and some are highly selective for Ca2+ or Mg2+ [7]. 
In accordance with their amino acid sequence diversity, TRP channels exhibit various 
activation and modulatory mechanisms, such as those involved in stimulation by G-protein-
coupled receptors, extracellular and intracellular ligands (including H+, Ca2+ and Mg2+), 
phosphatidylinositol-4,5-bisphosphate (PIP2), temperature and mechanical stretch [9]. 
The accumulating evidence demonstrating that TRP channels are important components 
of several human diseases has created huge interest for these channels as novel potential drug 
targets. Comprehensive reviews have been published on the modulation and potential 
pharmaceutical application of TRP channels [2, 10-13]. 
 
Figure 1: Mammalian TRP family tree 
The evolutionary distance is shown by the total branch lengths in point 
accepted mutations (PAM) units, which is the mean number of substitutions per 
100 residues [1]. 
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2. 2. TRPV subfamily 
 
The TRPV family includes six mammalian ion channels, TRPV1-TRPV6, with a large C- 
and an even larger N-terminal cytoplasmatic domain containing ankyrin repeat domains 
(ARD) [14, 15]. Ankyrin repeats, the 33-residue sequence motifs, are essential in channel 
function, ATP, PIP2 and calmodulin (CaM) binding [16] and protein-protein interactions  
[17, 18]. They are present in many proteins, with functions including signalling, cytoskeleton 
integrity, transcription and cellular localization [19, 20]. 
As polymodal thermo- and chemosensitive channels, TRPV1-TRPV4 are non-selective 
for cations and modestly permeable to Ca2+. In contrast, TRPV5 and TRPV6 are the only 
highly Ca2+-selective channels in the TRP family, and both channels are tightly regulated by 
the intracellular Ca2+ concentration [12, 21, 22]. 
TRPV channels can be activated through a variety of mechanisms. TRPV1-TRPV4 can 
act as thermosensors at a molecular level. Interestingly, each of these channels has a different 
thermal threshold for activation. When expressed in transfected permanent cell lines 
(HEK293 and CHO cells) and in frog oocytes [7, 23, 24], TRPV2, TRPV1, TRPV3 and 
TRPV4 are activated at 52 °C , 43 °C, 33 °C and below 33 °C, respectively. The TRPV 
family members, except for TRPV1, are insensitive to vanilloid compounds [7]. TRPV3 can 
be activated by essential oils from clove (eugenol), thyme (thymol) and oregano (carvacrol) 
[25]. Like TRPV1, TRPV3 is also activated by camphor [26]. TRPV4 can be activated by cell 
swelling caused by 5',6'-epoxyeicosatrienoic acid [27]. TRPV5 and TRPV6, originally named 
ECaC [28] and CAT1 [29], are Ca2+ entry channels responsible for Ca2+ absorption in the 
kidney and intestine, respectively. 
 
2. 3. TRPV1 
 
In 1997, the breakthrough work of Michael Caterina and colleagues in the field of somatic 
sensory biology and pain research led to the cloning of the vanilloid (capsaicin) receptor, 
TRPV1 [30]. The cloning of TRPV1 proved to be a significant step in the understanding of 
the molecular mechanisms that underlie the transduction of noxious thermal and chemical 
stimuli by sensory neurons [2]. 
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2. 3. 1. Characteristics of TRPV1 
 
As a TRPV subfamily member, TRPV1 can be characterized by some key properties that 
are common among the members of the family. It is built from four individual subunits 
containing six TMs [31], and it is believed to exist as a homo- or heteromeric complex form 
[30-32]. TRPV1 has a hydrophobic stretch between TM5 and TM6 forming the pore- and an 
ion selectivity filter region (Figure 2). 
The TRPV1 receptor is a non-selective ligand-gated cation channel with a ninefold higher 
permeability for Ca2+ than for Na+. It is an integrator of a wide variety of exogenous and 
endogenous physical and chemical stimuli, including capsaicin (CAPS), noxious heat 
(>43 °C) and protons (pH<5.2). Strictly speaking, CAPS and its biological analogues isolated 
from plants and animals are essentially sensitizers, because they act by lowering the thermal 
Figure 2: Putative structure of the TRPV1 receptor 
A - Schematic structure of a TRPV1 monomer based on the figure of Szállási et al. [2]. B - Homology model 
structure of two TRPV1 monomers facing each other. C- Homology model structure of the tetrameric TRPV1, side 
view. D - Homology model structure of the tetrameric TRPV1, top view The figure is based on the PDB file of 
Fernández-Ballester and Ferrer-Montiel [3]. 
A B
C D
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“physiological” activation threshold of TRPV1. Nevertheless, because these compounds bind 
directly to TRPV1, they are conveniently considered as direct activators, in contrast with 
compounds that do not bind TRPV1 and affect its functioning indirectly, which are referred to 
as sensitizers [33]. Besides CAPS, many complex amphiphilic molecules have been shown to 
activate or inhibit TRPV1. These include polyring compounds such as resiniferatoxin (RTX). 
RTX, a highly irritant diterpene related to the phorbol esters [34], the most potent natural 
diterpene agonist of TRPV1, is present in latexes of various Euphorbia species, such as  
E. resinifera, E. poissoni and E. unispina [35]. Bioassays rank RTX as a 3-4 orders of 
magnitude more potent agonist of TRPV1 than CAPS. Species-specific differences in RTX 
potency have also been described, e.g., RTX is a more potent agonist on rTRPV1 than its 
human ortholog (hTRPV1) [36, 37]. 
Further molecules with similar structures, such as quinazolinone [38], evodiamine [39] 
and 17-β-estradiol [40], as well as molecules with long acyl and amide chains, such as 
anandamide [41-47], olvanil and omega-3 polyunsaturated fatty acids, can also activate the 
channel [48]. Other natural TRPV1 agonists are 12-hydroperoxyeicosatetraenoic acid 
(12-HPETE) and N-arachidonoyl dopamine (NADA) [44, 49-51]. Piperine from black pepper, 
eugenol from cloves and zingerone from ginger have also been shown to activate TRPV1  
[52, 53]. Additionally, gingerols, present in raw ginger, and shogaols, which are dehydration 
products of gingerols present in steamed ginger, both of which possess a vanillyl moiety, also 
activate TRPV1 [37, 47, 54, 55]. Since both CAPS and its analogues are lipophilic, they are 
able to cross the cell membrane and act on binding sites present on the intracellular surface of 
TRPV1 [56]. TRPV1 can also be activated by 2-aminoethoxydiphenyl borate (2-APB). 
2-APB inhibits both IP3 receptors and the majority of TRP channels, though at higher 
concentrations it activates TRPV1, TRPV2 and TRPV3 [13, 57]. Allicin, one of the 
constituents of garlic, is also able to activate both TRPA1 and TRPV1 [58, 59]. Stimuli are 
detected and transduced through opening of the ion channel, which results in the entry of 
cations such as Ca2+ and Na+ to the neuron [30]. With regard to its uniqueness in its diverse 
operational features, which differ from the classical, more restrained proteins of voltage-gated 
and ligand-gated channels, as well as from the G-protein-coupled receptors, TRPV1 was 
dubbed a “multisteric nocisensor” in the recent review paper by Szolcsányi and Sándor [60]. 
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The inorganic dye Ruthenium Red (RuRed), is used in histology to stain aldehyde-fixed 
mucopolysaccharides. Long before the cloning of TRPV1, RuRed was demonstrated to be 
able to inhibit CAPS-induced responses in sensory neurons [61]. Later it was shown that 
RuRed is a non-competitive antagonist not only for TRPV1, but for most other TRP channels, 
functioning as a pore blocker [33]. The first competitive antagonist identified for TRPV1 was 
the CAPS analogue capsazepine (CapZ). CapZ is a relative potent antagonist on hTRPV1, but 
demonstrated much less potency on rTRPV1 [62, 63], illustrating the differences between 
species, a feature common for many TRPV1 antagonists. Since the discovery of CapZ, the 
number of TRPV1 patents has exceeded 1,000. Most of these antagonists show high affinity 
to TRPV1 and are competitive antagonists, binding to the same site as CAPS, and many of 
them have also demonstrated in vivo effects in various pain models [64]. The halogenated 
version of RTX, iodoresiniferatoxin (I-RTX) has been identified as a high-affinity antagonist 
of the TRPV1 channel and, similarly to RTX, it exerts different potency on hTRPV1 and 
rTRPV1 [65]. R4W2, a small positively charged hexapeptide, was identified to be a non-
competitive antagonist blocker of recombinant TRPV1 channels expressed in Xenopus 
oocytes [66], blocking CAPS-operated ionic currents with micromolar efficacy in a weakly 
voltage-dependent manner. R4W2 was later found to be a competitive antagonist of TRPV1 
also in primary cultures of adult rat dorsal root ganglion neurons (DRGs) [67]. 
Besides its involvement in pain sensation, TRPV1 displays a low level of activity at 
normal body temperature [68, 69]. Constitutive activity of TRPV1 is essential for regulation 
of body temperature, as evidenced by high fever as an adverse side-effect of many TRPV1 
blockers during clinical trials for their efficacy in the management or prophylaxis of pain  
[70, 71]. Moreover, at room temperature (24 °C) and pH 7.3, TRPV1 behaves as a voltage-
gated outwardly rectifying channel, since it can be activated, in the absence of any agonist, by 
depolarizing voltages (> +60 mV) [72]. 
One striking feature of TRPV1 is that the receptor can be sensitized and desensitized. This 
fact suggests that the TRPV1 function is subject to extensive modulation, which has 
significant implications for the involvement of TRPV1 in physiological and 
pathophysiological conditions. Some inflammatory mediators in damaged tissues, including 
growth factors, neurotransmitters, peptides or small proteins, lipids, chemokines and 
cytokines, sensitize TRPV1 to its agonists [73]. Even in concentrations that fail to activate a 
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current, CAPS can sensitize TRPV1 channels to protons and heat. Similarly, protons can 
sensitize TRPV1 channels to CAPS and heat [74, 75]. The elevation of temperature or local 
acidity can in principle augment the efficacies of partial agonists, transforming them from 
weakly or non-pain-producing ligands into noxious chemicals [76, 77]. Whereas protons 
sensitize TRPV1 directly, most of the mediators work through receptor pathways, which 
include receptor tyrosine kinases and G-protein-coupled receptors. It has been reported that 
phosphorylation by protein kinase A (PKA) [78-80] and protein kinase C (PKC) can sensitize 
TRPV1 to CAPS, protons or heat [49, 74, 81-84]. The phosphorylation of TRPV1 by PKC 
acts to potentiate CAPS- or proton-evoked responses and reduces the temperature threshold 
for TRPV1 activation. Others have suggested that isoforms of PKCα [85] or PKCμ [86] are 
responsible for the effects described above. Protein kinase D/PKCμ is a member of the protein 
kinase D serine/threonine kinase family that exhibits structural, enzymological and regulatory 
features distinct from those of the PKCs, with which they are related. TRPV1 can also be 
phosphorylated by Ca2+ calmodulin-dependent kinase II (CaMKII) [87], or Src kinase [88], 
whilst the phosphatase calcineurin produces desensitization of the TRPV1 receptor [89]. 
TRPV1 undergoes two types of desensitization on activation by CAPS or protons: acute 
(short-term) desensitization and tachyphylaxis or loss of sensitivity to repeated stimulations 
[16, 90]. Physiologically, TRPV1 desensitization can lead to the adaptation of peripheral 
neurons to pain perception. The regulatory lipid PIP2 is a putative intracellular modulator of 
TRPV1, although there is some debate as to whether it sensitizes or desensitizes the channel. 
Mutations in a C-terminal cytosolic region of TRPV1 indicate an inhibitory role for PIP2 
[91]. However, others have found that PIP2 sensitizes TRPV1 and that depletion leads to 
desensitization [16, 92-95]. Another important membrane lipid in terms of TRPV1 activity is 
cholesterol. Cholesterol is a major component of plasma membranes and is enriched in lipid 
rafts. It has been shown to modify the function of many classes of ion channels [96]. 
Cholesterol can modify channel activity indirectly by altering the physical properties of the 
surrounding lipid bilayer, and the highly ordered lipid rafts can serve as organizing centers for 
many signalling processes [97]. In recent years, compelling evidence has emerged of a 
specific interaction between cholesterol and several channels [96, 98, 99]. A supporting role 
of sphingomyelin and gangliosides has also been demonstrated [100]. Sántha et al. 
demonstrated that inhibition of neuronal ganglioside synthesis by inhibition of 
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glucosylceramide synthase reversibly decreased the CAPS-induced activation and TRPV1 
expression of cultured DRG neurons, apparently leaving other markers of nociceptive 
neurons, such as calcitonin gene related peptide (CGRP) and IB4, unaffected [101]. 
Intracellular ATP can also sensitize TRPV1. 
TRPV1 binds and is modulated by Ca2+/CaM, a ubiquitous Ca2+ sensor [102, 103].  
An increase in intracellular Ca2+ concentration causes TRPV1 desensitization, and CaM plays 
a role in mediating this effect [102-104]. CaM interacts in vitro with isolated peptides from 
the TRPV1 N-terminal region in a Ca2+-dependent manner [103], and also binds to the 
TRPV1 C-terminal region in a Ca2+-independent manner [102]. The response of TRPV1 to 
heat can be modified by tyrosine kinases or G-protein-coupled receptors. Channel activation 
can occur even at normal body temperatures [74, 83, 105]. Reducing agents such as 
dithiothreitol (DTT) strongly increase the thermally induced activity of the TRPV1 channel. 
Moreover, the oxidizing agents diamide and chloramine-T facilitate thermally induced 
TRPV1-mediated currents [106]. Alkylating agents, such as N-ethylmaleimide, strongly and 
irreversibly affect heat-evoked responses from TRPV1, lowering the thermal activation 
threshold in a DTT-dependent manner [106]. It follows from these data that TRPV1 is 
targeted by redox-active substances that directly modulate the channel activity, and that 
channel potentiation may occur under altered redox states in a tissue, e.g., during ischaemia 
and/or inflammation, presumably leading to hyperalgesia. 
Inflammatory agents such as bradykinin, serotonin, histamine or prostaglandins can 
further stimulate TRPV1 activity, either by PKC-dependent pathways [105, 107, 108], by 
releasing the channel from PIP2-dependent inhibition [91, 109], by a PKA-mediated recovery 
from inactivation [110], or by the formation of 12-HPETE [74, 111]. 
 
2. 3. 2. Vitally important functions of TRPV1 
 
The role of the TRP channels in pain and neurogenic inflammation have been very well 
covered by previous authors (e.g. [112-115]), reflecting the enormity of the role that these 
channels play in sensory nerve function at both central and peripheral levels [116]. Thus, 
TRPV1 plays a key role in the development of the burning pain sensation associated with 
acute exposure to heat or CAPS, and with inflammation in peripheral tissues [30, 87].  
The receptor seems to play an important role in certain chronic pain conditions, such as 
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neuropathic pain, osteoarthritis, bone cancer pain, inflammatory bowel disease and migraine 
[2, 117, 118].  
Its involvement in these painful disorders, TRPV1 enables a new way of painkilling in 
certain otherwise intractable pain conditions. RTX, being an ultra-potent TRPV1 agonist, can 
induce Ca2+-cytotoxicity and eventually ablates these neurons by rapid necrosis, followed by 
removal of the cell debris [76, 119-121]. Exploitation of the Ca2+-excytotoxic potential of 
RTX has been proposed for pain management, through its use as an ablative agent specific for 
TRPV1-expressing cells. In vivo RTX treatment eliminates TRPV1+ nociceptors in the 
peripheral nervous system (PNS) while bystander neurons and their functions are spared  
[76, 122]. Indeed, determination of specificity in vitro and in vivo in different animal models 
and human DRG cultures validated RTX as a “nano-scalpel” capable of “molecular 
neurosurgery” of specific inflammatory pain cells without affecting the other functionalities 
of the PNS and central nervous system (CNS) [76, 119, 121]. "RTX to treat severe pain 
associated with advanced cancer" is currently undergoing Phase II clinical trials [123]. 
TRPV1's role in the CNS is known to involve pain processing and modulation, 
neurogenesis [124] and thermoregulation [125], amongst others, but is currently less well 
understood. 
Jancsó and Wollemann [126] have reported that CAPS stimulates adenylate cyclase 
activity in the rat cerebral cortex in vitro. Furthermore, direct injection of CAPS into the 
preoptic area of the anterior hypothalamus [125] or intracerebroventricular region [127] of the 
rat brain causes hypothermia, suggesting a role for this channel in thermoregulation. 
Similarly, systemic administration of TRPV1 antagonists such as AMG517 [69], 
AMG0347 [128] and A-425619 [129] causes an increase in body temperature within 
approximately 1 hour of treatment [116]. However, antagonist-induced hyperthermia may not 
be mediated by hypothalamic TRPV1 as peripherally-restricted antagonists still have the 
capacity to cause an increase in body temperature [130]. 
Within the periphery, recent evidence has located TRPV1 on a variety of non-neuronal 
tissues (for more details, see Table 2 in the paper of Fernandes et al. [116]). Although TRPV1 
channel expression has been demonstrated in a wide variety of tissues, evidence of 
functionality has not yet been revealed for all of them. 
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One of the first cell types in which functionality was identified was the epidermal 
keratinocytes. Inoue et al. [131] demonstrated that both CAPS and acidification produced 
elevations in the intracellular Ca2+ concentration in cultured human epidermal keratinocytes 
that could be inhibited by the TRPV1 antagonist, CapZ [116]. Similarly, treatment of human 
skin fibroblasts with CAPS induced significant changes in the membrane current and the 
intracellular Ca2+ level that were antagonized by CapZ [132]. It is therefore clear that TRPV1 
is expressed and functional away from sensory nerves. 
Physiological or pathophysiological effects of non-neuronal TRPV1 have been implicated 
in inflammation, infection and immunity, the cardiovascular system and conditions such as 
obesity [116]. 
A physiological/pathophysiological role for non-neuronal TRPV1 is perhaps nowhere 
more apparent than in the case of inflammation, infection and immunity. Although the effects 
of these TRPV1 channels are non-neuronal, it is evident that they may well impact indirectly 
upon pain and/or neurogenic inflammation [116]. Keratinocytes functionally express TRPV1. 
These cells play an important role in maintaining the integrity of the immune response in skin 
as well as stimulating cutaneous inflammation via prostanoid and cytokine release [133]. 
TRPV1 activation by CAPS causes an increase in COX-2 expression in human keratinocytes, 
with a concomitant increase in PGE2 levels in vitro [134]. An increase in IL-8 is also 
observed [134] Stimulation of inflammatory mediator release by TRPV1 agonists from 
keratinocytes could well have a significant effect upon sensory nerves that have a high density 
in the skin [116]. 
However, there is accumulating evidence that TRPV1 has functional roles apart from 
sensory nerve activity [116]. Besides keratinocytes, peripheral blood mononuclear cells 
(PBMCs) are also directly affected by TRPV1 activation. For example, PBMCs undergo 
apoptosis when stimulated with CAPS or RTX, an effect that is reversed by the TRPV1 
antagonist AM630 [135]. There are various other cells involved in immunity that respond to 
TRPV1 and TRPA1 activation, including bone marrow-derived dendritic cells, where CAPS 
leads to dendritic cell maturation and an increase in antigen presentation [136]. 
TRPV1 is expressed, functional and active within cells relevant to inflammation, infection 
and immunity. It is clear from the studies that TRPV1 plays at least a paradoxical role in 
inflammation in vivo, for example, exacerbating inflammation in arthritis and yet in 
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experimentally induced sepsis, TRPV1-null mice demonstrate elevated levels of pathological 
markers in comparison with wild-type mice [117]. It cannot be ruled out that this is due to 
differing effects of neuronal and non-neuronal TRPV1 channels [116]. 
TRPV1 have been shown to control vascular responses either by the well-established 
neurogenic response that is mediated by sensory nerves [137] or via a direct effect on vascular 
tissue [138, 139]. However, the non-neuronal mechanisms involved in mediating 
vasodilatation and edema formation following TRPV1 activation in vivo are unclear. TRPV1 
on endothelial cells has been shown to regulate the expression and secretion of endothelial 
cell-derived calcitonin gene-related peptide (CGRP), which affords protective effects on 
endothelial cells [140]. Furthermore, CGRP is a potent vasodilator [141], and may therefore 
impact upon blood pressure. Indeed, TRPV1 activation on sensory nerves also causes CGRP 
release, leading to a profound decrease in vascular tone [142]. On the other hand, TRPV1 
expressed on vascular smooth muscle appears to cause vasoconstriction [139, 143, 144]. It has 
also been suggested that CAPS has biphasic effects on the vasculature: at lower 
concentrations, CAPS (up to 10 nM) evokes vasodilation in the skin due to sensory nerve 
activation, whereas higher concentrations (0.1–1 mM) elicit substantial constrictions in the 
skeletal muscle arterioles, due to non-neuronal TRPV1 stimulation [139]. It is unclear 
whether this difference is due to receptor sensitivity or a difference in TRPV1 receptor 
density in the two tissues. A similar biphasic effect of CAPS has been demonstrated also in 
the meningeal blood vessels [145]. TRPV1 may also play a role in vascular responses during 
chronic hypoxia, where upregulation of the TRPV1 gene and protein is observed [146]. 
Chronic hypoxia has been shown to enhance the ability of human pulmonary artery smooth 
muscle cells to proliferate and to increase resting levels of cytosolic Ca2+ and capacitative 
Ca2+ entry with both effects being inhibited in a dose-dependent manner by the TRPV1 
antagonist, CapZ [146]. These results suggest that TRPV1 on smooth muscle may be a critical 
pathway or mediator in chronic hypoxia-induced vascular changes [116]. 
Obesity is one of the most significant health issues in western society, due to the 
morbidity associated with this condition, which is increasing in prevalence. Obesity is 
induced by the hypertrophy of adipocytes and the recruitment of new adipocytes from 
precursor cells. These processes are dependent on the regulation of adipocyte differentiation. 
CAPS has been shown to inhibit adipocyte differentiation in vitro by activation of 
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AMP-activated protein kinase [147]. Furthermore, Hsu and Yen [148] have shown that 
treatment of preadipocytes with CAPS decreases the number of normal adipocytes and 
increases the number of early apoptotic and late apoptotic cells in a dose-dependent manner. 
Thus, the overall effect of TRPV1 modulation in obesity is stark. Both animal [149] and 
human [150] data have indicated that the consumption of CAPS- or non-pungent capsiate-
containing foods is correlated with a reduced incidence of obesity. Similarly, oral 
administration of CAPS alone also suppresses body fat accumulation in mice [150], and 
dietary CAPS can reduce obesity-induced insulin resistance and hepatic steatosis in mice fed 
a high fat diet [116, 151]. 
In recent years, a role for TRPV1 in thermoregulation has also been identified, which may 
be due, at least in part, to changes in thermogenesis (for reviews, see [68, 152, 153]).  
For many years, CAPS has been known to cause a centrally mediated hypothermia in mice 
[125]. In contrast, its intragastric administration enhances thermogenesis and heat diffusion 
[154]. Similarly, the jejunal administration of non-pungent CAPS analogues has been shown 
to increase energy expenditure via the direct activation of TRPV1 located on intestinal 
extrinsic nerves [155]. Interestingly, some TRPV1 antagonists cause hyperthermia, associated 
with increased thermogenesis [129] through a peripheral mechanism [130], whilst TRPV1 
gene knockdown does not affect body temperature in mice [156]. and TRPV1 knockout mice 
exhibit a normal basal body temperature [116, 128]. 
TRPV1 in the alimentary tract has also been implicated in metabolism, hair growth 
regulation [157] and the development of cancer [158]. 
Consequently, control of the TRPV1 function may have the potential to provide exciting 
opportunities for therapeutic interventions. Its known functions in both health and disease 
have been continuously expanding, promoting an improved understanding of TRPV1. 
 
2. 3. 3. TRPV1 expression 
 
TRPV1 channels are mainly expressed on primary sensory neurones. They have been 
detected in key areas of the pain transduction pathway: on terminals of small-to-medium-
diameter nociceptors, such as peptidergic and non-peptidergic C fibers, some Aδ fibers  
[30, 75]; in skin nerve endings, DRGs, nodose ganglia, trigeminal ganglia (TGs) of the PNS, 
as well as laminae I and II [75] of the dorsal horn of the spinal cord. Projections may also 
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extend into laminae V and X [75]. Moreover, TRPV1 has been found in different brain 
regions, such as in the dopaminergic neurons of the substantia nigra, the hippocampal 
pyramidal neurons, the hypothalamic neurons, neurons in the locus coeruleus, and in various 
layers of the cortex [27, 159, 160]. The channel is present to a lesser extent in the 
hippocampus, cortex, olfactory bulb and cerebellum in the CNS [46, 161]. However, more 
recently, the use of TRPV1 reporter mice has revolutionized the study of TRPV1 expression, 
and it has been suggested that the expression of this receptor is minimal within a few discrete 
brain regions, most obviously in the vicinity of the caudal hypothalamus [116, 144]. 
TRPV1 is additionally expressed in discrete spots in the plasma membrane and cytosol of 
different non-neuronal cells such as the endothelium, immune cells (lymphocytes, dendritic 
cells and mast cells), keratinocytes, smooth muscle cells and urothelium, thymocytes and 
macrophages, some of which are known to be involved in inflammation [158]. An increased 
level of TRPV1 expression has been demonstrated in the sensory fibers of patients with an 
inflamed oesophagus (gastro-oesophageal reflex disease) or an inflamed bowel (both 
ulcerative colitis and Crohn’s disease), or with chronic breast tenderness and pain [162]. 
There is likewise an increased TRPV1 expression in the sensory fibers of patients with rectal 
hypersensitivity and fecal urgency, and this increase is directly correlated with the degree of 
thermal and mechanical sensitivity [163]. 
 
2. 3. 4. TRPV1 and TRPA1 coexpression 
 
There have been debates about whether TRPV1 can [164-166] or can not [167-169] be 
activated by allyl isothiocyanate (AITC), an agonist of TRPA1. Previous to discovery of 
TRPV1 and TRPA1, it was routine to evaluate the pharmacological effects of vanilloids by 
mustard oil test. Since both TRPV1 and TRPA1 can evoke sterile inflammation, visualized by 
Evans Blue extravasation [119, 170], their functional loss induced by potent vanilloids could 
not be easily distinguished [171]. Story et al. proposed that TRPA1 might be another cation 
channel co-expressed with TRPV1 [168], but no systematic study has been carried out to 
verify this notion and reveal the functional consequences of co-deletion. 
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3. Aims 
The primary aim of this research is to determine sensory modalities that may be lost after 
the RTX treatment of newborn or adult mice, and to dissect potential side-effect(s) of 
molecular neurosurgery, a promising new area of treatment of otherwise intractable pain 
conditions. 
A second goal is to gather information relating to the structure and function of the channel 
by investigating the effects of divalent heavy metal cations on the TRPV1 and by collecting 
the literature data on the functionally important point mutations of the channel for prospective 
in silico modeling. 
To accomplish the main goals, the following specific aims were identified: 
 Determination of the potential effect of AITC on TRPV1. 
 Testing of the sensitivity of the mice treated with RTX to vanilloids, in order to 
verify the effectiveness of RTX treatment in deleting TRPV1+ neurons. 
 Assessment of the sensitivity of the mice treated with RTX to AITC, in order to 
investigate the extent of the coexpression of TRPV1 and TRPA1 in sensory 
neurons.
 Testing of the sensitivity of the RTX-treated mice with to heat, in order to assess 
the actual role of TRPV1 and coexpressed homologues in heat sensing. 
 Immunohistology and Western blotting experiments in order to characterize the 
distribution of TRPV1, TRPA1 and TRPM8 in the DRG and TG neurons of RTX 
treated or untreated mice. 
 Assessment of the interactions of divalent heavy metal cations with TRPV1 using 
vanilloid induced 45Ca2+ uptake assays. 
 Revalidation of the TRPV1 dependent Co2+ accumulation phenomenon by using 
(NH4)nSx histochemistry. 
 Validation of the Co2+ inhibition phenomenon in in vivo tests. 
 Collection of the mutational data of TRPV1 available in the literature and their 
organization in a form that facilitates in silico model building of the TRPV1. 
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4. Materials and methods 
 
Reagents stock solutions - (200 mM) of CoCl2, NiCl2, ZnSO4, CdCl2, CuSO4, CaCl2, 
CoCl2 and LaCl3 were dissolved in water and diluted as required to the working 
concentrations. To avoid the precipitation of insoluble La(OH)3 and La(CO3)3, the formation 
of radiocolloids and the loss of La3+ by adsorption to container surfaces, LaCl3 solution was 
prepared fresh daily in polyethylene vials [172]. RuRed and CapZ (Sigma-Aldrich, St. Louis, 
MO) were dissolved in dimethyl sulfoxide (DMSO). CAPS was dissolved initially as a 3 mM 
stock solution in 95% ethanol. The peptide R4W2 was synthesized in our laboratories, then 
dissolved in water and used as a 25 mM stock solution. Amitriptyline (AMI), purchased from 
Sigma-Aldrich, was dissolved in water. RTX (LC Laboratories, Woburn, MA) and CAPS 
(Sigma, St. Louis, MO) were dissolved in ethanol and further diluted in physiological saline 
solution. Allyl isothiocyanate (AITC) (Sigma, St. Louis, MO) was diluted in physiological 
salt solution and dispergated by ultrasonication before testing. 
 
Plasmids - The C-terminally epsilon-tagged rat TRPV1ε plasmid construct was prepared 
in the metallothionein (pMTH) plasmid vector as described earlier [31]. To avoid cell loss 
through the Ca2+-excytotoxic mechanism that occurs when TRPV1 is overexpressed at 37 ºC, 
only the basal activity of the pMTH promoter was used. The PKCε epitope tag allowed 
immunological detection of the TRPV1ε protein, as described earlier [173].  
 
Cell lines expressing TRPV1 ectopically - The HaCaT keratinocyte cell line was a kind 
gift of Prof. B. Farkas (Department of Dermatology, University of Cologne, Federal Republic 
of Germany) [105]. The COS-7 (CRL-1651) and BALB/c-3T3 (CCL-163) cell lines were 
obtained from ATCC. The 3T3 and HaCaT cell lines permanently expressing the rTRPV1 
channel were prepared as described earlier [174]. COS7 cells were transiently transfected with 
plasmid containing the wild-type TRPV1 channel by using the Fugene transfection reagent 
(Roche, Mannheim, Germany). The transfection efficacy was determined by flow 
cytofluorometry. 
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Primary DRG cultures - DRG cultures were prepared from E16 embryonic rats as 
reported earlier [31]. DRGs were dissected and then processed in Hank’s balanced salt buffer 
until plated in Dulbecco’s Modified Eagle Medium (DMEM). The DMEM contained 20 mM 
HEPES, pH 7.4, 7.5% fetal bovine serum, 7.5% horse serum, 5 mg/ml uridine supplemented 
with 2 mg/ml 5-fluoro-2’-deoxyuridine and 40 ng/ml nerve growth factor (NGF) to inhibit 
cell division and to promote the differentiation of long neuronal processes, respectively. Cells 
were seeded on 25 mm glass coverslips. 
 
45Ca2+ uptake assay - One day before the assay, HaCaT adherent cell lines ectopically 
expressing the C-terminally ε-tagged rTRPV1 and Cos7 cells transiently transfected with 
rTRPV1 were seeded in poly-D-lysine-coated 96-well flat-bottom plates (Orange Scientific, 
Braine-l’Alleud, Belgium) at a density of 20,000 cells/well. The plates were washed three 
times with assay medium (Ca2+- and Mg2+-free Hanks’ balanced salt solution supplemented 
with 0.8 mM MgCl2 and with 25 mM Tris-HCl, pH=7.4) at room temperature (20-25 ºC). 
CAPS was diluted from a 3 mM ethanol stock solution to the indicated final concentrations. 
Serial dilutions of reagents containing 45Ca2+ were prepared, and the 45Ca2+ uptake assay was 
performed for ten minutes at 24 °C using 1.33 μCi/ml of 45Ca2+ (Amersham Biosciences, 
Buckinghamshire, UK) in a final volume of 100 μl/well. To stop 45Ca2+ uptake and remove 
the free isotope, cells were washed three additional times and then lysed in 80 μl lysis 
buffer/well (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 5 mM 
EDTA) for 30 minutes. 70 μl aliquots of the solubilised cell extracts were mixed with 100 μl 
aliquots of Optiphase Supermix scintillation cocktail (Perkin Elmer, Wellesley, MA) and 
counted in a Perkin Elmer liquid scintillation counter. 
To measure the effect of temperature on the TRPV1 function in the 45Ca2+-uptake assay, 
TRPV1/HaCaT cells were plated on six-well plates. 45Ca2+ uptake was evoked with 10 ml 
preheated buffer. The procedure was followed as described above. 
After the measurement, the data were corrected for the basal activity of TRPV1 and 
normalized from zero to one, where zero denotes the counts per minute in TRPV1/HaCaT 
cells without CAPS and one denotes the counts per minute in TRPV1/HaCaT cells with 
CAPS. The results of three parallel measurements were averaged and evaluated with 
PRISM™ 3.01 software (GraphPad Software, Inc. San Diego, CA, USA). During curve 
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fitting, the “Analyze/Nonlinear regression (curve fit)/Sigmoidal dose-response” menu of 
PRISM™ software was applied.  
The curve-fitting equation was: Y = Ymin + (Ymax - Ymin)/(1 + 10(logEC50 - X)), where  
X = logarithm of concentration and Y = the response. 
 
RTX treatment - The studies were carried out on male CD/1 mice. 1 mg RTX was 
dissolved in 500 μl 96% ethanol, diluted in physiological saline and injected s.c. into the 
scruff of the neck in a volume of about 100 μl. The RTX was applied at a dosage of 50 μg/kg 
body weight under light ether anesthesia to avoid unnecessary pain. Control mice received 
vehicle. In the case of adult treatment, two to three months old adult mice weighing about 
30 g at the start of the experiments were tested 10 days after RTX treatment. Mice treated on 
the second day of life were tested at two months of age. In the case of chronic RTX treatment, 
RTX was added at 20 μg/kg body weight daily for three days. 
 
Eye wipe test - Eye wipe tests were performed on CD1 mice. 100 µM CAPS solution, or 
a solution containing 100 µM CAPS and 1 mM CoCl2, or a solution containing 100 µM 
CAPS and 5 µM CapZ, was dropped into the eye and the number of defensive wiping 
movements was then counted. 
 
Cold tail-flick test - Animals were held over ice-cold water (~5 °C) and their tails were 
approximately half-submerged into the bath. The time from immersion to tail removal or 
flicking was measured. 
 
Cold plate test - A micro-plate thermostat set at 5 °C was used to generate a cold surface. 
Tested mice were placed on the plate, and the time to the first response of forelimb 
withdrawal and shivering was recorded. 
 
Hot plate test - The animals were individually exposed to a hot plate maintained at 53 °C. 
The time up to forepaw licking was taken as the response time. 
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Water consumption - The daily water consumption of individually housed mice was 
measured. Each bottle contained tap water with AITC at a concentration of 0.1 mM. 
 
Protein extraction and Western blotting - Tissue samples were homogenized in 
modified RIPA buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM EDTA, 1% TritonX-100, 
Protease Inhibitor Cocktail - Roche, Mannheim, Germany) and incubated on ice for 
15 minutes to allow lysis to proceed. All samples were pre-cleared by centrifugation 
(15 minutes 12000g at 4 °C) before protein concentration determination by the bicinchonic 
acid (BCA) method (Sigma, St. Louis, MO). PAGE was performed as described in the Protein 
Electrophoresis technical manual of Amersham Biosciences (Buckinghamshire, UK). Protein 
samples were separated on 8% polyacrylamide gels, then transferred to Millipore Immobilon 
PVDF membrane using Tris-Glycine transfer buffer (0.192 M glycine, 25 mM Tris, 20% 
MetOH). Transfer was followed by blocking of the membrane (30 minutes at room 
temperature (RT) in 5% dry milk TBS-Tween), and incubation with primary antibody 
(overnight at 4 °C, in 0.5% BSA TBS-Tween), secondary antibody (2 hours at RT, in 1% dry 
milk TBS-Tween). Results were revealed by using the ECL method (SuperSignal West 
Chemiluminescent Substrate (Pierce Biotechnology Inc. Rockford, IL), Hyperfilm ECL - 
Amersham Biosciences, Buckinghamshire, UK). TBS: 50 mM Tris, 140 mM NaCl, pH 7.6; 
TBS-T: TBS with 0.5%Tween-20. Antibodies used and their dilutions: TRPV1 - 1:1000, 
(ABR Bioreagents, PA1-747); TRPA1 - 1:1000, (Transgenic Inc. Kumamoto, Japan. 
#KM120); TRPM8 - 1:1000, (Alomone Labs, Jerusalem, Israel #ACC-049); ß-actin - 1:1000 
(Sigma, St. Louis, MO #A5060); anti-mouse and anti-rabbit HRP - 1:10000 (Sigma, 
St. Louis, MO #A0168 and #A6154, respectively). 
 
Cobalt histochemistry - Rat DRG cells attached to coverslips were washed in buffer A 
(in millimolars: NaCl, 57.5; KCl, 5; MgCl2, 2; HEPES, 10; glucose, 12; sucrose, 139; pH 7.4) 
for 2 minutes, and then incubated at 37 ºC for 10 minutes in Co2+-uptake solution (buffer A + 
5 mM CoCl2) containing 20 µM CAPS. High (20 µM) capsaicin concentration was used in 
order to obtain a robust and easily detectable Co2+ signal. Following a wash in buffer A, the 
water-soluble Co2+ taken up by the cells was precipitated with 0.12 % ammonium polysulfide 
(Sigma-Aldrich) in buffer A, which resulted in the formation of dark, water-insoluble CoS in 
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TRPV1+ cells. Cells were fixed in 4% formaldehyde and mounted on glass slides, using 
Kaiser’s glycerol gelatin (Merck, Darmstadt, FRG). Cells were examined under a Nikon light 
microscope (Melville, NY, USA) and photographed with a SPOT RT-SE™ Digital Camera 
(Diagnostic Instruments). Pictures of the cells were analyzed by means of ImageJ 1.45s 
software (National Institutes of Health, USA), and the subsequent statistical analyses were 
performed with PRISM™ 3.01 software (GraphPad Software, Inc. San Diego, CA, USA). 
 
Immunhistochemistry - Over-anesthetized mice were perfused intracardially with 4% 
paraformaldehyde in 0.1 M sodium phosphate buffer (PB, pH 7.4). TGs were dissected out, 
and cryoprotected in 10% glycerol / 30% sucrose) overnight at 4 ºC. TGs were embedded in 
Tissue Tek OCT (Sakura Finetek, Torrance, CA) and frozen in dry ice. Frozen sections were 
cut on a Shandon Cryotome Fe (Thermo Fisher Middletown, VA) sliding microtome and 
collected in Superfrost slides kept at -20 °C. Sections were pre-incubated in blocking 
solutions (5% goat serum, 0.1% Triton-X in PBS pH=7.4). The sections were next incubated 
in primary antibody dilutions at 4 °C for 24 hours, and then with secondary antibody. 
Antibodies used and their dilutions: TRPV1 1:50 (our monoclonal antibody directly labeled 
with Alexa Fluor 488); TRPA1 1:50 (rabbit polyclonal, Transgenic Inc. Kumamoto, Japan. 
#KM120); TRPM8 1:50 (rabbit polyclonal, Alomone Labs, Jerusalem, Israel #ACC-049); anti 
rabbit IgG–TRITC 1:400 (Sigma, St. Louis, MO). Sections were mounted on standard glass 
slides and coverslipped with Dako Faramount Aqueous Mounting Medium (Dako, Glostrup, 
Denmark). 
 
Statistical analysis of the data - One-way ANOVA followed by Turkey’s post tests was 
performed with GraphPad Prism version 3.01 software (GraphPad Software, Inc. San Diego, 
CA, USA) to compare the data groups of the different measurements. 
 
All animal experimental protocols were approved by our institutional review committee 
and the responsible governmental agency. 
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5. Results 
5. 1. The effects of RTX-mediated molecular neurosurgery 
 
Although extremely specific for its target, TRPV1, RTX, can delete sensation modalities 
conferred by bystander sensor molecules, including other TRP channels co-expressed in the 
same neuron. A specific aim of this study, therefore was the determination of the potential 
loss/gain of sensations that RTX-mediated molecular surgery may cause. To determine the 
potential effect of AITC in vitro, we used a 
cell-based functional assay using a 
permanent cell line expressing TRPV1, but 
not TRPA1 ectopically. RTX and CAPS 
evoked a 45Ca2+ influx with a half-maximal 
effective concentration (EC50) of 2.6 nM and 
78 nM, respectively (3). In contrast to the 
report by Ohta et al. [83], however, we 
found that AITC has no effect on TRPV1-
expressing cells, since it did not evoke a 
Ca2+ influx at applied concentrations ranging 
from 125 nM to 2.5 mM. The lack of an 
AITC effect on TRPV1 and the selectivity of 
this ligand for TRPA1 has recently been 
shown by others, too [167, 175]. To dissect potential side-effect(s) of molecular neurosurgery 
in vivo, mice were treated with RTX either at birth or at adult age, the resulting changes in 
behavioral, cellular and molecular biomarkers (i.e. chemo, and heat sensitivity, tissue specific 
expression/distribution of TRPV1 and TRPA1) were systematically compared. As expected 
from previous studies [119], mice treated with RTX two days post-natal and tested at the age 
of two months had completely lost the sensitivity to vanilloids, since the CAPS-induced eye 
wipe, a behavioral marker of the TRPV1-conferred pain signal, was completely abrogated. 
We chose an RTX dose at which no mortality occurred. Under conditions applied in 
preliminary experiments, RTX-caused mortality was detected from 75 μg/kg body weight, 
while the maximal dose used in the subsequent experiments was 50 μg/kg body weight.  
Figure 3: 45Ca2+-influx of rTRPV1 HaCat cells 
HaCaT keratinocytes expressing rTRPV1 were 
challenged in agonist-induced 45Ca2+-influx assays for 
ten minutes. Cell-bound radioactivity was measured in 
a liquid scintillation counter. Only RTX and CAPS 
induced a Ca2+-influx, while AITC was totally 
ineffective. The experiment was repeated two additional 
times, with similar results. 
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We also noted that mice were unresponsive in AITC-induced eye wipe tests as well, as the 
AITC-induced eye wipes were completely abrogated. In accordance with that fact, these 
animals consumed AITC containing drinking water in a significantly higher volume overnight 
than untreated mice (2.7 ± 1.7 ml vs. 5.5 ± 1.5 ml), another signature of the specific loss of 
this sensory modality. Interestingly, they showed no change in temperature sensitivity in 
either the cold plate, or the hot plate assay (Figure 4). 
Figure 4: Changes in the chemical- and heat 
sensitivity of mice treated with RTX at 50 μg/kg 
body weight on the second day after birth.  
Mice were tested at second month of their life. 
Comparisons were made using age-matched control 
animals treated with vehicle only. Bars represent 
means plus S.D. (n=7). The experiments were 
repeated two additional times with similar results. A - 
Oral aversion to AITC. RTX-treated mice consumed 
significantly more AITC containing drinking water 
than untreated mice in a 24 h test. *P < 0.05 vs. 
control B, C - Eye wipe response to corneal 
application of 100 µM CAPS and 10 mM AITC. 
Neonatal RTX administration significantly reduced 
the eye wipe response to corneal application of CAPS 
and also to AITC. *P < 0.05 vs. control. D - Cold 
plate test. Paw withdrawal latency (left) or time to 
first shiver (right) were measured following placement 
of mice on a plate maintained at 5°C. Responses were 
not significantly different. E - Response latency in the 
tail immersion into 4°C cold water. No significant 
differences were seen between control and RTX 
treated animals. F - Licking latencies in the hot plate 
assay at 53°C. The responses were not significantly 
different. 
Figure 5: Changes in the chemical- and heat 
sensitivity of mice treated with 50 µg/kg RTX at 
adult age. 
Mice were tested two weeks later. Comparisons were 
made using age matched control animals treated with 
vehicle only. Bars represent means plus S.D. (n=7). 
The experiments were repeated two additional times 
with similar results. A - Oral aversion to AITC. RTX-
treated mice consumed significantly more AITC 
containing drinking water than untreated mice in 24 h 
tests. *P < 0.05 vs. control B, C - Eye wipe response 
to corneal application of 100 µM CAPS and 10 mM 
AITC. RTX administration significantly reduced the 
eye wipe response to corneal application of CAPS and 
AITC. *P < 0.05 vs. control. D - Cold plate test. Paw 
withdrawal latency (left) or time to first shiver (right) 
was measured following placement of mice on a plate 
maintained at 5°C. Treated mice showed more 
sensitivity to cold. *P < 0.0001 vs. control. E - 
Response latency in the tail immersion into 4°C cold 
water. Significant differences were seen between 
control and RTX treated animals. *P < 0.05 vs. 
control. F - Licking latencies in the hot plate assay at 
53°C Responses were significantly different. RTX 
treated animals had longer reaction times. *p < 0.05 
vs. control. 
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Mice treated with one dose of RTX at adult age become similarly unresponsive to chemical 
stimuli, i.e., they did not respond either to CAPS or AITC in the eye wipe tests, and they were 
also able to consume AITC-containing drinking water in high quantities. In addition, the 
animals that underwent RTX-mediated neurosurgery at adult age exhibited changes in heat 
sensitivity. As was expected from previous observations [119], the loss of TRPV1-expressing 
neurons resulted in decreased heat sensitivity. Surprisingly, however, the RTX-treated 
animals also became more sensitive to cold, showing a marked reduction in the response time 
(around 30%) on cold plate as measured in cold plate tail flick and cold plate shivering tests 
(Figure 5). In the case of chronic RTX treatment (3 x 20 µg/kg body weight rather than 
1 x 50 µg/kg body weight) the mice similarly became unresponsive to CAPS. However, these 
mice lost their heat sensitivity to a higher extent relative to the mice which took part in acute 
treatment, so chronic treatment seemed to be more effective than a single treatment in this 
respect (Figure 6). Immunohistological staining experiments performed on adult mice treated 
with 1 x 50 µg/kg body weight RTX confirmed that TRPV1 is indeed lost after the treatment. 
The staining was performed with a new monoclonal antibody developed in our laboratory. 
Our hybridoma cell line was established from a normal BALB/c mouse immunized previously 
with a crude plasma membrane fraction isolated from a BALB/c 3T3 cell line permanently 
expressing the rat TRPV1. By employing indirect fluorescent labeling technologies, the 
monoclonal antibody was verified to react with an extracellular loop of both rat and mouse 
TRPV1. Parallel to TRPV1, TRPA1 also disappeared from the TGs of the RTX treated 
Figure 6: Comparison of acute and chronic RTX 
treatment 
Chronic RTX (3 x 20 µg/kg body weight) is more 
effective than acute treatment (1 x 50 µg/kg body 
weight) as measured in a hot plate assay. Bars 
represent means plus S.D. Statistics were made by 
LSD post hoc test following one-way ANOVA, *P < 
0.05 vs. control. 
Figure 7: Microscopic images showing the effect 
of RTX on TRPV1+, TRPA1+ and TRPM8+ 
trigeminal ganglion neurons.  
Unlike TRPM8, both TRPV1 and TRPA1 
immunoreactivity was lost in the treated animals. 
Bar represents 0.2 mm. 
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animals (Figure 7), but the TRPM8-positive cells remained readily detectable. TRPA1 and 
TRPM8 were stained with commercially available antibodies. The correlation between 
TRPV1 and TRPA1 levels in the DRG and TG with the changes in chemical and heat 
sensitivity in mice treated at adult age was 
tested in Western blot experiments. In this 
case, TRPV1, TRPA1 and TRPM8 were 
immunostained with commercially available 
polyclonal antibodies. Our Western blotting 
experiments confirmed that, in parallel with 
TRPV1, TRPA1 also disappeared from the 
TGs of the RTX-treated animals; the 
decrease was 83% in the case of TRPV1, 
and 86% in the case of TRPA1, while the 
amount of TRPM8 changed only barely,  
 non-significantly (Figure 8). 
 
5. 2. The effects of divalent heavy metal cations on the TRPV1 receptor 
 
Various studies have revealed that positively charged molecules can act as TRPV1 
receptor channel blockers by plugging the pore. RuRed (a well-known but non-specific 
TRPV1 pore blocker) [176], R4W2 (a positively charged hexapeptide) [67] and 
anti-calmodulins/antipsychotic tricyclics [177] have been demonstrated to be able to bind to 
the DXEXXEXXD domain of TRPV1, whereby they block the movement of Ca2+ through the 
pore region. 
We assessed the effects of various metal cations on the vanilloid-induced activity of the 
TRPV1 channel. In the 45Ca2+ uptake assay, the EC50 of CAPS for wild-type TRPV1 was 
determined to be 0.0860 µM. Approximately 1 µM CAPS caused the full activation 
(maximum effective concentration - EC100) of TRPV1 at pH 7.5. Channel blocker-screening 
assays were therefore carried out with 2 µM CAPS (an excess amount of agonist), which does 
not cause Ca2+ cytotoxicity during the 10-min incubation period. The interactions of the metal 
ions with TRPV1 were studied by using a vanilloid-induced 45Ca2+-uptake assay. Experiments 
Figure 8: Western blot analysis of the trigeminal 
ganglions 
Western blot shows the level of TRPV1, TRPA1 and 
TRPM8 proteins in the lysates of pooled trigeminal 
ganglions obtained from control and RTX treated 
mice. Similarly to TRPV1, TRPA1 also disappears 
from the trigeminal ganglions of treated animals, 
while TRPM8 does not change. Sigma beta-actin 
was used in the Western blot as an internal control.
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were carried out on the TRPV1/HaCaT permanent indicator cell line. Channel opening was 
induced by CAPS in the presence of progressively increasing divalent metal cation (M2+) 
concentrations in the uptake solution. 
Incubation of the cells in uptake solutions 
containing both 45Ca2+ and Mg2+, Mn2+ or 
La3+ (data not shown) resulted in little or no 
effect, even at the highest concentration 
(4 mM), whereas Zn2+ proved to be a weak 
(IC50 = 27 µM) and only partial inhibitor of 
the 2 µM CAPS-induced 45Ca2+ uptake. The 
other cations effectively blocked the 
vanilloid-induced Ca2+ entry into 
TRPV1/HaCaT cells, with the following 
sequence of potency: Co2+ (IC50 = 13 µM) > 
Cd2+ (IC50 = 38 µM) > Ni2+ (IC50 = 62 µM) > Cu2+ (IC50 = 200 µM) (Figure 9). To assess the 
effect of Co2+, the most potent TRPV1 inhibitor, on the heat-activated TRPV1 channels, the 
activity of TRPV1 was investigated in the presence either of 2 μM CAPS alone or of 2 μM 
CAPS + 250 μM Co2+, at both 37 °C and 42 °C. The negative control did not contain CAPS. 
In this assay, high temperature activated the TRPV1 channels and also increased the 
Figure 9: Ranking divalent cations as channel 
blockers 
Efficacy of M2+ inhibitors of TRPV1 ranked by 
vanilloid-induced 45Ca2+ uptake. The sequence of 
potency is: Co2+ > Cd2+ > Ni2+ > Cu2+ >>> Zn2+ 
Data are mean values ± S.D. of the results of three 
independent experiments.  
Figure 10: Co2+ effect on heat-induced TRPV1 
activity 
Co2+ inhibits heat-induced Ca2+ uptake at 37 °C 
and at 42 °C in vanilloid-induced 45Ca2+ uptake 
assay. Bars represent means plus S.D. of the 
results of three independent experiments. Statistical 
significance was assessed by post hoc LSD t tests 
after significant one-way analysis of variance 
(ANOVA). P<0.05. 
Figure 11: Effect of selective channel blockers on 
the TRPV1 activity 
RuRed, R4W2 and AMI, selective channel blockers of 
TRPV1, were also tested for better comparison of 
inhibitors. Data are means plus S.D. of the results 
of three independent experiments. 
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CAPS-evoked 45Ca2+ influx. Co2+ reduced both the heat and CAPS-induced 45Ca2+ influx 
(Figure 10). 
To compare the potency of Co2+ with those of the other positively charged channel 
blockers, we measured the IC50 values of RuRed, AMI and R4W2, which are known to have a 
docking site in the pore loop of TRPV1. The inhibitor potentials of these pore blockers were 
measured via the CAPS-induced 45Ca2+ uptake. All of them inhibited CAPS-activated 
TRPV1, with the following IC50 values: RuRed = 1 µM, AMI = 20 µM and R4W2 = 100 µM 
(Figure 11). 
For a better understanding of the inhibition kinetics of Co2+ on TRPV1, increasing 
concentrations of both Co2+ and CAPS were applied in the vanilloid-induced 45Ca2+-uptake 
assays. The Ca2+ uptake of TRPV1/HaCaT cells was inhibited by the simultaneous presence 
of Co2+ in a dose-dependent manner. However, increasing concentrations of Co2+ decreased 
only the maximal response of efficacy (Emax) of Ca2+ entry; the affinity of CAPS for TRPV1 
did not change. The inflection point in the CAPS dose-response curves in each of the Co2+ 
co-incubation studies was found at ~0.08 µM (i.e. EC50), independently of the Co2+ 
concentration. The Co2+ inhibition patterns unequivocally indicated channel blocking kinetics 
(Figure 12A). 
Figure 12: Co2+ inhibits Ca2+ entry through the TRPV1 channel 
A - Kinetics of inhibition of Ca2+ transport by Co2+ in TRPV1+ cells. Data are mean values plus S.D. of the 
results of three independent experiments. B - Kinetics of competition between Co2+ and cold Ca2+ in 
TRPV1+ cells. C - Co2+ blockage at different CAPS concentrations. Representative data are shown from 
independent experiments repeated at least three times. D - IC50 values as a function of CAPS concentrations. 
IC50 values of Co2+ in the presence of 0.0625, 0.125, 0.25, 0.5, 1, 2 or 4 μM CAPS are 94.81, 57.97, 73.17, 
32.6, 19.22, 22.55 and 15.62 μM, respectively.
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By varying the concentrations of Co2+ and Ca2+ and measuring the radioactive 45Ca2+ 
influx, we assessed whether there was a competition between Co2+ and Ca2+. The effect of 
dilution on the amount of accumulated 45Ca2+ did not appear at extracellular cold Ca2+ 
concentrations below 1 mM (Figure 9), indicating that TRPV1+ cells accumulate Ca2+ very 
effectively from the extracellular space and collect them putatively into ER or mitochondria. 
Increasing cold Ca2+ concentration decreased the inhibitory effect of Co2+ (IC50 values in the 
presence of 0 µM, 15.625 µM, 31.25 µM, 62.5 µM and 125 µM cold Ca2+: 7.944 µM, 
51.22 µM, 72.69 µM, 79.09 µM and 189.1 µM, respectively), showing that the effect of Co2+ 
on Ca2+ entry mainly depends on the competition for entry sites. These results suggest that the 
Co2+ entry through the TRPV1 channel is slower, and the Co2+ displacing the Ca2+ from the 
pore region of TRPV1 slows down or inhibits the Ca2+ uptake (Figure 12B). 
The prolonged agonist stimulation of TRPV1 has been reported to result in an increased 
permeability to larger cations [178] or small molecules [179], due to conformational changes 
in the open state of the TRPV1. Thus, we analyzed the kinetics of the channel-blocking 
activity of Co2+ by employing different CAPS concentrations. An anticipated shift in the IC50 
of Co2+ would be evidence supporting the idea that Co2+ entry depends on the TRPV1 open 
stages. We indeed observed a shift in the IC50 of Co2+, which decreased with increasing CAPS 
concentration (Figure 12C). Consequently, increasing agonist concentration enhances the 
blocking ability of Co2+. To investigate this phenomenon, we plotted the IC50 values as a 
function of CAPS concentration. Curve-fitting analysis confirmed a strong interrelationship 
between IC50 and the CAPS dose applied (Figure 12D), suggesting that the increased 
efficiency of inhibition correlates with the different open-state conformations of the TRPV1 
channel. 
We traced Co2+ upon vanilloid induction in sensory neuron cultures prepared from DRGs 
of rat embryos. To test Co2+-accumulation patterns, cells were co-incubated with 20 µM 
CAPS in Co2+-containing Ca2+-uptake medium and the Co2+ was then localized by means of 
(NH4)nSx histochemistry. These experiments revealed that Co2+ not only competes with Ca2+, 
but also enters into the cytosol of specific PNS sensory neurons. Functionally responsive 
vanilloid-sensitive neurons (i.e. TRPV1+) exhibited dark-brown Co2+ precipitates inside the 
rounded neuronal bodies (Appendix Figure 1E). As expected from previous studies, TRPV1 is 
endogenously expressed in approximately one-third of the cultured neurons [180-183]. 
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Without CAPS, no intracellular Co2+ accumulation was observed (data not shown). Similar 
experiments were carried out on rTRPV1/HaCaT and rTRPV1/3T3 cell lines.  
The accumulation of Co2+ was blocked by RuRed, a channel blocker of heat and vanilloid 
pain signalling. Moreover, the dose-dependent inhibition of the cellular entry of Co2+ was 
determined by the co-
application of 5 µM 
CapZ, a long-known 
competitive antagonist of 
pungent vanilloids. After 
analysis of the photographs 
of the cells with the  
Image J program, statistical 
analysis of the data 
further confirmed our 
findings: the mean gray 
values of CAPS-exposed, 
CAPS-free, and CapZ-
exposed cells proved to 
be significantly different 
(CAPS without Co2+: 
72.05 ± 12.38 (S.D.), 
n = 146; CAPS + Co2+: 
124.4 ± 21.51 (S.D.), 
n = 111; CAPS + Co2+ + 
CapZ: 76.92 ± 22.21 
(S.D.), n = 100; P values 
of the t tests: CAPS without Co2+ vs. CAPS + Co2+: P<0.0001; CAPS + Co2+ vs. CAPS + 
Co2+ + CapZ: P<0.0001; CAPS without Co2+ vs. CAPS + Co2+ + CapZ: P=0.0290) (Appendix 
Figure 1). The gray values were measured on the negatives of the images: the darker the cells, 
the higher the gray values. Analysis of the pictures in Figure 13, showing TRPV1-expressing 
HaCaT cells, resulted in the same outcome. Following ANOVA, the groups were compared 
Figure 13: Co2+ histochemistry on the HaCaT cell line expressing 
TRPV1 ectopically. 
Cells were incubated for 10 minutes in buffer A containing: A - 20 μM CAPS 
+ 5mM Co2+; B - 5mM Co2+ without CAPS; C - 20 μM CAPS + 5mM Co2+ 
+ 300 nM CapZ; D - 20 μM CAPS + 5mM Co2+ + 5 μM CapZ; E - 20 μM 
CAPS +5 mM Co2+ +100 μM CapZ; F 20 μM CAPS + 5 mM Co2+ + 500 nM 
RuRed; G - 20 μM CAPS + 5 mM Co2+ +7 μM RuRed; H - 20 μM CAPS +5 
mM Co2+ +100 μM RuRed. The dark precipitates indicate the presence of 
intracellular CoS that is blockable with RuRed, a channel blocker of heat 
and vanilloid pain signalling. Co-application of CapZ, a competitive 
antagonist of pungent vanilloids, also inhibited the cellular entry of Co2+ in 
a dose-dependent manner: this is a well characterized evidence-based 
method of localization of intracellular Co2+. I - Gray values of the HaCaT 
cell line expressing TRPV1 measured by means of ImageJ software. 
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by using t tests. Each t test except that involving CAPS without Co2+ vs. CAPS + Co2+ + 
100 µM CapZ indicated a significant difference between the pairs of groups (P<0.05) (Figure 
13).  
No substantial staining could be observed on 3T3 cells (Appendix Figure 2A-E). 
Statistical analysis of the gray values of the cells indicated no significant darkening in the 
absence of TRPV1 in the cell membrane. 
In order to rule out the possibility that Co2+ can enter the cells through voltage-gated 
calcium channels (VGCCs), 3T3 cells were challenged with 50 mM extracellular KCl.  
These cells did not show any VGCC activity: the high extracellular KCl concentration-
induced depolarization that opens the VGCC channels did not cause 45Ca2+ accumulation in 
the 45Ca2+ -uptake assay.  
Moreover, the VGCC blocker Nisoldipine did not decrease the CAPS induced TRPV1-
mediated 45Ca2+ accumulation (data not shown). No Co2+ staining was observed in the 
presence of 50 mM extracellular KCl (Appendix Figure 2F-J). ANOVA indicated no 
significant differences among the groups (P=0.9150). These results confirm that the 
CAPS-induced Ca2+ and Co2+ influx in TRPV1/3T3 cells is due exclusively to the TRPV1 
channel activity. 
Besides the in vitro demonstration of Co2+ antagonism, we further validated this Co2+ 
inhibition phenomenon in tests of eye 
wiping in response to pungent vanilloids 
[184]. Co2+ again decreased the frequency of 
vanilloid-evoked defending movements. 
Inhibition experiments with CapZ cross-
validated and confirmed our earlier findings 
(Figure 14). 
To follow the line with the resolution of 
the structure and function of the TRPV1 
channel, the next specific goal of this 
research was to create an overview of the 
currently available results of site-directed 
mutagenesis studies on transient receptor 
Figure 14: Eye wipe responses to the corneal 
application of CAPS alone or together with Co2+ 
or CapZ. 
Co2+ decreased the frequency of vanilloid-evoked 
defending movements. Inhibition experiments with 
CapZ cross-validated and confirmed our earlier 
findings Statistical significance of inhibition was 
assessed by means of the paired t test (P<0.05). 
Data are means plus S.D. of the results of eight 
independent experiments (n08). 
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potential vanilloid type 1 (TRPV1) receptor. Systematization of the vast number of data on 
the functionally important amino acid mutations of TRPV1 may provide a clearer picture of 
this field, and may promote a deeper understanding of the relationship between the structure 
and function of TRPV1. We summarized information on 112 unique mutated sites along the 
TRPV1, exchanged to multiple different residues in many cases. These mutations influence 
the effect or binding of different agonists, antagonists, and channel blockers, alter the 
responsiveness to heat, acid, and voltage dependence, affect the channel pore characteristics, 
and influence the regulation of the receptor function by phosphorylation, glycosylation, 
calmodulin, PIP2, ATP, and lipid binding.  
The above mentioned data is published in a form that facilitates in silico molecular 
modeling of the receptor by promoting easier establishment of boundary conditions [185], but 
its detailed discussion would exceed the limits of this thesis. Appendix Table 1 summarizes 
the information of the mutants, enabling an effective usability and easier comprehensibility of 
the data. Figure 15 indicates the mutated residues and the functional changes evoked by them, 
and also depicts the most important structural properties of TRPV1.  
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 Figure 15: Summary of the mutated sites of rTRPV1  
The figure summarizes the effect of 112 unique mutated sites along the rTRPV1 on the function of the 
channel. Coloured circles indicate the involvement of the given residue in the corresponding process. 
Coloured boxes show the putative location of some structural elements on the rTRPV1 sequence. Sequence 
and region information: TRPV1_RAT (O35433) (www.uniprot.org)  
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6. Discussion 
 
As it is at least a thousand fold more potent analogue of CAPS, RTX applied either 
intrathecally or intraganglionically can execute a highly specific, TRPV1-targeted molecular 
neurosurgery to eliminate the cellular generator of inflammatory as well as cancer-associated 
pain [76, 119]. The literature data reveal, that 24 hours after CAPS treatment a population of 
primary sensory neurons of both newborn [186] and adult rats [84] exhibit TUNEL staining, 
indicating that the neurons are killed by apoptosis. Similarly to CAPS, but with a 3-4 orders 
of magnitude more potent agonist activity on TRPV1, RTX can induce Ca2+ cytotoxicity and 
eventually ablates these neurons by rapid necrosis, followed by removal of the cell debris  
[76, 88, 107, 119]. RTX has been shown to eliminate inflammatory pain by specific Ca2+ 
cytotoxicity in newborn [108] and adult rats [119], and it exerts an anti-nociceptive effect in 
adult mice [111], monkeys [170] and dogs [187]. A number of in vitro and in vivo 
experiments have validated the safety and efficacy of the molecular neurosurgery 
management of arthritic and cancer pain, even in large animals such as dogs and monkeys, 
promoting human trials and the registration of RTX as an alternative drug in pain 
inflammation and various neuropathy indications [170, 187]. Contrary to TRPV1 antagonists 
as painkillers, intraganglional or intrathecal RTX treatment provide a permanent solution to 
incurable chronic pain. 
Moreover, we have found that RTX-treated mice also display a loss of TRPA1-dependent 
chemical sensitivity, confirming previous observations that TRPV1 co-expresses with TRPA1 
in a number of nociceptive neurons in the PNS. The potential effect of RTX on TRPA1 is 
excluded by previous publications. For example, cultured DRG neurons of TRPV-/- mice did 
not show a stimulus-evoked rise in intracellular free Ca2+ in response to RTX, proving that 
none of the remaining TRP receptors are vanilloid-sensitive [188]. Moreover, I-RTX did not 
interfere with DRG neuron activation in response to TRPA1 agonists [162], confirming that 
TRPA1 does not bind vanilloid ligands. We can conclude that RTX-mediated molecular 
neurosurgery additionally eliminates most or all TRPA1-containing neurons as well via 
TRPV1 activation, as indicated by the almost complete loss of specific immunoreactivity in 
sensory nociceptors. The RNA diagnostics with RT-PCR technology in DRG samples from 
RTX-treated and untreated rats demonstrate a significant decrease of both receptors [163]. 
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The observation in these studies extend and corroborate the results of Ruparel et al. [189] that 
AITC can heterologously inactivate TRPV1, probably located in the same nociceptor neurons. 
However, Ruparel et al. interpreted their results as a consequence of TRPV1 desensitization 
involving signaling events. Although transient, functional desensitization based on signaling 
events might also be induced by low-dose vanilloids in other models [102, 110], in our case 
RTX treatment obviously induces the loss of both TRPV1+ and TRPA1+ neurons.  
As we have confirmed, the treated animals became insensitive to vanilloids for a lifetime, 
indicating that the mechanism is indeed deletion-, and not signaling-based. RTX-treated mice 
are also insensitive to AITC, which can occur only if TRPA1 expression is coincident with 
TRPV1 expression in the vast majority of nociceptive neurons that normally confer the pain 
signal to endogenous substances produced in pain and inflammation. Co-ablation of TRPV1+ 
neurons with TRPA1 receptors by the RTX treatment has been circumstantially verified in 
experiments carried out in TRPV1 knockouts. In concert with evidence here, TRPV1-/- 
genotyped mice still express TRPA1 in their inflammatory pain sensor neurons, and therefore 
preserve sensitivity to AITC [190] and behave like wild-types. The neuron subtype specificity 
of TRPA1 was characterized in cell cultures by Story et al. [168], who noted that TRPM8 is 
expressed in a distinct cell population. Moreover, the vast majority of TRPA1-positive cells 
were co-localized with the CGRP neuropeptide, another prominent biomarker of TRPV1+ 
inflammatory pain-sensing neurons. With regard to these data, two markedly distinct 
populations of cold-responsive neurons can be distinguished: 1, TRPM8-positive neurons that 
lack TRPV1 and TRPA1 expression and are resistant to RTX treatment, and 2, TRPA1+ 
neurons that express TRPV1 as well and can be deleted with either AITC or RTX. Adult mice 
treated with RTX as neonates exhibited an impaired response to both CAPS and AITC in eye 
wipe tests and agonist-laced water consumption assays. In hot plate experiments, the response 
time of the treated animals was not significantly different from that of normal controls. 
Similar to our results, Gamse et al. have found that mice treated with CAPS as neonates 
demonstrated normal response times in hot plate and tail-withdrawal latency tests. In contrast, 
mice treated at adulthood revealed greatly prolonged latencies in both thermal sensitivity. 
Thus, responses to noxious chemicals in adulthood were only moderately inhibited in mice 
treated as newborn, but almost completely abolished if the vanilloid was administered to 
adults [191]. Nociceptive thresholds reported in neonatal CAPS-treated animals are 
Discussion 
33 
apparently contradictory. Several groups have reported a small increase in the thermal 
nociceptive threshold [171, 192] whereas others detected little if any effect in hot plate tests 
[193, 194]. It has been claimed that perineural RTX selectively inhibits inflammatory 
hyperalgesia [195]. We have determined in serial experiments that the heat threshold increase 
depends on the efficacy of the RTX treatment: the heat insensitivity of the animal becomes 
more pronounced if RTX ablates TRPV1+ nociceptors almost completely. Chronic, repeated 
RTX gave the best results, while neonatal treatments were less effective. Based on 
comparative data collected from TRPV1-null mice (little [196] or no effect [197] in hot plate 
test), we can conclude that there might be additional heat receptors. The complete lack of 
signal transmitted by TRPV1+ neurons leads to the most complete heat insensitivity in mice 
lacking TRPV1+ neurons rather than the TRPV1 receptor only. Obata et al. noted that 
inflammation and nerve injury increase the expression of TRPA1, but not TRPM8, in DRG 
neurons. The occurrence of cold hyperalgesia coincided with NGF-induced up-regulation of 
TRPA1 in a distinct set of sensory neurons [198]. Moreover, through the intrathecal 
administration of an anti-sense-oligo specific for TRPA1, Katsura et al. could suppress nerve-
ligation-induced cold hyperalgesia, but anti-TRPM8 had little or any effect [199]. In contrast 
with these observations, we found that not TRPA1, but TRPM8 is the main cold sensor.  
To explain this unexpected finding, at least two alternative hypotheses can be proposed.  
First, following the RTX-mediated neuronal drop-out, the intense arborization of resistant 
nerve endings can produce NGF, a validated exocrine transducer of gene inducer in nerve 
injury, which might cause the overexpression of TRPM8, a prominent cold pain signal 
transducer [200]. In fact, in response to inflammations and nerve injuries, the NGF expression 
of nociceptors and thermoceptors is known to be induced in correlation with sensitization to 
cold and allodynia [201, 202]. Intraplantar injection of CAPS produces a transient thermal 
and mechanical hyperalgesia within three to six hours, that disappears by 24 hours. 
Interestingly, CAPS injection upregulates proinflammatory cytokines and NGF within 1 hour, 
after which the cytokine levels return to the control levels [203]. However, we did not observe 
the upregulation of TRPM8 channel in RTX-treated mice by Western blotting or RT-PCR.  
In accordance with this, DRG samples from RTX-treated and untreated rats did not display a 
significant change at the TRPM8 level [204]. 
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On the other hand, sensory stimuli are known to “compete” with each other for 
representation at the level of the brain. As an example, blind individuals have a better 
auditory ability than sighted subjects, revealing a mechanism that apparently compensates for 
the loss of vision [205]. Analogously, cold hypersensation might confer an imbalance in the 
representation of sensory stimuli signaling heat and cold at the levels of the CNS.  
Due to neuronal plasticity, mice treated at neonatal age can most likely compensate for the 
imbalance caused by that drop-out of C-type afferents neurons, while the effect of RTX 
treatment in adulthood can not be compensated by “fine-tuning”. Importantly, our 
experimental data in this paper predict a shift in heat perception in humans following RTX 
injection, as conceptualized in the clinical trial protocol to treat severe cancer pain.  
Similar changes might be expected during the application of reversible, specific inhibitors of 
TRPV1, currently in development by different pharmaceutical companies. Such a behavioral 
change, however, was not obvious in cancer/arthritis patient dogs treated via the intrathecal 
rout of application [187], nor in monkeys targeted with this molecular neurosurgery agent at 
the TG [170]. Nevertheless, clinical trial of RTX in cancer pain patients may provide the 
answers to this question via thorough monitoring of potential changes in cold sensation, if 
these take place in humans at all. 
After investigation of the effects caused by the deletion of the TRPV1+ neurons at the level 
of a whole organism, we focused on the working of the ion channel, itself.  
Testing the effects of various metal cations on the vanilloid-induced activity of the TRPV1 
channel, we demonstrated that Mg2+, Mn2+ or La3+ caused little or no decrease in channel 
activity, whereas Zn2+ proved to be a weak and only partial inhibitor of 2 µM CAPS-induced 
45Ca2+ uptake. The other cations effectively blocked the vanilloid-induced Ca2+ entry into 
TRPV1/HaCaT cells, with the following sequence of potency: Co2+ > Cd2+ > Ni2+ > Cu2+. 
It was reported by Nilius et al. [206] that Co2+ reduced the inward Ca2+ current through 
ECaC1 (TRPV5), a close relative of TRPV1, sharing around 30% homology with it.  
Fast and reversible recovery of the current upon washout of the inhibitor was detected during 
their experiments. Furthermore, they identified other M2+-s as effective inhibitors of the Ca2+ 
influx. Their results indicated the following overall blocking sequence: Pb2+ = Cu2+ = Gd3+ > 
Cd2+ > Zn2+ > La3+ >Co2+ > Fe2+ >> Fe3+. Zeng et al. found Cu2+ to be a potent inhibitor of the 
whole-cell current evoked by intracellular ADP-ribose through TRPM2, another member of 
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the TRP group. The inhibitory effect of Cu2+ was irreversible, and occurred only if Cu2+ was 
administered in outside-out patches, suggesting that the action site is located extracellularly. 
The TRPM2 current was also blocked by Hg2+, Pb2+, Fe2+ and Se2+ [207]. 
In accord with the above-mentioned findings, we also observed ion influx-inhibitory effects 
of M2+-s on the TRP channel. Depending on the TRP channel type, differences in the 
sequence of blocking potency could be detected. Furthermore, the blocking effects of the 
individual cations could be reversible or irreversible, depending on the channel type.  
The three channels are close relatives and share high degree of sequence and structural 
homology with one another, which explains the similar responses to M2+-s. Having diverged 
from a common ancestor, TRP channels operate on uniform principles. However, during 
evolution the TRP superfamily has evolved for various specialized functions. TRPV1 and 
TRPV5, for example, belong to different subgroups of the TRPV family; TRPV1-4 are 
non-ion-selective, whilst TRPV5-6 are highly Ca2+-selective. Hence, this functional 
adaptation may cause the differences in the M2+-evoked responses. 
As concerns our own results, Co2+ reduced not only the CAPS-induced but also the 
heat-induced 45Ca2+ influx. When increasing concentrations of both Co2+ and CAPS were 
applied, the Co2+ inhibition patterns indicated channel-blocking kinetics. Our dose-response 
and Co2+ accumulation experiments revealed a competition for binding sites and a co-entry 
mechanism. We presume that Co2+ inhibits TRPV1 through its ability to bind to the ion 
selectivity filter of the channel: it passes through the ion channel much more slowly than 
Ca2+. Ca2+ entry is also slowed down by the binding of Co2+, which occupies the appropriate 
amino acid residues of the ion selectivity filter. This hypothesis seems to be further supported 
by the findings of Sajadi [208], who determined the stability constants of the 1:1 complexes 
formed between M2+ and L-tryptophan and other amino acids. The sequence obtained in the 
case of tryptophan was Ca2+ < Mg2+ < Mn2+ < Co2+ < Ni2+ < Cu2+ > Zn2+, which follows the 
Irving-Williams sequence [209]. The order of the stability constants was similar in the cases 
of methionine, alanine, leucine, valine and glycine. The amino acid sequence of the putative 
pore region is STSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGD (Q8NER1, 
UniProt), containing all the tested amino acids but valine. The stability constants formed 
between M2+ and tryptophan were Ca2+: 2.55 ± 0.08; Mg2+: 2.84 ± 0.08; Mn2+: 3.34 ± 0.05; 
Co2+: 4.34 ± 0.07; Ni2+: 5.31 ± 0.06; Cu2+: 8.05 ± 0.05 and Zn2+: 5.00 ± 0.08. The stability 
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constants for Mg2+ and Mn2+ are close to that for Ca2+, so these ions can probably readily pass 
through the open channel of TRPV1. Co2+, Ni2+ and Cu2+ can be characterized by much 
higher complex-forming strength, shedding light on the elevated TRPV1-blocking potency. 
Interestingly, for these three M2+-s, an unexpected relationship can be observed between the 
stability constant and the TRPV1-blocking potency. The stronger the bond, the weaker the 
TRPV1-inhibition potency is. The ionic radii (in picometers) of these cations are Ca2+: 100; 
Mg2+: 72; Mn2+: 67; Co2+: 65; Ni2+: 69; Cu2+: 73 and Zn2+: 74 [210]. Ca2+ is likely to have the 
ideal ionic radius and stability constant in its reactions with amino acids in order to be 
effectively passed along the carbonyl groups of the peptide backbone in the ion selectivity 
filter and the pore loop. Co2+ has a medium stability constant and the smallest ionic radius, 
which is probably not adequate for efficient transport. These two parameters seem to be 
equally involved in the appropriate ion influx. The stronger the M2+-amino acid complex and 
the smaller the ionic radius is, the more probable it is that M2+ will block the Ca2+ influx 
through the TRPV1 channel. As another interesting finding in our experiments, Zn2+ seemed 
to be an only weak and partial inhibitor of the ion current. Its stability constant is almost as 
high as that of Co2+, suggesting a strong TRPV1-blocking ability, whereas its ionic radius is 
much larger than that of Co2+. Interestingly, the IC50 of Zn2+ is the second lowest exceeding 
only that of Co2+, but Zn2+ can achieve a decrease of merely 30% of the maximal ion influx. 
The TRPV1 channel is a non-selective cation channel, but still shows preference for Ca2+. 
The sequence of permeability is Ca2+ > Mg2+ > Na+ = K+ = Cs+ [30]. In addition to all these, 
TRPV1 also conducts protons [211]. Following prolonged exposure to agonists, TRPV1 
becomes permeable even to larger organic cations, including dyes such as YO-PRO1 and 
FM1-43 [178] and a lidocaine derivative QX-314 [179]. Increasing agonist concentration 
enhances the blocking ability of Co2+, suggesting a correlation between the increased efficacy 
of inhibition and the different open-state conformations of the TRPV1 channel. Further 
experiments (involving patch-clamp recordings) would be needed to clarify the inhibitory 
effect of Co2+ on the fluxes of the other cations or molecules mentioned above. However, no 
channel blocker or antagonist of TRPV1 has been reported that is able to block the flux of 
only one specific ion, and antagonists seem to block all these influxes. For example, CapZ 
blocks the influxes of both Ca2+ and Na+ [212]. Overall, we presume that Co2+ can also block 
the ion currents mentioned above. 
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Before the exploration of TRPV1 protein, Co2+ histochemistry was a very useful tool for the 
identification of vanilloid-sensitive primary afferent neurons with C- and Aδ fibers after in 
vivo experiments. Co2+ uptake and the post mortem determination of Co2+ deposits quite 
accurately identified C- and Aδ afferents, the neuronal subset that can be activated by 
treatment with a vanilloid agonist, CAPS [213, 214]. Likewise, as previously documented in a 
subpopulation of pseudo-unipolar neurons [215], we have now demonstrated selective 
vanilloid-induced Co2+ accumulation in the cytosol of DRG primary cultures and TRPV1-
transfected HaCaT and 3T3 cells. The accumulation of Co2+ could be blocked by RuRed or 
CapZ in a dose-dependent manner. The CAPS-induced Ca2+ and Co2+ influxes in TRPV1/3T3 
cells proved to be due exclusively to the TRPV1 channel and not to VGCC activity. 
Co2+ inhibited the pain-evoked defensive movements in eye wipe tests in response to 
pungent vanilloids. However, not only TRPV1, but also some other Ca2+ channels of the 
sensory neurons, such as VGCCs, can be blocked by Co2+ [216]. VGCCs share structural 
homology with the TRPV1 channel. The α1 subunit of VGCCs is organized in four 
homologous domains (I-IV), with six transmembrane segments (S1-S6) in each [217].  
There is an additional region (H5) between S5 and S6 which forms a part of the pore region of 
the channel [218]. Within each H5 region, there exist conserved glutamate residues, 
significantly homologous to conventional EF-hand motifs [219], acting as the selectivity filter 
[220]. Mn2+, Ni2+ and Cd2+, in contrast with Co2+, are known to be stronger blockers of the 
VGCCs. Cu2+, Mn2+ and Co2+ blocked high-voltage activated currents conducted by Ba2+ with 
IC50-s of 920 nM, 58 µM and 65 µM, respectively [221, 222]. All of these ions exert their 
effects through high-affinity docking to the cation-binding site at the IIIS5–H5 pore region of 
the VGCCs [223, 224]. Since Co2+ has a higher IC50 for VGCCs (≈65 µM) than for TRPV1 
(≈15 µM), we can conclude that decrease in the number of eye wipes might be due, at least 
partially, to an inhibitory effect of Co2+ on TRPV1. 
Most painkiller drugs are competitive agonists and target the CAPS-binding domain [225]. 
As the 646DLEFTENYD acidic tetrad sequence of the TRPV1 receptor is unique among Ca2+-
binding proteins, this permits the design of painkillers targeting the channel orifice of TRPV1 
and acting as channel blockers. A deeper comprehension of the structural background and 
dynamics of the competition of Ca2+ with other M2+-s for entry may result in the discovery of 
novel channel blocker painkillers. Furthermore, our data can facilitate a more complete 
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understanding of the structure and function of the TRPV1. The data depicted in Table 1 can 
provide a powerful tool for building an in silico model of the channel. Our experimental data 
may effectively contribute to the fine-tuning of the ion selectivity filter region of the model. 
Our results may additionally contribute to the resolution of the architecture of not only the 
TRPV1 but all TRP superfamily members. The specific effects of the selected M2+-s on the 
given ion channel pore region can serve as a valuable constraint during in silico modeling of 
the pore region. By comparing the different cation action profiles of the pore regions, the 
models can be fine-tuned. The information on the structure-function relationship of TRPV1 
may promote the discovery of new, promising, more effective and safe drugs for the treatment 
of neurogenic inflammation and pain-related diseases and may offer new opportunities for 
therapeutic interventions. 
 
7. Summary 
 
The aims of this research were to determine sensory modalities that may be lost after the 
RTX treatment of newborn or adult mice, to dissect potential side-effect(s) of molecular 
neurosurgery, to gather information about the structure and function of the channel by 
investigating the effects of M2+ on the TRPV1 and by collecting the literature data on the 
functionally important point mutations of the channel for prospective in silico modeling. 
 
The findings of the research work can be summarized as follows: 
1, 
 AITC had no effect on TRPV1-expressing cells. 
2, 
 Mice treated either with one dose of RTX two days post-natal, or one dose of RTX at 
adult age, or daily with a dose of RTX for three days at adult age completely lost their 
sensitivity to vanilloids and to AITC. 
 Immunohistological staining and Western blotting experiments confirmed TRPV1 and 
TRPA1 loss in the DRG and TG of mice treated with one dose of RTX as neonates, or 
one dose of RTX at adult age, or daily with a dose of RTX for three days at adult age. 
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 These data indicate that TRPA1 expression is coincident with TRPV1 expression in the 
vast majority of nociceptive neurons that normally confer pain signal to endogenous 
substances produced in pain and inflammation. 
3,  
 Mice treated with RTX two days post-natal and tested at the age of two months 
interestingly showed no change in temperature sensitivity either to heat or to cold. Due 
to neuronal plasticity, mice treated at neonatal age can most likely compensate for the 
imbalance caused by that drop-out of C-type afferents neurons. 
 Mice treated with one dose of RTX at adult age become less sensitive to heat and, 
surprisingly, more sensitive to cold. Two hypotheses can be put forward to explain this 
finding: 1, The NGF-mediated overexpression of TRPM8 caused by TRPV1+ neuron 
loss. 2, The imbalance caused by the drop-out of C-type afferent neurons may cause 
alterations in the representation of sensory stimuli signaling heat and cold at the levels 
of the CNS. 
 Mice treated daily with a dose of RTX for three days at adult age lost their heat 
sensitivity to a higher extent as compared with mice subjected to acute treatment, 
because the heat threshold increase depends on the efficacy of the RTX treatment. The 
heat insensitivity of the animal becomes more pronounced if RTX ablates TRPV1+ 
nociceptors almost completely. Chronic, repeated RTX treatment gave the best results, 
while neonatal treatments were less effective. 
 Immunohistological staining and Western blotting experiments indicated that TRPM8+ 
cells remained intact in the DRG and TG of mice treated with one dose of RTX as 
neonates, or one dose of RTX at adult age, or daily with a dose of RTX for three days at 
adult age. 
 On the basis of these data, two markedly distinct populations of cold-responsive neurons 
can be distinguished: 1, TRPM8+ neurons that lack TRPV1 and TRPA1 expression and 
are resistant to RTX treatment, and 2, TRPA1+ neurons that express TRPV1 as well and 
can be deleted with either AITC or RTX. 
4, 
 Neither Mg2+, Mn2+ nor La3+ significantly changed the function of TRPV1. 
 Zn2+ proved to be a weak and only partial inhibitor of the CAPS-induced 45Ca2+ uptake. 
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 Co2+, Cd2+, Ni2+ and Cu2+ effectively blocked the vanilloid-induced Ca2+ entry into 
TRPV1/HaCaT cells, with the following sequence of potency: Co2+ > Cd2+ > Ni2+ > 
Cu2+. 
 Co2+ reduced both the heat and CAPS-induced 45Ca2+ influx to a similar extent as did 
RuRed, AMI or R4W2. 
 Increasing concentrations of Co2+ decreased only the Emax of Ca2+ entry in a vanilloid-
induced 45Ca2+-uptake assay; the affinity of CAPS for TRPV1 did not change. Co2+ 
inhibition patterns indicated channel-blocking kinetics. 
 Increasing cold Ca2+ concentration, in a vanilloid-induced 45Ca2+-uptake assay, 
decreased the inhibitory effect of Co2+, showing that the effect of Co2+ on Ca2+ entry 
mainly depends on the competition for entry sites. 
 Increasing CAPS concentration in a vanilloid-induced 45Ca2+-uptake assay, caused a 
shift in the IC50 of Co2+, increasing agonist concentration enhancing the blocking ability 
of Co2+, suggesting that the increased efficiency of inhibition correlates with the 
different open-state conformations of the TRPV1 channel. 
 We presume that the efficacy of the TRPV1 blocking effect caused by M2+ is 
determined by the combined impact of the ionic radii of the M2+ and the stability 
constants of the complexes formed between M2+ and amino acids. Ca2+ is likely to have 
the ideal ionic radius and stability constant in its reactions with amino acids in order to 
be effectively passed along the carbonyl groups of the peptide backbone in the ion 
selectivity filter and the pore loop. The stronger the M2+-amino acid complex and the 
smaller the ionic radius is, the more probable it is that M2+ will block the Ca2+ influx 
through the TRPV1 channel. 
 (NH4)nSx histochemistry experiments on rTRPV1/HaCaT and rTRPV1/3T3 cell lines 
and sensory neuron cultures prepared from DRGs of rat embryos revealed that Co2+ not 
only competes with Ca2+, but also enters into the cytosol of TRPV1+ cells, through the 
TRPV1 channel.  
 (NH4)nSx histochemistry experiments following extracellular KCl exposure of 
rTRPV1/3T3 cells ruled out the role of VGCCs in Co2+ accumulation. 
 Co2+ decreased the frequency of vanilloid-evoked defending movements in tests of eye 
wiping. 
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5, 
 An overview of the currently available results of site-directed mutagenesis studies on 
TRPV1 receptor was created and published [185] containing summarized information 
on 112 unique mutated sites along the TRPV1. The mutations influence the effects or 
binding of different agonists, antagonists, and channel blockers, alter the responsiveness 
to heat, acid, and voltage dependence, affect the channel pore characteristics, and 
influence the regulation of the receptor function by phosphorylation, glycosylation, 
CaM, PIP2, ATP and lipid binding. 
Acknowledgement 
42 
8. Acknowledgement 
 
First of all I wish to express my deep gratitude to my supervisors, Dr. Gerda Szakonyi, Prof. 
Dr. György Dombi and Dr. Zoltán Oláh, for their guidance and encouragement, especially 
during the more challenging moments of my work. 
I would like to thank Katalin Jósvay and Csaba Vizler for their generous help and advice in 
the experimental work, and for critically reviewing the manuscript. 
I express my special thanks to Erzsébet Kusz for her supportive help and useful advice in the 
tissue culture laboratory. 
I would also like to thank all of my co-authors and colleagues in the Institute of 
Pharmaceutical Analysis and in the Institute of the Biochemistry of Biological Research 
Centre of the Hungarian Academy of Sciences for their kind collaboration. 
I am deeply grateful to my family and friends for their patience and love. 
 
 
Financial support 
This work was supported by grants from the National Office for Research and Technology 
(OMFB-01630; OMFB-01703, OMFB-01576/2006, BAROSS_DA07-DA_TECH_07-2008-
0043 and ERC_09_HU 3D_TRPV1). The Project named “TÁMOP-4.2.1/B-09/1/KONV-
2010-0005-Creating the Center of Excellence at the University of Szeged” was supported by 
the European Union and co-financed by the European Regional Development Fund. 
 
References 
43 
9. References 
 
1. Clapham DE: TRP channels as cellular sensors. Nature 2003, 426:517-524. 
2. Szallasi A, Cortright DN, Blum CA, Eid SR: The vanilloid receptor TRPV1: 10 
years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 
2007, 6:357-372. 
3. Fernandez-Ballester G, Ferrer-Montiel A: Molecular modeling of the full-length 
human TRPV1 channel in closed and desensitized states. J Membr Biol 2008, 
223:161-172. 
4. Carlson AE, Westenbroek RE, Quill T, Ren D, Clapham DE, Hille B, Garbers DL, 
Babcock DF: CatSper1 required for evoked Ca2+ entry and control of flagellar 
function in sperm. Proc Natl Acad Sci U S A 2003, 100:14864-14868. 
5. Cosens DJ, Manning A: Abnormal electroretinogram from a Drosophila mutant. 
Nature 1969, 224:285-287. 
6. O'Neill J, Brock C, Olesen AE, Andresen T, Nilsson M, Dickenson AH: Unravelling 
the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev 
2012, 64:939-971. 
7. Venkatachalam K, Montell C: TRP channels. Annu Rev Biochem 2007, 76:387-417. 
8. Owsianik G, Talavera K, Voets T, Nilius B: Permeation and selectivity of TRP 
channels. Annu Rev Physiol 2006, 68:685-717. 
9. Li M, Yu Y, Yang J: Structural biology of TRP channels. Adv Exp Med Biol 2011, 
704:1-23. 
10. Landry Y, Gies JP: Drugs and their molecular targets: an updated overview. 
Fundam Clin Pharmacol 2008, 22:1-18. 
11. Okuhara DY, Hsia AY, Xie M: Transient receptor potential channels as drug 
targets. Expert Opin Ther Targets 2007, 11:391-401. 
12. Nilius B, Vennekens R: TRP Channels and Human Diseases. In Vanilloid Receptor 
TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders. Edited 
by Gomtsyan A, Faltynek CR: John Wiley & Sons, Inc., Hoboken, NJ, USA.; 2010 
13. Xu SZ, Zeng F, Boulay G, Grimm C, Harteneck C, Beech DJ: Block of TRPC5 
channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and 
voltage-dependent effect. Br J Pharmacol 2005, 145:405-414. 
14. Jin X, Touhey J, Gaudet R: Structure of the N-terminal ankyrin repeat domain of 
the TRPV2 ion channel. J Biol Chem 2006, 281:25006-25010. 
15. McCleverty CJ, Koesema E, Patapoutian A, Lesley SA, Kreusch A: Crystal structure 
of the human TRPV2 channel ankyrin repeat domain. Protein Sci 2006, 15:2201-
2206. 
16. Lishko PV, Procko E, Jin X, Phelps CB, Gaudet R: The ankyrin repeats of TRPV1 
bind multiple ligands and modulate channel sensitivity. Neuron 2007, 54:905-918. 
17. Hellwig N, Albrecht N, Harteneck C, Schultz G, Schaefer M: Homo- and 
heteromeric assembly of TRPV channel subunits. J Cell Sci 2005, 118:917-928. 
18. Jung J, Lee SY, Hwang SW, Cho H, Shin J, Kang YS, Kim S, Oh U: Agonist 
recognition sites in the cytosolic tails of vanilloid receptor 1. J Biol Chem 2002, 
277:44448-44454. 
19. Mosavi LK, Cammett TJ, Desrosiers DC, Peng ZY: The ankyrin repeat as 
molecular architecture for protein recognition. Protein Sci 2004, 13:1435-1448. 
References 
44 
20. Sedgwick SG, Smerdon SJ: The ankyrin repeat: a diversity of interactions on a 
common structural framework. Trends Biochem Sci 1999, 24:311-316. 
21. Vennekens R, Hoenderop JG, Prenen J, Stuiver M, Willems PH, Droogmans G, Nilius 
B, Bindels RJ: Permeation and gating properties of the novel epithelial Ca(2+) 
channel. J Biol Chem 2000, 275:3963-3969. 
22. Yue L, Peng JB, Hediger MA, Clapham DE: CaT1 manifests the pore properties of 
the calcium-release-activated calcium channel. Nature 2001, 410:705-709. 
23. Dhaka A, Viswanath V, Patapoutian A: Trp ion channels and temperature 
sensation. Annu Rev Neurosci 2006, 29:135-161. 
24. Lawson JJ, McIlwrath SL, Woodbury CJ, Davis BM, Koerber HR: TRPV1 unlike 
TRPV2 is restricted to a subset of mechanically insensitive cutaneous nociceptors 
responding to heat. J Pain 2008, 9:298-308. 
25. Xu H, Delling M, Jun JC, Clapham DE: Oregano, thyme and clove-derived flavors 
and skin sensitizers activate specific TRP channels. Nat Neurosci 2006, 9:628-635. 
26. Moqrich A, Hwang SW, Earley TJ, Petrus MJ, Murray AN, Spencer KS, Andahazy 
M, Story GM, Patapoutian A: Impaired thermosensation in mice lacking TRPV3, a 
heat and camphor sensor in the skin. Science 2005, 307:1468-1472. 
27. Nilius B, Owsianik G, Voets T, Peters JA: Transient receptor potential cation 
channels in disease. Physiol Rev 2007, 87:165-217. 
28. Hoenderop JG, van der Kemp AW, Hartog A, van de Graaf SF, van Os CH, Willems 
PH, Bindels RJ: Molecular identification of the apical Ca2+ channel in 1, 25-
dihydroxyvitamin D3-responsive epithelia. J Biol Chem 1999, 274:8375-8378. 
29. Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM, Hediger 
MA: Molecular cloning and characterization of a channel-like transporter 
mediating intestinal calcium absorption. J Biol Chem 1999, 274:22739-22746. 
30. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The 
capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 
1997, 389:816-824. 
31. Kedei N, Szabo T, Lile JD, Treanor JJ, Olah Z, Iadarola MJ, Blumberg PM: Analysis 
of the native quaternary structure of vanilloid receptor 1. J Biol Chem 2001, 
276:28613-28619. 
32. Moiseenkova-Bell VY, Stanciu LA, Serysheva, II, Tobe BJ, Wensel TG: Structure of 
TRPV1 channel revealed by electron cryomicroscopy. Proc Natl Acad Sci U S A 
2008, 105:7451-7455. 
33. Vriens J, Appendino G, Nilius B: Pharmacology of vanilloid transient receptor 
potential cation channels. Mol Pharmacol 2009, 75:1262-1279. 
34. Szallasi A, Blumberg PM: Resiniferatoxin, a phorbol-related diterpene, acts as an 
ultrapotent analog of capsaicin, the irritant constituent in red pepper. 
Neuroscience 1989, 30:515-520. 
35. Hergenhahn M, Kusumoto S, Hecker E: On the active principles of the spurge 
family (Euphorbiaceae). V. Extremely skin-irritant and moderately tumor-
promoting diterpene esters from Euphorbia resinifera Berg. J Cancer Res Clin 
Oncol 1984, 108:98-109. 
36. Szallasi A: The vanilloid (capsaicin) receptor: receptor types and species 
differences. Gen Pharmacol 1994, 25:223-243. 
References 
45 
37. Witte DG, Cassar SC, Masters JN, Esbenshade T, Hancock AA: Use of a fluorescent 
imaging plate reader--based calcium assay to assess pharmacological differences 
between the human and rat vanilloid receptor. J Biomol Screen 2002, 7:466-475. 
38. Culshaw AJ, Bevan S, Christiansen M, Copp P, Davis A, Davis C, Dyson A, 
Dziadulewicz EK, Edwards L, Eggelte H, et al: Identification and biological 
characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists 
that are effective in models of chronic pain. J Med Chem 2006, 49:471-474. 
39. Pearce LV, Petukhov PA, Szabo T, Kedei N, Bizik F, Kozikowski AP, Blumberg PM: 
Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol 
Chem 2004, 2:2281-2286. 
40. Xu S, Cheng Y, Keast JR, Osborne PB: 17beta-estradiol activates estrogen receptor 
beta-signalling and inhibits transient receptor potential vanilloid receptor 1 
activation by capsaicin in adult rat nociceptor neurons. Endocrinology 2008, 
149:5540-5548. 
41. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V: Overlap between 
the ligand recognition properties of the anandamide transporter and the VR1 
vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like 
activity. FEBS Lett 2000, 483:52-56. 
42. Ross RA: Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003, 
140:790-801. 
43. Ahern GP: Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol 
Chem 2003, 278:30429-30434. 
44. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim 
D, Oh U: Direct activation of capsaicin receptors by products of lipoxygenases: 
endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000, 97:6155-
6160. 
45. Jordt SE, Tominaga M, Julius D: Acid potentiation of the capsaicin receptor 
determined by a key extracellular site. Proc Natl Acad Sci U S A 2000, 97:8134-
8139. 
46. Szallasi A, Blumberg PM: Vanilloid (Capsaicin) receptors and mechanisms. 
Pharmacol Rev 1999, 51:159-212. 
47. Yang BH, Piao ZG, Kim YB, Lee CH, Lee JK, Park K, Kim JS, Oh SB: Activation of 
vanilloid receptor 1 (VR1) by eugenol. J Dent Res 2003, 82:781-785. 
48. Jara-Oseguera A, Simon SA, Rosenbaum T: TRPV1: on the road to pain relief. Curr 
Mol Pharmacol 2008, 1:255-269. 
49. Premkumar LS, Qi ZH, Van Buren J, Raisinghani M: Enhancement of potency and 
efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. J 
Neurophysiol 2004, 91:1442-1449. 
50. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM: Modulation of 
trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists 
anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br 
J Pharmacol 2004, 141:1118-1130. 
51. Suh YG, Oh U: Activation and activators of TRPV1 and their pharmaceutical 
implication. Curr Pharm Des 2005, 11:2687-2698. 
52. Liu L, Simon SA: Similarities and differences in the currents activated by 
capsaicin, piperine, and zingerone in rat trigeminal ganglion cells. J Neurophysiol 
1996, 76:1858-1869. 
References 
46 
53. McNamara FN, Randall A, Gunthorpe MJ: Effects of piperine, the pungent 
component of black pepper, at the human vanilloid receptor (TRPV1). Br J 
Pharmacol 2005, 144:781-790. 
54. Dedov VN, Tran VH, Duke CC, Connor M, Christie MJ, Mandadi S, Roufogalis BD: 
Gingerols: a novel class of vanilloid receptor (VR1) agonists. Br J Pharmacol 
2002, 137:793-798. 
55. Iwasaki Y, Morita A, Iwasawa T, Kobata K, Sekiwa Y, Morimitsu Y, Kubota K, 
Watanabe T: A nonpungent component of steamed ginger--[10]-shogaol--increases 
adrenaline secretion via the activation of TRPV1. Nutr Neurosci 2006, 9:169-178. 
56. Jung J, Hwang SW, Kwak J, Lee SY, Kang CJ, Kim WB, Kim D, Oh U: Capsaicin 
binds to the intracellular domain of the capsaicin-activated ion channel. J 
Neurosci 1999, 19:529-538. 
57. Bootman MD, Collins TJ, Mackenzie L, Roderick HL, Berridge MJ, Peppiatt CM: 2-
aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ 
entry but an inconsistent inhibitor of InsP3-induced Ca2+ release. FASEB J 2002, 
16:1145-1150. 
58. Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, Yamoah EN, 
Basbaum AI, Julius D: TRPA1 mediates the inflammatory actions of 
environmental irritants and proalgesic agents. Cell 2006, 124:1269-1282. 
59. Macpherson LJ, Geierstanger BH, Viswanath V, Bandell M, Eid SR, Hwang S, 
Patapoutian A: The pungency of garlic: activation of TRPA1 and TRPV1 in 
response to allicin. Curr Biol 2005, 15:929-934. 
60. Szolcsanyi J, Sandor Z: Multisteric TRPV1 nocisensor: a target for analgesics. 
Trends Pharmacol Sci 2012, 33:646-655. 
61. Dray A, Bettaney J, Forster P: Resiniferatoxin, a potent capsaicin-like stimulator of 
peripheral nociceptors in the neonatal rat tail in vitro. Br J Pharmacol 1990, 
99:323-326. 
62. Docherty RJ, Yeats JC, Piper AS: Capsazepine block of voltage-activated calcium 
channels in adult rat dorsal root ganglion neurones in culture. Br J Pharmacol 
1997, 121:1461-1467. 
63. Liu L, Simon SA: Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic 
acetylcholine receptors in rat trigeminal ganglia. Neurosci Lett 1997, 228:29-32. 
64. Xia R, Dekermendjian K, Lullau E, Dekker N: TRPV1: a therapy target that 
attracts the pharmaceutical interests. Adv Exp Med Biol 2011, 704:637-665. 
65. Seabrook GR, Sutton KG, Jarolimek W, Hollingworth GJ, Teague S, Webb J, Clark 
N, Boyce S, Kerby J, Ali Z, et al: Functional properties of the high-affinity TRPV1 
(VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate 
ester) iodo-resiniferatoxin. J Pharmacol Exp Ther 2002, 303:1052-1060. 
66. Planells-Cases R, Aracil A, Merino JM, Gallar J, Perez-Paya E, Belmonte C, 
Gonzalez-Ros JM, Ferrer-Montiel AV: Arginine-rich peptides are blockers of VR-1 
channels with analgesic activity. FEBS Lett 2000, 481:131-136. 
67. Himmel HM, Kiss T, Borvendeg SJ, Gillen C, Illes P: The arginine-rich hexapeptide 
R4W2 is a stereoselective antagonist at the vanilloid receptor 1: a Ca2+ imaging 
study in adult rat dorsal root ganglion neurons. J Pharmacol Exp Ther 2002, 
301:981-986. 
68. Gavva NR: Body-temperature maintenance as the predominant function of the 
vanilloid receptor TRPV1. Trends Pharmacol Sci 2008, 29:550-557. 
References 
47 
69. Gavva NR, Bannon AW, Surapaneni S, Hovland DN, Jr., Lehto SG, Gore A, Juan T, 
Deng H, Han B, Klionsky L, et al: The vanilloid receptor TRPV1 is tonically 
activated in vivo and involved in body temperature regulation. J Neurosci 2007, 
27:3366-3374. 
70. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak 
A, Darling M, Gore A, et al: Pharmacological blockade of the vanilloid receptor 
TRPV1 elicits marked hyperthermia in humans. Pain 2008, 136:202-210. 
71. Wang S, Poon K, Oswald RE, Chuang HH: Distinct modulations of human 
capsaicin receptor by protons and magnesium through different domains. J Biol 
Chem 2010, 285:11547-11556. 
72. Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, Nilius B: The 
principle of temperature-dependent gating in cold- and heat-sensitive TRP 
channels. Nature 2004, 430:748-754. 
73. Ma W, Quirion R: Inflammatory mediators modulating the transient receptor 
potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and 
neuropathic pain. Expert Opin Ther Targets 2007, 11:307-320. 
74. Rosenbaum T, Simon SA: TRPV1 Receptors and Signal Transduction. 2007. 
75. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann 
BE, Basbaum AI, Julius D: The cloned capsaicin receptor integrates multiple pain-
producing stimuli. Neuron 1998, 21:531-543. 
76. Olah Z, Szabo T, Karai L, Hough C, Fields RD, Caudle RM, Blumberg PM, Iadarola 
MJ: Ligand-induced dynamic membrane changes and cell deletion conferred by 
vanilloid receptor 1. J Biol Chem 2001, 276:11021-11030. 
77. Sprague J, Harrison C, Rowbotham DJ, Smart D, Lambert DG: Temperature-
dependent activation of recombinant rat vanilloid VR1 receptors expressed in 
HEK293 cells by capsaicin and anandamide. Eur J Pharmacol 2001, 423:121-125. 
78. De Petrocellis L, Harrison S, Bisogno T, Tognetto M, Brandi I, Smith GD, Creminon 
C, Davis JB, Geppetti P, Di Marzo V: The vanilloid receptor (VR1)-mediated 
effects of anandamide are potently enhanced by the cAMP-dependent protein 
kinase. J Neurochem 2001, 77:1660-1663. 
79. Rathee PK, Distler C, Obreja O, Neuhuber W, Wang GK, Wang SY, Nau C, Kress M: 
PKA/AKAP/VR-1 module: A common link of Gs-mediated signaling to thermal 
hyperalgesia. J Neurosci 2002, 22:4740-4745. 
80. Vlachova V, Teisinger J, Susankova K, Lyfenko A, Ettrich R, Vyklicky L: Functional 
role of C-terminal cytoplasmic tail of rat vanilloid receptor 1. J Neurosci 2003, 
23:1340-1350. 
81. Bhave G, Hu HJ, Glauner KS, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RWt: 
Protein kinase C phosphorylation sensitizes but does not activate the capsaicin 
receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci U S 
A 2003, 100:12480-12485. 
82. Zhang X, Du XN, Zhang GH, Jia ZF, Chen XJ, Huang DY, Liu BY, Zhang HL: 
Agonist-dependent potentiation of vanilloid receptor transient receptor potential 
vanilloid type 1 function by stilbene derivatives. Mol Pharmacol 2012, 81:689-700. 
83. Tominaga M, Wada M, Masu M: Potentiation of capsaicin receptor activity by 
metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and 
hyperalgesia. Proc Natl Acad Sci U S A 2001, 98:6951-6956. 
References 
48 
84. Varga A, Bolcskei K, Szoke E, Almasi R, Czeh G, Szolcsanyi J, Petho G: Relative 
roles of protein kinase A and protein kinase C in modulation of transient 
receptor potential vanilloid type 1 receptor responsiveness in rat sensory neurons 
in vitro and peripheral nociceptors in vivo. Neuroscience 2006, 140:645-657. 
85. Olah Z, Karai L, Iadarola MJ: Protein kinase C(alpha) is required for vanilloid 
receptor 1 activation. Evidence for multiple signaling pathways. J Biol Chem 
2002, 277:35752-35759. 
86. Wang Y, Kedei N, Wang M, Wang QJ, Huppler AR, Toth A, Tran R, Blumberg PM: 
Interaction between protein kinase Cmu and the vanilloid receptor type 1. J Biol 
Chem 2004, 279:53674-53682. 
87. Jung J, Shin JS, Lee SY, Hwang SW, Koo J, Cho H, Oh U: Phosphorylation of 
vanilloid receptor 1 by Ca2+/calmodulin-dependent kinase II regulates its 
vanilloid binding. J Biol Chem 2004, 279:7048-7054. 
88. Jin X, Morsy N, Winston J, Pasricha PJ, Garrett K, Akbarali HI: Modulation of 
TRPV1 by nonreceptor tyrosine kinase, c-Src kinase. Am J Physiol Cell Physiol 
2004, 287:C558-563. 
89. Docherty RJ, Yeats JC, Bevan S, Boddeke HW: Inhibition of calcineurin inhibits 
the desensitization of capsaicin-evoked currents in cultured dorsal root ganglion 
neurones from adult rats. Pflugers Arch 1996, 431:828-837. 
90. Koplas PA, Rosenberg RL, Oxford GS: The role of calcium in the desensitization of 
capsaicin responses in rat dorsal root ganglion neurons. J Neurosci 1997, 17:3525-
3537. 
91. Prescott ED, Julius D: A modular PIP2 binding site as a determinant of capsaicin 
receptor sensitivity. Science 2003, 300:1284-1288. 
92. Liu B, Zhang C, Qin F: Functional recovery from desensitization of vanilloid 
receptor TRPV1 requires resynthesis of phosphatidylinositol 4,5-bisphosphate. J 
Neurosci 2005, 25:4835-4843. 
93. Stein AT, Ufret-Vincenty CA, Hua L, Santana LF, Gordon SE: Phosphoinositide 3-
kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the 
plasma membrane. J Gen Physiol 2006, 128:509-522. 
94. Ufret-Vincenty CA, Klein RM, Hua L, Angueyra J, Gordon SE: Localization of the 
PIP2 sensor of TRPV1 ion channels. J Biol Chem 2011, 286:9688-9698. 
95. Yao J, Qin F: Interaction with phosphoinositides confers adaptation onto the 
TRPV1 pain receptor. PLoS Biol 2009, 7:e46. 
96. Levitan I, Fang Y, Rosenhouse-Dantsker A, Romanenko V: Cholesterol and ion 
channels. Subcell Biochem 2010, 51:509-549. 
97. Levitan I, Christian AE, Tulenko TN, Rothblat GH: Membrane cholesterol content 
modulates activation of volume-regulated anion current in bovine endothelial 
cells. J Gen Physiol 2000, 115:405-416. 
98. Levitan I: Cholesterol and Kir channels. IUBMB Life 2009, 61:781-790. 
99. Liu M, Huang W, Wu D, Priestley JV: TRPV1, but not P2X, requires cholesterol 
for its function and membrane expression in rat nociceptors. Eur J Neurosci 2006, 
24:1-6. 
100. Szoke E, Borzsei R, Toth DM, Lengl O, Helyes Z, Sandor Z, Szolcsanyi J: Effect of 
lipid raft disruption on TRPV1 receptor activation of trigeminal sensory neurons 
and transfected cell line. Eur J Pharmacol 2010, 628:67-74. 
References 
49 
101. Santha P, Oszlacs O, Dux M, Dobos I, Jancso G: Inhibition of glucosylceramide 
synthase reversibly decreases the capsaicin-induced activation and TRPV1 
expression of cultured dorsal root ganglion neurons. Pain 2010, 150:103-112. 
102. Numazaki M, Tominaga T, Takeuchi K, Murayama N, Toyooka H, Tominaga M: 
Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc 
Natl Acad Sci U S A 2003, 100:8002-8006. 
103. Rosenbaum T, Gordon-Shaag A, Munari M, Gordon SE: Ca2+/calmodulin 
modulates TRPV1 activation by capsaicin. J Gen Physiol 2004, 123:53-62. 
104. Vyklicky L, Novakova-Tousova K, Benedikt J, Samad A, Touska F, Vlachova V: 
Calcium-dependent desensitization of vanilloid receptor TRPV1: a mechanism 
possibly involved in analgesia induced by topical application of capsaicin. Physiol 
Res 2008, 57 Suppl 3:S59-68. 
105. Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA: Protein kinase C 
activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, 
heat and anandamide. J Physiol 2001, 534:813-825. 
106. Susankova K, Tousova K, Vyklicky L, Teisinger J, Vlachova V: Reducing and 
oxidizing agents sensitize heat-activated vanilloid receptor (TRPV1) current. Mol 
Pharmacol 2006, 70:383-394. 
107. Cesare P, Dekker LV, Sardini A, Parker PJ, McNaughton PA: Specific involvement 
of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 
1999, 23:617-624. 
108. Premkumar LS, Ahern GP: Induction of vanilloid receptor channel activity by 
protein kinase C. Nature 2000, 408:985-990. 
109. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, 
Julius D: Bradykinin and nerve growth factor release the capsaicin receptor from 
PtdIns(4,5)P2-mediated inhibition. Nature 2001, 411:957-962. 
110. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RWt: cAMP-dependent 
protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct 
phosphorylation. Neuron 2002, 35:721-731. 
111. Shin HJ, Gye MH, Chung KH, Yoo BS: Activity of protein kinase C modulates the 
apoptosis induced by polychlorinated biphenyls in human leukemic HL-60 cells. 
Toxicol Lett 2002, 135:25-31. 
112. Bevan S, Andersson DA: TRP channel antagonists for pain--opportunities beyond 
TRPV1. Curr Opin Investig Drugs 2009, 10:655-663. 
113. Cortright DN, Szallasi A: TRP channels and pain. Curr Pharm Des 2009, 15:1736-
1749. 
114. Stucky CL, Dubin AE, Jeske NA, Malin SA, McKemy DD, Story GM: Roles of 
transient receptor potential channels in pain. Brain Res Rev 2009, 60:2-23. 
115. Fernandes ES, Russell FA, Spina D, McDougall JJ, Graepel R, Gentry C, Staniland 
AA, Mountford DM, Keeble JE, Malcangio M, et al: A distinct role for transient 
receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 
1, in tumor necrosis factor alpha-induced inflammatory hyperalgesia and 
Freund's complete adjuvant-induced monarthritis. Arthritis Rheum 2011, 63:819-
829. 
116. Fernandes ES, Fernandes MA, Keeble JE: The functions of TRPA1 and TRPV1: 
moving away from sensory nerves. Br J Pharmacol 2012, 166:510-521. 
References 
50 
117. Alawi K, Keeble J: The paradoxical role of the transient receptor potential 
vanilloid 1 receptor in inflammation. Pharmacol Ther 2010, 125:181-195. 
118. Dux M, Santha P, Jancso G: The role of chemosensitive afferent nerves and TRP 
ion channels in the pathomechanism of headaches. Pflugers Arch 2012, 464:239-
248. 
119. Karai L, Brown DC, Mannes AJ, Connelly ST, Brown J, Gandal M, Wellisch OM, 
Neubert JK, Olah Z, Iadarola MJ: Deletion of vanilloid receptor 1-expressing 
primary afferent neurons for pain control. J Clin Invest 2004, 113:1344-1352. 
120. Szabo T, Olah Z, Iadarola MJ, Blumberg PM: Epidural resiniferatoxin induced 
prolonged regional analgesia to pain. Brain Res 1999, 840:92-98. 
121. Zhou HY, Zhang HM, Chen SR, Pan HL: Increased nociceptive input rapidly 
modulates spinal GABAergic transmission through endogenously released 
glutamate. J Neurophysiol 2007, 97:871-882. 
122. Caudle RM, Karai L, Mena N, Cooper BY, Mannes AJ, Perez FM, Iadarola MJ, Olah 
Z: Resiniferatoxin-induced loss of plasma membrane in vanilloid receptor 
expressing cells. Neurotoxicology 2003, 24:895-908. 
123. Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer 
[http://clinicaltrials.gov/ct2/show/NCT00804154?term=resiniferatoxin&rank=1] 
124. Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, Childs J, Greenberg 
DA: Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. 
Mol Pharmacol 2004, 66:204-208. 
125. Jancso-Gabor A, Szolcsanyi J, Jancso N: Stimulation and desensitization of the 
hypothalamic heat-sensitive structures by capsaicin in rats. J Physiol 1970, 
208:449-459. 
126. Jancso G, Wollemann M: The effect of capsaicin on the adenylate cyclase activity 
of rat brain. Brain Res 1977, 123:323-329. 
127. Dib B: Effects of intracerebroventricular capsaicin on thermoregulatory behavior 
in the rat. Pharmacol Biochem Behav 1982, 16:23-27. 
128. Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon 
AW, Norman MH, Louis JC, Treanor JJ, et al: Nonthermal activation of transient 
receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits 
autonomic cold-defense effectors. J Neurosci 2007, 27:7459-7468. 
129. Gavva NR, Bannon AW, Hovland DN, Jr., Lehto SG, Klionsky L, Surapaneni S, 
Immke DC, Henley C, Arik L, Bak A, et al: Repeated administration of vanilloid 
receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 
blockade. J Pharmacol Exp Ther 2007, 323:128-137. 
130. Tamayo N, Liao H, Stec MM, Wang X, Chakrabarti P, Retz D, Doherty EM, 
Surapaneni S, Tamir R, Bannon AW, et al: Design and synthesis of peripherally 
restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. J Med 
Chem 2008, 51:2744-2757. 
131. Inoue K, Koizumi S, Fuziwara S, Denda S, Denda M: Functional vanilloid receptors 
in cultured normal human epidermal keratinocytes. Biochem Biophys Res 
Commun 2002, 291:124-129. 
132. Kim SJ, Lee SA, Yun SJ, Kim JK, Park JS, Jeong HS, Lee JH, Moon SJ, Won YH: 
Expression of vanilloid receptor 1 in cultured fibroblast. Exp Dermatol 2006, 
15:362-367. 
References 
51 
133. Grone A, Fonfara S, Baumgartner W: Cell type-dependent cytokine expression 
after canine distemper virus infection. Viral Immunol 2002, 15:493-505. 
134. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB: Activation of 
epidermal vanilloid receptor-1 induces release of proinflammatory mediators in 
human keratinocytes. J Pharmacol Exp Ther 2003, 304:217-222. 
135. Saunders CI, Kunde DA, Crawford A, Geraghty DP: Expression of transient 
receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral 
blood. Mol Immunol 2007, 44:1429-1435. 
136. Basu S, Srivastava P: Immunological role of neuronal receptor vanilloid receptor 1 
expressed on dendritic cells. Proc Natl Acad Sci U S A 2005, 102:5120-5125. 
137. Geppetti P, Nassini R, Materazzi S, Benemei S: The concept of neurogenic 
inflammation. BJU Int 2008, 101 Suppl 3:2-6. 
138. Earley S, Gonzales AL, Crnich R: Endothelium-dependent cerebral artery dilation 
mediated by TRPA1 and Ca2+-Activated K+ channels. Circ Res 2009, 104:987-
994. 
139. Kark T, Bagi Z, Lizanecz E, Pasztor ET, Erdei N, Czikora A, Papp Z, Edes I, Porszasz 
R, Toth A: Tissue-specific regulation of microvascular diameter: opposite 
functional roles of neuronal and smooth muscle located vanilloid receptor-1. Mol 
Pharmacol 2008, 73:1405-1412. 
140. Luo D, Zhang YW, Peng WJ, Peng J, Chen QQ, Li D, Deng HW, Li YJ: Transient 
receptor potential vanilloid 1-mediated expression and secretion of endothelial 
cell-derived calcitonin gene-related peptide. Regul Pept 2008, 150:66-72. 
141. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I: Calcitonin gene-related 
peptide is a potent vasodilator. Nature 1985, 313:54-56. 
142. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius 
D, Hogestatt ED: Vanilloid receptors on sensory nerves mediate the vasodilator 
action of anandamide. Nature 1999, 400:452-457. 
143. Keeble JE, Brain SD: Capsaicin-induced vasoconstriction in the mouse knee joint: 
a study using TRPV1 knockout mice. Neurosci Lett 2006, 401:55-58. 
144. Cavanaugh DJ, Chesler AT, Jackson AC, Sigal YM, Yamanaka H, Grant R, O'Donnell 
D, Nicoll RA, Shah NM, Julius D, Basbaum AI: Trpv1 reporter mice reveal highly 
restricted brain distribution and functional expression in arteriolar smooth 
muscle cells. J Neurosci 2011, 31:5067-5077. 
145. Dux M, Santha P, Jancso G: Capsaicin-sensitive neurogenic sensory vasodilatation 
in the dura mater of the rat. J Physiol 2003, 552:859-867. 
146. Wang YX, Wang J, Wang C, Liu J, Shi LP, Xu M: Functional expression of 
transient receptor potential vanilloid-related channels in chronically hypoxic 
human pulmonary arterial smooth muscle cells. J Membr Biol 2008, 223:151-159. 
147. Hwang JT, Park IJ, Shin JI, Lee YK, Lee SK, Baik HW, Ha J, Park OJ: Genistein, 
EGCG, and capsaicin inhibit adipocyte differentiation process via activating 
AMP-activated protein kinase. Biochem Biophys Res Commun 2005, 338:694-699. 
148. Hsu CL, Yen GC: Effects of capsaicin on induction of apoptosis and inhibition of 
adipogenesis in 3T3-L1 cells. J Agric Food Chem 2007, 55:1730-1736. 
149. Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ, Zhao 
ZG, Zhu SJ, et al: Activation of transient receptor potential vanilloid type-1 
channel prevents adipogenesis and obesity. Circ Res 2007, 100:1063-1070. 
References 
52 
150. Ohnuki K, Haramizu S, Oki K, Watanabe T, Yazawa S, Fushiki T: Administration of 
capsiate, a non-pungent capsaicin analog, promotes energy metabolism and 
suppresses body fat accumulation in mice. Biosci Biotechnol Biochem 2001, 
65:2735-2740. 
151. Kang JH, Goto T, Han IS, Kawada T, Kim YM, Yu R: Dietary capsaicin reduces 
obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-
fat diet. Obesity (Silver Spring) 2010, 18:780-787. 
152. Romanovsky AA, Almeida MC, Garami A, Steiner AA, Norman MH, Morrison SF, 
Nakamura K, Burmeister JJ, Nucci TB: The transient receptor potential vanilloid-1 
channel in thermoregulation: a thermosensor it is not. Pharmacol Rev 2009, 
61:228-261. 
153. Caterina MJ: Transient receptor potential ion channels as participants in 
thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol 
2007, 292:R64-76. 
154. Masamoto Y, Kawabata F, Fushiki T: Intragastric administration of TRPV1, 
TRPV3, TRPM8, and TRPA1 agonists modulates autonomic thermoregulation in 
different manners in mice. Biosci Biotechnol Biochem 2009, 73:1021-1027. 
155. Kawabata F, Inoue N, Masamoto Y, Matsumura S, Kimura W, Kadowaki M, Higashi 
T, Tominaga M, Inoue K, Fushiki T: Non-pungent capsaicin analogs (capsinoids) 
increase metabolic rate and enhance thermogenesis via gastrointestinal TRPV1 
in mice. Biosci Biotechnol Biochem 2009, 73:2690-2697. 
156. Toth DM, Szoke E, Bolcskei K, Kvell K, Bender B, Bosze Z, Szolcsanyi J, Sandor Z: 
Nociception, neurogenic inflammation and thermoregulation in TRPV1 
knockdown transgenic mice. Cell Mol Life Sci 2011, 68:2589-2601. 
157. Bodo E, Biro T, Telek A, Czifra G, Griger Z, Toth BI, Mescalchin A, Ito T, 
Bettermann A, Kovacs L, Paus R: A hot new twist to hair biology: involvement of 
vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J 
Pathol 2005, 166:985-998. 
158. White JP, Urban L, Nagy I: TRPV1 function in health and disease. Curr Pharm 
Biotechnol 2011, 12:130-144. 
159. Cortright DN, Krause JE, Broom DC: TRP channels and pain. Biochim Biophys Acta 
2007, 1772:978-988. 
160. Gunthorpe MJ, Szallasi A: Peripheral TRPV1 receptors as targets for drug 
development: new molecules and mechanisms. Curr Pharm Des 2008, 14:32-41. 
161. Toth A, Boczan J, Kedei N, Lizanecz E, Bagi Z, Papp Z, Edes I, Csiba L, Blumberg 
PM: Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat 
brain. Brain Res Mol Brain Res 2005, 135:162-168. 
162. Yiangou Y, Facer P, Dyer NH, Chan CL, Knowles C, Williams NS, Anand P: 
Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001, 
357:1338-1339. 
163. Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, Williams NS, Anand P: 
Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal 
hypersensitivity and faecal urgency. Lancet 2003, 361:385-391. 
164. Everaerts W, Gees M, Alpizar YA, Farre R, Leten C, Apetrei A, Dewachter I, van 
Leuven F, Vennekens R, De Ridder D, et al: The capsaicin receptor TRPV1 is a 
crucial mediator of the noxious effects of mustard oil. Curr Biol 2011, 21:316-321. 
References 
53 
165. Mori N, Kawabata F, Matsumura S, Hosokawa H, Kobayashi S, Inoue K, Fushiki T: 
Intragastric administration of allyl isothiocyanate increases carbohydrate 
oxidation via TRPV1 but not TRPA1 in mice. Am J Physiol Regul Integr Comp 
Physiol 2011, 300:R1494-1505. 
166. Ohta T, Imagawa T, Ito S: Novel agonistic action of mustard oil on recombinant 
and endogenous porcine transient receptor potential V1 (pTRPV1) channels. 
Biochem Pharmacol 2007, 73:1646-1656. 
167. Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, 
Patapoutian A: Noxious cold ion channel TRPA1 is activated by pungent 
compounds and bradykinin. Neuron 2004, 41:849-857. 
168. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, 
Hergarden AC, Andersson DA, Hwang SW, et al: ANKTM1, a TRP-like channel 
expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003, 
112:819-829. 
169. Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, Hogestatt ED, Julius 
D, Jordt SE, Zygmunt PM: Pungent products from garlic activate the sensory ion 
channel TRPA1. Proc Natl Acad Sci U S A 2005, 102:12248-12252. 
170. Tender GC, Walbridge S, Olah Z, Karai L, Iadarola M, Oldfield EH, Lonser RR: 
Selective ablation of nociceptive neurons for elimination of hyperalgesia and 
neurogenic inflammation. J Neurosurg 2005, 102:522-525. 
171. Jancso G, Jancso-Gabor A: Effect of capsaicin on morphine analgesia--possible 
involvement of hypothalamic structures. Naunyn Schmiedebergs Arch Pharmacol 
1980, 311:285-288. 
172. Enyeart JJ, Xu L, Enyeart JA: Dual actions of lanthanides on ACTH-inhibited leak 
K(+) channels. Am J Physiol Endocrinol Metab 2002, 282:E1255-1266. 
173. Olah Z, Lehel C, Jakab G, Anderson WB: A cloning and epsilon-epitope-tagging 
insert for the expression of polymerase chain reaction-generated cDNA 
fragments in Escherichia coli and mammalian cells. Anal Biochem 1994, 221:94-
102. 
174. Pecze L, Szabo K, Szell M, Josvay K, Kaszas K, Kusz E, Letoha T, Prorok J, Koncz I, 
Toth A, et al: Human keratinocytes are vanilloid resistant. PLoS ONE 2008, 
3:e3419. 
175. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V: 
The activity of anandamide at vanilloid VR1 receptors requires facilitated 
transport across the cell membrane and is limited by intracellular metabolism. J 
Biol Chem 2001, 276:12856-12863. 
176. Garcia-Martinez C, Morenilla-Palao C, Planells-Cases R, Merino JM, Ferrer-Montiel 
A: Identification of an aspartic residue in the P-loop of the vanilloid receptor that 
modulates pore properties. J Biol Chem 2000, 275:32552-32558. 
177. Olah Z, Josvay K, Pecze L, Letoha T, Babai N, Budai D, Otvos F, Szalma S, Vizler C: 
Anti-calmodulins and tricyclic adjuvants in pain therapy block the TRPV1 
channel. PLoS ONE 2007, 2:e545. 
178. Chung MK, Guler AD, Caterina MJ: TRPV1 shows dynamic ionic selectivity 
during agonist stimulation. Nat Neurosci 2008, 11:555-564. 
179. Binshtok AM, Bean BP, Woolf CJ: Inhibition of nociceptors by TRPV1-mediated 
entry of impermeant sodium channel blockers. Nature 2007, 449:607-610. 
References 
54 
180. Fernihough J, Gentry C, Bevan S, Winter J: Regulation of calcitonin gene-related 
peptide and TRPV1 in a rat model of osteoarthritis. Neurosci Lett 2005, 388:75-
80. 
181. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ: p38 MAPK activation by NGF in 
primary sensory neurons after inflammation increases TRPV1 levels and 
maintains heat hyperalgesia. Neuron 2002, 36:57-68. 
182. Malin S, Molliver D, Christianson JA, Schwartz ES, Cornuet P, Albers KM, Davis 
BM: TRPV1 and TRPA1 function and modulation are target tissue dependent. J 
Neurosci 2011, 31:10516-10528. 
183. Zhang X, Huang J, McNaughton PA: NGF rapidly increases membrane expression 
of TRPV1 heat-gated ion channels. EMBO J 2005, 24:4211-4223. 
184. Pecze L, Pelsoczi P, Kecskes M, Winter Z, Papp A, Kaszas K, Letoha T, Vizler C, 
Olah Z: Resiniferatoxin mediated ablation of TRPV1+ neurons removes TRPA1 
as well. Can J Neurol Sci 2009, 36:234-241. 
185. Winter Z, Buhala A, Otvos F, Josvay K, Vizler C, Dombi G, Szakonyi G, Olah Z: 
Functionally important amino acid residues in the transient receptor potential 
vanilloid 1 (TRPV1) ion channel -- an overview of the current mutational data. 
Mol Pain 2013, 9:30. 
186. Jin HW, Ichikawa H, Fujita M, Yamaai T, Mukae K, Nomura K, Sugimoto T: 
Involvement of caspase cascade in capsaicin-induced apoptosis of dorsal root 
ganglion neurons. Brain Res 2005, 1056:139-144. 
187. Brown DC, Iadarola MJ, Perkowski SZ, Erin H, Shofer F, Laszlo KJ, Olah Z, Mannes 
AJ: Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a 
canine bone cancer model. Anesthesiology 2005, 103:1052-1059. 
188. Tousova K, Susankova K, Teisinger J, Vyklicky L, Vlachova V: Oxidizing reagent 
copper-o-phenanthroline is an open channel blocker of the vanilloid receptor 
TRPV1. Neuropharmacology 2004, 47:273-285. 
189. Pecze L, Winter Z, Josvay K, Otvos F, Kolozsi C, Vizler C, Budai D, Letoha T, 
Dombi G, Szakonyi G, Olah Z: Divalent heavy metal cations block the TRPV1 
Ca(2+) channel. Biol Trace Elem Res 2013, 151:451-461. 
190. Banvolgyi A, Pozsgai G, Brain SD, Helyes ZS, Szolcsanyi J, Ghosh M, Melegh B, 
Pinter E: Mustard oil induces a transient receptor potential vanilloid 1 receptor-
independent neurogenic inflammation and a non-neurogenic cellular 
inflammatory component in mice. Neuroscience 2004, 125:449-459. 
191. Gamse R: Capsaicin and nociception in the rat and mouse. Possible role of 
substance P. Naunyn Schmiedebergs Arch Pharmacol 1982, 320:205-216. 
192. Holzer P, Jurna I, Gamse R, Lembeck F: Nociceptive threshold after neonatal 
capsaicin treatment. Eur J Pharmacol 1979, 58:511-514. 
193. Cervero F, McRitchie HA: Neonatal capsaicin and thermal nociception: a paradox. 
Brain Res 1981, 215:414-418. 
194. Hayes AG, Scadding JW, Skingle M, Tyers MB: Effects of neonatal administration 
of capsaicin on nociceptive thresholds in the mouse and rat. J Pharm Pharmacol 
1981, 33:183-185. 
195. Neubert JK, Mannes AJ, Karai LJ, Jenkins AC, Zawatski L, Abu-Asab M, Iadarola 
MJ: Perineural resiniferatoxin selectively inhibits inflammatory hyperalgesia. 
Mol Pain 2008, 4:3. 
References 
55 
196. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, 
Koltzenburg M, Basbaum AI, Julius D: Impaired nociception and pain sensation in 
mice lacking the capsaicin receptor. Science 2000, 288:306-313. 
197. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, 
Latcham J, Clapham C, Atkinson K, et al: Vanilloid receptor-1 is essential for 
inflammatory thermal hyperalgesia. Nature 2000, 405:183-187. 
198. Obata K, Katsura H, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, Fukuoka T, 
Tokunaga A, Tominaga M, Noguchi K: TRPA1 induced in sensory neurons 
contributes to cold hyperalgesia after inflammation and nerve injury. J Clin 
Invest 2005, 115:2393-2401. 
199. Katsura H, Obata K, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, Fukuoka T, 
Tokunaga A, Sakagami M, Noguchi K: Antisense knock down of TRPA1, but not 
TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats. Exp 
Neurol 2006, 200:112-123. 
200. Reid G, Babes A, Pluteanu F: A cold- and menthol-activated current in rat dorsal 
root ganglion neurones: properties and role in cold transduction. J Physiol 2002, 
545:595-614. 
201. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM: Behavioral signs of ongoing pain 
and cold allodynia in a rat model of neuropathic pain. Pain 1994, 59:369-376. 
202. Takahashi K, Sato J, Mizumura K: Responses of C-fiber low threshold 
mechanoreceptors and nociceptors to cold were facilitated in rats persistently 
inflamed and hypersensitive to cold. Neurosci Res 2003, 47:409-419. 
203. Saade NE, Massaad CA, Ochoa-Chaar CI, Jabbur SJ, Safieh-Garabedian B, Atweh SF: 
Upregulation of proinflammatory cytokines and nerve growth factor by 
intraplantar injection of capsaicin in rats. J Physiol 2002, 545:241-253. 
204. Frederick J, Buck ME, Matson DJ, Cortright DN: Increased TRPA1, TRPM8, and 
TRPV2 expression in dorsal root ganglia by nerve injury. Biochem Biophys Res 
Commun 2007, 358:1058-1064. 
205. Lessard N, Pare M, Lepore F, Lassonde M: Early-blind human subjects localize 
sound sources better than sighted subjects. Nature 1998, 395:278-280. 
206. Nilius B, Prenen J, Vennekens R, Hoenderop JG, Bindels RJ, Droogmans G: 
Pharmacological modulation of monovalent cation currents through the 
epithelial Ca2+ channel ECaC1. Br J Pharmacol 2001, 134:453-462. 
207. Zeng B, Chen GL, Xu SZ: Divalent copper is a potent extracellular blocker for 
TRPM2 channel. Biochem Biophys Res Commun 2012, 424:279-284. 
208. Sajadi SAA: Complex Bilding Behavior of L-Tryptophan and Related Amino 
Acids, a Comparative Investigation. American Journal of Chemistry 2011, 1:60-64. 
209. Irving H, Williams RJP: The stability of transition-metal complexes. Journal of the 
Chemical Society 1953:3192–3210. 
210. Shannon R: Revised effective ionic radii and systematic studies of interatomic 
distances in halides and chalcogenides. Acta Crystallographica Section A 1976, 
32:751-767. 
211. Vulcu SD, Liewald JF, Gillen C, Rupp J, Nawrath H: Proton conductance of human 
transient receptor potential-vanilloid type-1 expressed in oocytes of Xenopus 
laevis and in Chinese hamster ovary cells. Neuroscience 2004, 125:861-866. 
212. Grant ER, Dubin AE, Zhang SP, Zivin RA, Zhong Z: Simultaneous intracellular 
calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-
References 
56 
transfected human embryonic kidney cells: a method to resolve ionic dependence 
of VR1-mediated cell death. J Pharmacol Exp Ther 2002, 300:9-17. 
213. Hu-Tsai M, Winter J, Woolf CJ: Regional differences in the distribution of 
capsaicin-sensitive target-identified adult rat dorsal root ganglion neurons. 
Neurosci Lett 1992, 143:251-254. 
214. Winter J, Evison CJ, O'Brien C, Benowitz L, Lindsay RM, Mulderry P, Woolf C: 
Neurotoxic damage evokes regenerative responses from adult rat sensory 
neurones. Neurosci Lett 1992, 146:48-52. 
215. Reichling DB, Barratt L, Levine JD: Heat-induced cobalt entry: an assay for heat 
transduction in cultured rat dorsal root ganglion neurons. Neuroscience 1997, 
77:291-294. 
216. Nishimura T, Krier J, Akasu T: Effects of vasoactive intestinal contractor on 
voltage-activated Ca2+ currents in feline parasympathetic neurons. Am J Physiol 
1993, 265:G1158-1168. 
217. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J: International Union of 
Pharmacology. XLVIII. Nomenclature and structure-function relationships of 
voltage-gated calcium channels. Pharmacol Rev 2005, 57:411-425. 
218. Guy HR, Conti F: Pursuing the structure and function of voltage-gated channels. 
Trends Neurosci 1990, 13:201-206. 
219. Doughty SW, Blaney FE, Orlek BS, Richards WG: A molecular mechanism for 
toxin block in N-type calcium channels. Protein Eng 1998, 11:95-99. 
220. Mikala G, Bahinski A, Yatani A, Tang S, Schwartz A: Differential contribution by 
conserved glutamate residues to an ion-selectivity site in the L-type Ca2+ channel 
pore. FEBS Lett 1993, 335:265-269. 
221. Castelli L, Tanzi F, Taglietti V, Magistretti J: Cu2+, Co2+, and Mn2+ modify the 
gating kinetics of high-voltage-activated Ca2+ channels in rat palaeocortical 
neurons. J Membr Biol 2003, 195:121-136. 
222. Hagiwara S, Byerly L: Calcium channel. Annu Rev Neurosci 1981, 4:69-125. 
223. Thevenod F, Jones SW: Cadmium block of calcium current in frog sympathetic 
neurons. Biophys J 1992, 63:162-168. 
224. Winegar BD, Kelly R, Lansman JB: Block of current through single calcium 
channels by Fe, Co, and Ni. Location of the transition metal binding site in the 
pore. J Gen Physiol 1991, 97:351-367. 
225. Gavva NR, Tamir R, Klionsky L, Norman MH, Louis JC, Wild KD, Treanor JJ: 
Proton activation does not alter antagonist interaction with the capsaicin-binding 
pocket of TRPV1. Mol Pharmacol 2005, 68:1524-1533. 
226. Myers BR, Bohlen CJ, Julius D: A yeast genetic screen reveals a critical role for 
the pore helix domain in TRP channel gating. Neuron 2008, 58:362-373. 
227. Mohapatra DP, Nau C: Desensitization of capsaicin-activated currents in the 
vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein 
kinase pathway. J Biol Chem 2003, 278:50080-50090. 
228. Mohapatra DP, Wang SY, Wang GK, Nau C: A tyrosine residue in TM6 of the 
Vanilloid Receptor TRPV1 involved in desensitization and calcium permeability 
of capsaicin-activated currents. Mol Cell Neurosci 2003, 23:314-324. 
229. Latorre R, Zaelzer C, Brauchi S: Structure-functional intimacies of transient 
receptor potential channels. Q Rev Biophys 2009, 42:201-246. 
References 
57 
230. Kwak J, Wang MH, Hwang SW, Kim TY, Lee SY, Oh U: Intracellular ATP 
increases capsaicin-activated channel activity by interacting with nucleotide-
binding domains. J Neurosci 2000, 20:8298-8304. 
231. Grandl J, Kim SE, Uzzell V, Bursulaya B, Petrus M, Bandell M, Patapoutian A: 
Temperature-induced opening of TRPV1 ion channel is stabilized by the pore 
domain. Nat Neurosci 2010, 13:708-714. 
232. Jordt SE, Julius D: Molecular basis for species-specific sensitivity to "hot" chili 
peppers. Cell 2002, 108:421-430. 
233. Numazaki M, Tominaga M: Nociception and TRP Channels. Curr Drug Targets 
CNS Neurol Disord 2004, 3:479-485. 
234. Numazaki M, Tominaga T, Toyooka H, Tominaga M: Direct phosphorylation of 
capsaicin receptor VR1 by protein kinase Cepsilon and identification of two 
target serine residues. J Biol Chem 2002, 277:13375-13378. 
235. Ho KW, Ward NJ, Calkins DJ: TRPV1: a stress response protein in the central 
nervous system. Am J Neurodegener Dis 2012, 1:1-14. 
236. Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, Zhang TJ, Viswanadhan 
VN, Toth A, Pearce LV, et al: Molecular determinants of vanilloid sensitivity in 
TRPV1. J Biol Chem 2004, 279:20283-20295. 
237. Lee JH, Lee Y, Ryu H, Kang DW, Lee J, Lazar J, Pearce LV, Pavlyukovets VA, 
Blumberg PM, Choi S: Structural insights into transient receptor potential 
vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and 
mutational studies. J Comput Aided Mol Des 2011, 25:317-327. 
238. Chou MZ, Mtui T, Gao YD, Kohler M, Middleton RE: Resiniferatoxin binds to the 
capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane 
domain. Biochemistry 2004, 43:2501-2511. 
239. Johnson DM, Garrett EM, Rutter R, Bonnert TP, Gao YD, Middleton RE, Sutton KG: 
Functional mapping of the transient receptor potential vanilloid 1 intracellular 
binding site. Mol Pharmacol 2006, 70:1005-1012. 
240. Sutton KG, Garrett EM, Rutter AR, Bonnert TP, Jarolimek W, Seabrook GR: 
Functional characterisation of the S512Y mutant vanilloid human TRPV1 
receptor. Br J Pharmacol 2005, 146:702-711. 
241. Ryu S, Liu B, Yao J, Fu Q, Qin F: Uncoupling proton activation of vanilloid 
receptor TRPV1. J Neurosci 2007, 27:12797-12807. 
242. Boukalova S, Marsakova L, Teisinger J, Vlachova V: Conserved residues within the 
putative S4-S5 region serve distinct functions among thermosensitive vanilloid 
transient receptor potential (TRPV) channels. J Biol Chem 2010, 285:41455-
41462. 
243. Voets T, Owsianik G, Janssens A, Talavera K, Nilius B: TRPM8 voltage sensor 
mutants reveal a mechanism for integrating thermal and chemical stimuli. Nat 
Chem Biol 2007, 3:174-182. 
244. Brauchi S, Orta G, Mascayano C, Salazar M, Raddatz N, Urbina H, Rosenmann E, 
Gonzalez-Nilo F, Latorre R: Dissection of the components for PIP2 activation and 
thermosensation in TRP channels. Proc Natl Acad Sci U S A 2007, 104:10246-
10251. 
245. Picazo-Juarez G, Romero-Suarez S, Nieto-Posadas A, Llorente I, Jara-Oseguera A, 
Briggs M, McIntosh TJ, Simon SA, Ladron-de-Guevara E, Islas LD, Rosenbaum T: 
References 
58 
Identification of a binding motif in the S5 helix that confers cholesterol sensitivity 
to the TRPV1 ion channel. J Biol Chem 2011, 286:24966-24976. 
246. Bohlen CJ, Priel A, Zhou S, King D, Siemens J, Julius D: A bivalent tarantula toxin 
activates the capsaicin receptor, TRPV1, by targeting the outer pore domain. Cell 
2010, 141:834-845. 
247. Kitaguchi T, Swartz KJ: An inhibitor of TRPV1 channels isolated from funnel 
Web spider venom. Biochemistry 2005, 44:15544-15549. 
248. Welch JM, Simon SA, Reinhart PH: The activation mechanism of rat vanilloid 
receptor 1 by capsaicin involves the pore domain and differs from the activation 
by either acid or heat. Proc Natl Acad Sci U S A 2000, 97:13889-13894. 
249. Aneiros E, Cao L, Papakosta M, Stevens EB, Phillips S, Grimm C: The biophysical 
and molecular basis of TRPV1 proton gating. EMBO J 2011, 30:994-1002. 
250. Grimm C, Aneiros E, de Groot M: Dissecting TRPV1: lessons to be learned? 
Channels (Austin) 2011, 5:201-204. 
251. Siemens J, Zhou S, Piskorowski R, Nikai T, Lumpkin EA, Basbaum AI, King D, 
Julius D: Spider toxins activate the capsaicin receptor to produce inflammatory 
pain. Nature 2006, 444:208-212. 
252. Susankova K, Ettrich R, Vyklicky L, Teisinger J, Vlachova V: Contribution of the 
putative inner-pore region to the gating of the transient receptor potential 
vanilloid subtype 1 channel (TRPV1). J Neurosci 2007, 27:7578-7585. 
253. Salazar H, Jara-Oseguera A, Hernandez-Garcia E, Llorente I, Arias O, II, Soriano-
Garcia M, Islas LD, Rosenbaum T: Structural determinants of gating in the 
TRPV1 channel. Nat Struct Mol Biol 2009, 16:704-710. 
254. Kuzhikandathil EV, Wang H, Szabo T, Morozova N, Blumberg PM, Oxford GS: 
Functional analysis of capsaicin receptor (vanilloid receptor subtype 1) 
multimerization and agonist responsiveness using a dominant negative mutation. 
J Neurosci 2001, 21:8697-8706. 
255. Grycova L, Holendova B, Bumba L, Bily J, Jirku M, Lansky Z, Teisinger J: 
Integrative binding sites within intracellular termini of TRPV1 receptor. PLoS 
ONE 2012, 7:e48437. 
256. Grycova L, Lansky Z, Friedlova E, Obsilova V, Janouskova H, Obsil T, Teisinger J: 
Ionic interactions are essential for TRPV1 C-terminus binding to calmodulin. 
Biochem Biophys Res Commun 2008, 375:680-683. 
 
 
 
Appendix 
 
10. Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix figure 1: Co2+ histochemistry on the 3T3 cell line expressing TRPV1 ectopically. 
Cells were incubated for 10 minutes in buffer A containing A - 20 μM CAPS + 5 mM Co2+; B - 20 μM CAPS + 5 
mM Co2+ +5 μM CapZ; C - 5 mM Co2+ without CAPS. The dark CoS precipitate indicates the presence of 
intracellular Co2+ that is blockable with CapZ, a competitive antagonist of pungent vanilloids. D - Gray values 
of the 3T3 cell line expressing TRPV1 measured by means of ImageJ software. E - Co2+ histochemistry in 
CAPS-sensitive rat DRG neurons. Scale bar = 0.05 mm. These results confirm that Co2+ not only acts as a 
blocker but also enters the cell with Ca2+ through the TRPV1 channel. 
Appendix 
 
Appendix figure 2: Co2+ histochemistry on the 3T3 cell line.  
Cells were incubated for 10 minutes in buffer A containing: A - 20 μM CAPS +5 mM Co2+; B - 20 μM 
CAPS + 5 mM Co2+ + 5 μM CapZ; C - 5 mM Co2+ without CAPS. D - 20 μM CAPS without Co2+. No 
CoS precipitate could be observed in the absence of TRPV1 protein in the cell membrane. E - Gray 
values of the 3T3 cell line measured by means of ImageJ software. Cells were incubated for 10 min in: 
F - buffer A containing 5 mM Co2+; G - buffer A without Co2+; H - modified buffer A containing 50 
mM KCl + 2.5 mM NaCl + 5 mM Co2+; I - modified buffer A containing 50 mM KCl + 12.5 mM NaCl 
without Co2+. J - Gray values of the 3T3 cell line measured by means of ImageJ software. These 
results confirm that Co2+ does not enter the 3T3 cells through VGCCs.
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Appendix table 1: Summary table of the mutated sites of rTRPV1 
 
Residue Mutated to Role in the channel function / Impact of the mutation on the channel function Refs 
C73 S Its mutation caused gain of function and strong toxicity when expressed in Saccharomyces cerevisiae. [226] 
I75 F Its mutation caused gain of function mutation and weaker toxicity when expressed in Saccharomyces cerevisiae. [226] 
I76 T Its mutation caused gain of function mutation and weaker toxicity when expressed in Saccharomyces cerevisiae. [226] 
V78 G Its mutation caused gain of function mutation and weaker toxicity when expressed in Saccharomyces cerevisiae. [226] 
R114 A, E, Δ Its deletion or mutation abrogated vanilloid and proton activation and RTX binding, without effecting heat activation. [18] 
R115 D Its mutation abrogated vanilloid activation and RTX binding, without effecting heat activation. [18] 
S116 A 
The residue is phosphorylated by PKA and is involved in 
desensitization. 
It is also functional target for PKCµ. Its mutation abolished 
phosphorylation by PKCμ and enhanced the channel response to 
CAPS by PKCμ. 
[81, 86, 227, 228] 
T144  Its phosphorylation by PKA causes sensitization of heat-evoked responses. [74, 79] 
K155 A, E 
Its mutation caused impaired TRPV1-ARD interaction with ATP, 
and impaired tachyphylaxis, even in the absence of ATP. The 
mutant channel did not interact with CaM, and was slightly more 
sensitive to CAPS than the wild type. 
Its mutation resulted in a constitutively active channel, and 
caused gain of function mutation and weaker toxicity when 
expressed in Saccharomyces cerevisiae. 
[16, 226] 
C157  The residue is covalently modified by allicin causing allicin activation of the channel. [229] 
K160 A, E 
Its mutation caused impaired TRPV1-ARD interaction with ATP, 
and impaired tachyphylaxis, even in the absence of ATP. The 
mutant channel did not interact with CaM, and was slightly more 
sensitive to CAPS than the wild type. 
Its mutation resulted in a constitutively active channel, caused 
gain of function mutation and strong toxicity when expressed in 
Saccharomyces cerevisiae. 
[16, 226] 
H166 R 
Its mutation caused gain of function mutation and weaker 
toxicity when expressed in Saccharomyces cerevisiae. Its 
mutation resulted in significant response to pH 6.4 (threshold 
concentration for proton-activation). 
[226] 
D178 N Its mutation abolished the ATP-mediated upregulation of TRPV1. [230] 
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Residue Mutated to Role in the channel function / Impact of the mutation on the channel function Refs 
Y199 A, F 
When both sites were mutated, Y199/Q202 impaired the TRPV1-
ARD interaction with ATP and ATP-mediated tachyphylaxis. 
The mutated channel was slightly more sensitive to CAPS than 
the wild type. Mutant channels formed a weaker complex with 
CaM than wild type but it still had a 1:1 stoichiometric ratio. 
Phosphorylation of hTRPV1 Y200 (Y199 in rTRPV1) by Src 
kinase increases the surface expression of TRPV1 and accounts 
for rapid sensitizing actions of NGF. When mutated, Src-
dependent, NGF-induced Tyr phosphorylation was completely 
abolished. 
[16, 183] 
Q202 A 
When both sites were mutated, Y199/Q202 impaired the TRPV1-
ARD interaction with ATP and ATP-mediated tachyphylaxis. 
The mutated channel was slightly more sensitive to CAPS than 
the wild type. Mutant channels formed a weaker complex with 
CaM than wild type but it still had a 1:1 stoichiometric ratio. 
[16] 
N310 D Its mutation caused gain of function and weaker toxicity when expressed in Saccharomyces cerevisiae. [226] 
S343 G, R, Its mutation caused gain of function and strong/weak toxicity when expressed in Saccharomyces cerevisiae. [226] 
A350 T Its mutation caused gain of function and strong toxicity when expressed in Saccharomyces cerevisiae. [226] 
I352 N, T 
Its mutation caused gain of function mutation and weaker 
toxicity when expressed in Saccharomyces cerevisiae. Its 
mutation also caused significant response to pH 6.4 (threshold 
concentration for proton-activation). 
[226] 
T370  
The residue is phosphorylated by PKA. It is involved in 
desensitization of the channel, and in the sensitization of heat-
evoked TRPV1 responses when phosphorylated by PKA. 
[74, 79, 81, 227, 
228] 
F489 Y Mutation resulted in a rightward shift of the CAPS concentration of half-maximal activation. [231] 
R491 E, G, Mutation caused reduction in CAPS sensitivity. [232] 
S502 A 
Its phosphorylation by PKC potentiates CAPS, proton, and 
thermal responses, and that by PKA sensitizes the heat-evoked 
responses. 
It is a CaMKII phosphorylation site. 
When associated with T704I, S502A was found to lose the 
ability to be activated by CAPS and to lose the ability of 
vanilloid binding. 
Its mutation reduced PMA enhancement of CAPS-evoked 
currents, but had no effect on direct activation by PMA. 
[74, 79, 81, 87, 
233, 234] 
Y511 A, C, F, Its mutation abolished CAPS responses, and RTX binding yet leave activation by heat and protons intact. [232, 235-238] 
S512 A, F, T, Y 
Its mutation abolished CAPS responses and RTX binding, yet 
left activation by heat and protons intact. It is involved in I-RTX 
binding. 
[232, 235, 239, 
240] 
Q519 N Its mutation ablated the vanilloid sensitivity. [232] 
F522 L Its mutation ablated the vanilloid sensitivity. [232] 
M523 L Its mutation ablated the vanilloid sensitivity. [232] 
S532 C Its mutation ablated the vanilloid sensitivity. [232] 
K535 E Its mutation ablated the vanilloid sensitivity, and affected proton responses. [232, 241] 
E536 L, W Its mutation ablated the vanilloid sensitivity, and affected proton responses. [232, 241] 
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Residue Mutated to Role in the channel function / Impact of the mutation on the channel function Refs 
V538 A, G, I, L, T Its mutation ablated proton activation, but not the proton potentiation. [241] 
A539 P Its mutation affected proton responses. [241] 
M547 A, I, L, Q The residue is involved in RTX binding, CAPS sensitivity, I-RTX sensitivity and proton sensitivity. [232, 236-239] 
W549  It is involved in vanilloid binding. [3, 236] 
T550 A, C, I, S, Y, Δ, 
It is an important molecular determinant in vanilloid sensitivity. 
Participates in Caps and RTX binding. 
Its deletion reduced CAPS sensitivity of the channel. 
[232, 236-238] 
R557 A, E, K, L 
It is involved in CAPS potentiation of heat-induced currents and 
in the transduction of the CAPS-binding signal to the opening of 
the pore. 
It is also important in deactivation gating process, 2-APB 
activation and for voltage-dependent gating.  
It contributes to the voltage modulation of the CAPS-induced 
currents and the CAPS potentiation of the heat-induced currents. 
[242] 
Q560 H, R 
It is involved in the transduction of the CAPS-binding signal to 
the opening of the pore. 
It is also important in deactivation gating process and for 2-APB 
activation. 
Its mutation caused significant response to pH 6.4 (threshold 
concentration for proton-activation). 
Its mutation caused gain of function of the channel and weaker 
toxicity when expressed in Saccharomyces cerevisiae. 
[226, 242] 
Q561 H, R Its mutation caused gain of function of the channel and strong toxicity when expressed in Saccharomyces cerevisiae. [226] 
M562 D Its mutation caused significant response to pH 6.4 (threshold concentration for proton-activation). [226] 
G563 S The residue is involved in the voltage gating of the channel. [242] 
E570 A, L, Q, R 
The residue contributes to the voltage modulation of the CAPS-
induced currents and the CAPS potentiation of the heat-induced 
currents. 
It is involved in the transduction of the CAPS-binding signal to 
the opening of the pore and in the 2-APB activation of the 
channel.  
It is also a relevant heat-sensing factor. 
[242] 
K571 E The residue is a specific binding site for 2-APB. It is involved in voltage sensing and in TRPV1-lipid interactions. [3, 242-244] 
R575 A The residue is involved in voltage sensing and in TRPV1-lipid interactions. [3, 243, 244] 
D576 N, R 
The residue is involved in the voltage-dependent gating of 
TRPV1, and contributes to the voltage modulation of the CAPS-
induced currents and the CAPS potentiation of the heat-induced 
currents. 
It contributes to the transduction of the CAPS-binding signal to 
the opening of the pore. 
[242] 
R579 A, D, E 
The residue contributes to the voltage modulation of the CAPS-
induced currents and to the CAPS potentiation of heat-induced 
currents. It is involved in the voltage sensing and in TRPV1-lipid 
interactions. Its mutation decreased the cholesterol response of 
the channel. 
[3, 242-245] 
Appendix 
 
Residue Mutated to Role in the channel function / Impact of the mutation on the channel function Refs 
M581 T 
The residue contributes to the transduction of the CAPS-binding 
signal to the opening of the pore, and to the deactivation gating 
process. It is involved in voltage gating. 
Its mutation caused gain of function of the channel and strong 
toxicity when expressed in Saccharomyces cerevisiae. 
[226, 242] 
F582 Q Its mutation decreased the cholesterol response of the channel. [245] 
L585 I Its mutation abolished the cholesterol response of the channel. [245] 
I599 A Its mutation caused reduced DkTx responses. [246] 
E600 A, D, H, K, Q, S, V 
The residue is involved in the proton potentiation, but not in 
proton activation. 
Its mutation to neutral or positive residues potentiates responses 
to CAPS or heat, and introduction of a residue with lower pKa 
decreased the channel sensitivity to CAPS or heat. 
[45, 231] 
D601 N 
Its mutation reduced the proton-activated currents significantly, 
without altering the heat- or CAPS-evoked responses, and 
without eliminating the ability of protons to potentiate the 
responses to these stimuli. 
[45] 
M609 T, V 
Its mutation caused gain of function of the channel and 
strong/weak toxicity when expressed in Saccharomyces 
cerevisiae. 
[226] 
C616 G The residue is involved in DTT interaction. [74, 106, 188] 
C621 G 
The residue is responsible for the extracellular modulation of 
TRPV1 by reducing agents. It is involved in DTT interaction. Its 
mutation and when associated with C616G and C634G 
significantly reduced DDT potentiation without having any effect 
on the CAPS, heat or voltage gating of the channel. 
[74, 106, 188] 
N625 D Its mutation caused toxicity when expressed in Saccharomyces cerevisiae. [226] 
Y627 A, W 
The residue contributes to, but do not play a pivotal role in the 
proton activation. Its mutation enhanced the sensitivity to the 
acylpolyamine toxins AG489 and AG505. 
[241, 247] 
N628 D, K, R, W 
The residue plays essential roles in the heat response without 
affecting the CAPS responses or the desensitization of the 
channel. It is involved in proton-induced potentiation. 
Its mutation reduced the heat responses in amplitude and shifted 
them to higher temperatures, dramatically decreased the 
sensitivity to the acylpolyamine toxins AG489 and AG505 and 
caused toxicity when expressed in Saccharomyces cerevisiae. 
[189, 226, 231, 
241, 247] 
S629 A The residue contributes to, but do not play a pivotal role in the proton activation. [241] 
T633 A, S, V 
Its mutation eliminated the proton-activated currents while 
leaving normal responses to CAPS and low pH potentiation. 
Its mutation exhibited a weaker response to heat in amplitude, 
however, the thermal activation threshold was unchanged. 
[241] 
C634 G, S, W 
It is involved in DTT interaction, its mutation and when 
associated with C616G and C621G significantly reduced DDT 
potentiation without having any effect on the CAPS, heat or 
voltage gating of the channel. 
Its mutation also enhanced the sensitivity to the acylpolyamine 
toxins AG489 and AG505, and caused toxicity when expressed 
in Saccharomyces cerevisiae. 
[74, 106, 188, 
226, 247] 
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E636 Q, W 
The residue is a specific contributor to the CAPS response 
without affecting the proton or thermal sensitivity. 
Its mutation dramatically decreased the sensitivity to the 
acylpolyamine toxins AG489 and AG505. 
[45, 247, 248] 
F638 W Its mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505. [247] 
F640 
A, C, D, E, 
G, H, I, K, 
L, M, N, P, 
Q, R, S, T, 
V, W, Y, 
The residue is critical for heat activation. 
Its mutation was constitutively active, and caused strong toxicity 
when expressed in Saccharomyces cerevisiae. 
Its mutation also enhanced the sensitivity to heat and CAPS, and 
abolished the proton potentiation of the channel. This mutation 
affected gating rather than permeation properties of the channel. 
[226] 
T641 S 
The residue is involved in acid activation and potentiation. 
Its mutant displayed large constitutive channel activation and 
caused toxicity when expressed in Saccharomyces cerevisiae. 
[226] 
D646 N, W 
The residue is a specific contributor to the CAPS response 
without affecting the proton or thermal sensitivity, and it is 
engaged in inhibition by RuRed. 
Its mutation reduced the permeability of divalent cations and 
dramatically decreased the sensitivity to the acylpolyamine 
toxins AG489 and AG505. 
[45, 176, 189, 
228, 248] 
L647 W Its mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505. [247] 
E648 A, Q 
The residue is a specific contributor to the CAPS response 
without affecting the proton or thermal sensitivity. 
↕ 
Its mutation reduced the proton-activated currents significantly, 
without altering the heat- or CAPS-evoked responses, and 
without eliminating the ability of protons to potentiate the 
responses to these stimuli. 
[45, 248] 
F649 A, W Its mutation caused reduced DkTx responses, and enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505. [246, 247] 
T650 S 
The residue is involved in proton-induced potentiation. 
Its mutation caused large constitutive channel activation with 
abolished pH sensitivity. 
Its mutation caused toxicity when expressed in Saccharomyces 
cerevisiae. 
[226] 
E651 Q, W 
The residue is important in pH activation. 
Its mutation dramatically decreased the sensitivity to the 
acylpolyamine toxins AG489 and AG505. 
[45, 189, 241, 
247] 
N652 D, T 
The residue plays essential roles in the heat response without 
affecting the CAPS responses or the desensitization of the 
channel. Its mutation reduced the heat responses in amplitude 
and shifted them to higher temperatures. 
Its mutation also caused gain of function and strong toxicity 
when expressed in Saccharomyces cerevisiae. 
[226, 231] 
Y653 T 
The residue plays essential roles in the heat response without 
affecting the CAPS responses or the desensitization of the 
channel. Its mutation reduced the heat responses in amplitude 
and shifted them to higher temperatures. 
[231] 
K656 E, Q Its mutation caused toxicity when expressed in Saccharomyces cerevisiae. [226] 
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A657 P, W The residue is critical for DkTx binding, its mutation showed loss of DkTx sensitivity. [246] 
V658 A 
The residue is involved in acid potentiation. 
Its mutation showed a potentiation effect under moderately acidic 
conditions. 
Its mutation also caused toxicity when expressed in 
Saccharomyces cerevisiae. 
[226] 
F659 
A, C, E, H, 
I, K, L, S, T, 
V, W, Y 
The residue is involved in proton activation, and is a key 
integrator of voltage sensing, proton activation and potentiation. 
Its mutation caused lack of both voltage-dependent proton 
activation and potentiation, whereas activation by heat or CAPS 
was preserved. 
Its mutation caused reduced DkTx responses and caused toxicity 
when expressed in Saccharomyces cerevisiae. 
[226, 246, 249-
251] 
Y666 A Its mutation resulted in non-functional channel. [252] 
I668 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-potentiated CAPS currents. [252] 
L669 A The residue is involved in heat activation but not in CAPS activation, nor in the heat potentiation of the CAPS currents.  [252] 
Y671 A 
The residue might contribute to allosteric coupling between 
temperature- and CAPS- dependent activation mechanisms. 
Its mutation affected the heat-induced current responses, lowered 
the CAPS EC50 value of the channel. Responses to CAPS were 
not potentiated by heat in the mutant containing channel, in fact 
CAPS-evoked responses were inhibited by heat. 
The residue is involved in the regulation of permeability of 
divalent cations, it gates the access of smaller cations. 
[176, 228, 235, 
252, 253] 
I672 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-potentiated CAPS currents. [252] 
L673 A, I 
Its mutation caused gain of function and strong toxicity when 
expressed in Saccharomyces cerevisiae. 
Its mutation also reduced CAPS sensitivity, heat-induced current 
responses and heat-potentiated CAPS currents. 
[226, 252] 
L674 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-potentiated CAPS currents. [252] 
L675 A Its mutation reduced CAPS sensitivity and heat-potentiated CAPS currents. [252] 
N676 A, F 
Its mutation influenced the ability of CAPS and RTX to activate 
TRPV1 without changing the response of the channel to protons. 
Its mutation to Ala resulted in non-functional channel. 
[252, 254] 
M677 A 
Its mutation in a triple mutant (N676F/M677A/L678P) 
influenced the ability of CAPS and RTX to activate TRPV1 
without changing the response of the channel to protons. 
Its mutation alone blunted heat-induced current responses 
without a significant change of CAPS- or heat-potentiated CAPS 
currents. 
[252, 254] 
L678 A, P 
Its mutation influenced the ability of CAPS and RTX to activate 
TRPV1 without changing the response of the channel to protons. 
Its mutation also blunted heat-induced current responses, with a 
leftward shift in the temperature threshold. 
[252, 254] 
I679 A Its mutation retained normal sensitivities to CAPS and heat, although it completely removed their mutual potentiation. [252] 
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Residue Mutated to Role in the channel function / Impact of the mutation on the channel function Refs 
L681 A The residue is involved in the regulation of permeability of divalent cations, it regulates the permeability of large cations. [235, 252, 253] 
M682 A Its mutation caused impaired CAPS- and heat- activation, and significantly reduced their mutual potentiation. [252] 
E684 G, V 
Its mutation caused gain of function and strong toxicity when 
expressed in Saccharomyces cerevisiae. 
Its mutation caused significant response to pH 6.4 (threshold 
concentration for proton-activation). 
[226] 
I689 V Its mutation caused gain of function mutation and weaker toxicity when expressed in Saccharomyces cerevisiae. [226] 
K694 A The residue participates in PIP2 binding. [255] 
K698 A The residue participates in PIP2 binding. [255] 
Q700 A The residue participates in PIP2 binding. [255] 
R701 A The residue participates in PIP2 binding. [244, 255] 
T704 I 
The residue is a CaMKII phosphorylation site. 
PMA decreases the binding of 3H-RTX to TRPV1 through 
interaction with this residue. 
When associated with S502A, its mutation lost the ability to be 
activated by CAPS and lost the ability of vanilloid binding. 
[48, 81, 87, 109, 
234] 
K710 A, R 
The residue participates in PIP2 binding. 
Its mutation caused gain of function and strong toxicity when 
expressed in Saccharomyces cerevisiae. 
[226, 244, 255] 
Q727  The residue has key roles in heat activation. [244] 
F742 S Its mutation caused gain of function and strong toxicity when expressed in Saccharomyces cerevisiae. [226] 
W752  The residue has key roles in heat activation. [244] 
E761 K, Q, Δ 
Its deletion or mutation blocks RTX binding and proton- and 
CAPS-induced currents without affecting TRPV1 activation by 
heat. 
[18, 228, 252]  
K770 A The residue participates in PIP2 binding. [255] 
R771 A The residue participates in PIP2 binding. [255] 
R778 A The residue has key roles in PIP2 binding. [255, 256] 
R781 A The residue has key roles in PIP2 binding. [255, 256] 
R785 A The residue participates in PIP2 binding. [255, 256] 
W787 R Its mutation caused gain of function and strong toxicity when expressed in Saccharomyces cerevisiae. [226] 
L792 P 
Its mutation caused gain of function mutation and weaker 
toxicity when expressed in Saccharomyces cerevisiae. 
Its mutation caused significant response to pH 6.4 (threshold 
concentration for proton-activation). 
[226] 
L796 P, V Its mutation caused gain of function and strong/weaker toxicity when expressed in Saccharomyces cerevisiae. [226] 
S800 A Its phosphorylation by PKC potentiates CAPS, acid, and thermal responses. [74, 81, 233] 
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Mammalian temperature sensors of the transient receptor
potential (TRP) family are tetrameric 6-transmembrane cation
channels gated by heat, cold, as well as either endogenous or
exogenous agonists1,2. The vanilloid receptor (VR1/TRPV1) is a
non-selective ligand-gated Na+/Ca2+-channel3-6. TRPV1 is
selectively activated by heat above 42ºC, pH < 6.37, endogenous
lipid mediators such as anandamide and oleoylethanolamide4,8,9,
intracellular signaling molecules10,11 and plant toxins, including
capsaicin (CAPS) and resiniferatoxin (RTX).
TRPA1 has recently been suggested to serve as receptor of
noxious cold temperature12, and it transduces pain induced by
ABSTRACT: Objectives: Resiniferatoxin, the most potent agonist of inflammatory pain/vanilloid receptor/cation channel (TRPV1) can
be used for neuron subtype specific ablation of pain generating cells at the level of the peripheral nervous system by Ca2+-excytotoxicity.
Molecular neurosurgery is an emerging technology either to alleviate severe pain in cancer or treat/prevent different local neuropathies.
Our aim was determining sensory modalities that may be lost after resiniferatoxin treatment. Methods: Newborn or adult mice were
treated with resiniferatoxin, then changes in chemical and heat sensitivity were correlated with alterations of the cell composition of
sensory ganglions. Results: Only mice treated at adult age became less sensitive to heat stimuli, while both treatment groups lost
sensitivity to specific vanilloid agonists of TRPV1 and, interestingly, to allyl-isothiocyanate, a selective agonist of TRPA1. Our in vivo
and post mortem analytical results confirmed that TRPV1 and TRPA1 function together and resiniferatoxin-mediated neurosurgery
removes both sensor molecules. Discussion: In adult mice resiniferatoxin causes: i) desensitization to heat and ii) sensitization to cold.
Cold hyperalgesia, an imbalance in thermosensation, might be conferred by a prominent cold receptor that is expressed in surviving
resiniferatoxin-resistant sensory neurons and compensates for pain signals lost with TRPA1 and TRPV1 double positive cells in the
peripheral nervous system.
RÉSUMÉ: L’ablation de neurones TRPV1+ par la résinifératoxine élimine aussi les neurones TRPA1. Objectifs : La résinifératoxine, l’agoniste
le plus puissant de la douleur inflammatoire/du récepteur vanilloïde/du canal cationique (TRPV1), peut être utilisée pour l’ablation spécifique par
excytotoxicité Ca2+, d’un sous-type de neurones faisant partie des cellules génératrices de douleur au niveau du système nerveux périphérique. La
neurochirurgie moléculaire est une technologie émergente, pour soulager la douleur cancéreuse sévère ou pour traiter ou prévenir différentes
neuropathies locales. Notre but était de déterminer les pertes sensitives suite au traitement par la résinifératoxine. Méthodes : Des souris ont été traitées
par la résinifératoxine à la période néonatale ou adulte et les changements de la sensibilité chimique et calorique ont été corrélés aux altérations de la
composition cellulaire des ganglions sensitifs. Résultats : Seules les souris traitées à l’âge adulte sont devenues moins sensibles aux stimuli caloriques
alors que les deux groupes traités ont perdu la sensibilité aux agonistes vanilloïdes spécifiques de TRPV1 et, ce qui est fort intéressant, à l’allyl-
isothiocyanate, un agoniste sélectif de TRPA1. Nos résultats d’analyses in vivo et post mortem ont confirmé que TRPV1 et TRPA1 fonctionnent
conjointement et que la neurochirurgie au moyen de la résinifératoxine élimine les deux molécules détectrices. Discussion : Chez les souris adultes la
résinifératoxine cause : 1) une désensibilisation à la chaleur et 2) une sensibilisation au froid. Une hyperalgésie au froid, qui est un déséquilibre dans
la thermosensibilité, pourrait être médiée par un récepteur important au froid qui est exprimé dans les neurones sensitifs résistants à la résinifératoxine
survivants et qui compense pour les signaux douloureux perdus des cellules doublement positives pour TRPA1 et TRPV1 dans le système nerveux
périphérique.
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ORIGINALARTICLE
isothiocyanate pharmacophore of the pungent ingredients of
mustard oil11 and garlic13. However, various observations 11,14,15
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now call into question that TRPA1 is a bona fide cold
sensor12,16,17, that prompted functional investigations, such as
ours described here.
Resiniferatoxin, the most potent natural diterpene agonist of
TRPV1, is present in latexes of various Euphorbia species, such
as E. resinifera, E. poissoni and E. unispina18. Bioassays rank
RTX as a 3-4 orders of magnitude more potent agonist of TRPV1
than CAPS, the active ingredient of chili pepper19. One of us
proposed exploitation of the Ca2+-excytotoxic potential of RTX
for pain management, using it as an ablative agent specific for
TRPV1 expressing cells. In vivo RTX treatment eliminates
TRPV1+ nociceptors in the peripheral nervous system while
bystander neurons and their functions are spared4,20. Indeed,
determination of specificity in vitro and in vivo in different
animal models and human dorsal root ganglion cultures
validated RTX as a “nano-scalpel” capable of “molecular
neurosurgery” of specific inflammatory pain cells without
affecting the other function-alities of the peripheral and central
nervous system4,5,21.
Although vanilloids had been used previously in vivo22, we
started to employ RTX in various routs of applications, such as
systemic, epidural, intra-nerve and intra-ganglionic injections in
adult5,23,24 as well as newborn rats (Olah, Karai, Iadarola,
unpublished observation). Systematic studies with a therapeutic
mechanisms in mind shifted the desensitization paradigm and
identification of the vanilloid receptor have helped interpretation
of long-term loss of response to thermal and stimuli evoked by
noxious chemicals. Our selective ablation pain management
technology by usurpation of nociceptive neurons for elimination
of hyperalgesia and neurogenic inflammation is distinct from the
desensitization theory proposed previously25. Resiniferatoxin is
now a validated drug lead to remove TRPV1+ inflammatory pain
generator cells. We demonstrated that RTX preserves bystander
sensory cells and motoneurons in rats, dogs, monkeys and
human embryonic dorsal root ganglion (DRG) cultures4,5,26,27.
Resiniferatoxin, although extremely specific to its target,
TRPV1, can delete sensation modalities conferred by bystander
sensor molecules, including other TRP channels co-expressed in
the same neuron. Therefore, the specific aim of this study was to
determine potential loss/gain of sensations that RTX-mediated
molecular surgery may cause. Furthermore, previous to
discovery of TRPV1 and TRPA1, it was routine to evaluate the
pharmacological effects of vanilloids by mustard oil test. The
discovery that allyl isothiocyanate is a cognate ligand of TRPA1
and not TRPV1 implies that this test only can work due to co-
expression of these TRP channels. Since both TRPV1 and
TRPA1 can evoke sterile inflammation, visualized by Evans
Blue extravasation5,27, their functional loss induced by potent
vanilloids could not be easily distinguished28. Story et al
proposed that TRPA1 might be another cation channel co-
expressed with TRPV112, but no systematic study has been
carried out to verify this notion and reveal the functional
consequences of co-deletion. According to our data in this paper,
allyl isothiocyanate, the pungent ingredient in mustard oil,
selectively targets TRPA1 only, and has no agonist side effect on
TRPV1. In addition we also described the unenexpected effects
of RTX treatment on cold sensitivity of the treated animals.
MATERIAL AND METHODS
Reagents
Resiniferatoxin (LC Laboratories, Woburn, MA) and
capsaicin (Sigma, St. Louis, MO) were dissolved in ethanol and
further diluted in physiological saline solution. Allyl
isothiocyanate (AITC) (Sigma, St. Louis, MO) was diluted in
physiological salt solution and dispergated by ultrasonication
before testing.
45Ca2+ uptake assay
One day before the assay, HaCaT cells permanently
expressing rat TRPV16 were seeded in 96-well flat bottom plates
(Orange Scientific, Braine-l’Alleud, Belgium) at a density of
20.000 cells/well. Assays were performed using a BioMek 1000
robotized liquid handler (Beckman Instruments, Fullerton, CA).
The plates were washed three times with assay medium (Ca2+-
and Mg2+-free Hanks’ balanced salt solution supplemented with
0.8 mM MgCl2 and with 25 mM TRIS-HCl, pH=7.4). The serial
dilutions of reagents containing 45Ca2+ were prepared using the
robot. The 45Ca2+-uptake assay was performed for ten minutes
(m) at 24°C using 1.33 μCi/ml of 45Ca2+ (Amersham Bio-
sciences, Buckinghamshire, UK) in 100 μl final volume/well. To
stop 45Ca2+ uptake and remove the free isotope, cells were
washed three additional times and then lysed in 80 μl/well lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-
100, 0.1% SDS, 5 mM EDTA) for 30 minutes. Seventy μl
aliquots of the solubilized cell extracts were mixed with 100 μl
aliquots of Optiphase Supermix scintillation cocktail (Perkin
Elmer, Wellesley, MA) and counted in a Perkin Elmer liquid
scintillation counter.
RTX treatment
The studies were carried out on male CD/1 mice. One mg
RTX was dissolved in 500 μl 96% ethanol and diluted in
physiological saline and injected s.c into the scruff of the neck in
a volume of about 100 μl. The RTX was applied at the dosage of
50 μg/kg body weight under light ether anesthesia to avoid
unnecessary pain. Control mice received vehicle. In the case of
adult treatment, two to three months old adult mice weighing
about 30 g at the start of the experiments were tested ten days
after RTX treatment. Mice treated on the second day of life were
tested at two months of age. In the case of chronic RTX
treatment RTX was added at 20 μg/kg body weight daily for
three days.
All animal experimental protocols were approved by our
institutional review committee, then the responsible govern-
mental agency.
Cold tail-flick test
Animals were held over ice cold water (~5°C) and their tails
submerged approximately half length into the bath. The time
from immersion to tail removal or flicking was measured.
Cold plate test
A microplate thermostate set at 5°C was used to generate a
cold surface. Tested mice were placed on the plate, then time to
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first response of forelimbs withdrawal and shivering was
recorded.
Hot plate test
The animals were individually exposed to the hot plate
maintained at 53°C. The time for forepaw licking was taken as
reaction time.
Water consumption
The daily water consumption of individually housed mice
was measured. Each bottle contained tap water with allyl
isothiocyanate at a concentration of 0.1 mM.
Eye wipe test
The eye wipe test was performed in anaesthetized animals.
The 100 μM capsaicin solution and the 1 mM AITC solution was
dropped into the eye and the number of defensive wiping
movements was counted.
Production of a monoclonal antibody recognizing an
extracellular loop of intact TRPV1
BALB/c 3T3 cells expressing the rat TRPV1 driven by the
metallothionein promoter of the pMET plasmid4 were induced
with 75 μM Zn2+ overnight. The induction resulted in a twofold
elevation of vanilloid-induced Ca-uptake measured in a
robotized 45Ca2+ uptake assay. The TRPV1 overexpressing cells
were homogenized, the debris was removed by centrifuging,
then the homogenization and centrifuging steps were repeated
once more. The cell membrane fraction was recovered by
ultracentrifuging the supernatant. After determination of the
protein content, the aliquotted cell membrane suspension was
stored at -85°C. BALB/c mice were injected with 100 μl
membrane suspension containing 300 μg total protein mixed
with 100 μl complete Freund’s adjuvant, then the immunization
was repeated three times using incomplete Freund’s adjuvant. A
last boost was given in the form of an ip injection of 100 μl
membrane homogenate and three days later spleen cells of the
immunized mice were fused with SP/2 myeloma cells. A
hybridoma clone producing antibody to an extracellular loop of
the intact TRPV1 molecule was selected by testing pooled, then
individual hybridoma supernatants on intact TRPV1-expressing
3T3 cells by flow cytofluorometry using a FITC labeled anti-
mouse secondary antibody. The resulting hybridoma clone was
verified to produce a monoclonal antibody recognizing the intact
rat TRPV1 expressed by the transformed 3T3 cell line, as well as
the naturally expressed molecule in rat or mouse trigeminal
ganglion or the prostate. The monoclonal antibody was directly
labeled with green fluorescence using Alexa Fluor 488
Monoclonal Antibody Labeling Kit (Invitrogen, Carlsbad, CA,).
Protein Extraction and Western Blot
Tissue samples were homogenized in modified RIPA buffer
(50 mM Tris-HCl, 140 mM NaCl, 5 mM EDTA, 1% TritonX-
100, Protease Inhibitor Cocktail - Roche, Mannheim, Germany)
and incubated on ice for 15 minutes to let lysis proceed. All
samples were precleared by centrifugation (15' 12000 g at 4°C)
before determining protein concentrations using the bicinchonic
acid (BCA) method (Sigma, St. Louis, MO). PAGE was done as
described in the Protein Electrophoresis technical manual of
Amersham Biosciences (Buckinghamshire, UK). Protein
samples were separated on 8% polyacrylamide gels, then
transferred to Millipore Immobilon PVDF membrane using Tris-
Glycine transfer buffer (0.192 M Glycine, 25 mM Tris, 20%
MetOH). Transfer was followed by blocking of the membrane
(30' at RT in 5% dry milk TBS-T), incubation with primary
antibody (overnight at 4°C, in 0.5% BSA TBS-T), secondary
antibody (2h at RT, in 1% dry milk TBS-T), results were
revealed using the ECL method (SuperSignal West
Chemiluminescent Substrate (Pierce Biotechnology Inc.
Rockford, IL), Hyperfilm ECL - Amersham Biosciences,
Buckinghamshire, UK). TBS: 50 mM Tris, 140 mM NaCl, pH
7.6; TBS-T: TBS with 0.5% Tween-20. Antibodies used and their
dilutions: TRPV1 - 1:1000, ABR Bioreagents, PA1-747; TRPA-
1 - 1:1000, Transgenic Inc. Kumamoto, Japan. #KM120;
TRPM8 - 1:1000, Alomone Labs, Jerusalem, Israel #ACC-049,
ß-actin - 1:1000 (Sigma, St. Louis, MO #A5060), anti-mouse
and anti-rabbit HRP - 1:10000 (Sigma, St. Louis, MO #A0168
and #A6154, respectively).
Immunhistochemistry
Over-anesthesized mice were perfused intracardially with 4%
paraformaldehyde in 0.1 M sodium phosphate buffer (PB, pH
7.4). Trigeminal ganglions were dissected out, and cryoprotected
in 10% glycerol/30% sucrose) overnight at 4ºC. Trigeminal
ganglions were embedded in Tissue Tek OCT (Sakura Finetek,
Torrance, CA) and frozen in dry ice. Frozen sections were cut on
an Shandon Cryotome Fe (Thermo Fisher Middletown, VA)
sliding microtome and collected in Superfrost slides kept at -
20°C. Sections were pre-incubated in blocking solutions (5%
goat serum, 0,1% Triton-X in PBS pH=7.4). After that the
sections were incubated in primary antibody dilutions at 4°C for
24 hours then secondary antibody. Antibodies used and their
dilutions: anti-TRPV1 1:50 (our monoclonal antibody directly
labeled with Alexa Fluor 488), anti TRPA1 1:50 (rabbit
polyclonal, Transgenic Inc. Kumamoto, Japan. #KM120) anti
TRPM8 1:50 (rabbit polyclonal, Alomone Labs, Jerusalem,
Israel #ACC-049) anti rabbit IgG – TRITC 1:400 (Sigma, St.
Louis, MO) . Sections were mounted on standard glass slides
and coverslipped with Dako Faramount Aqueous Mounting
Medium (Dako, Glostrup, Denmark).
RESULTS
To determine the potential effect of allyl isothiocyanate in
vitro we used a cell-based functional assay using a permanent
cell line expressing TRPV1 but not TRPA1 ectopically.
Resiniferatoxin and CAPS evoked 45Ca-influx with an EC50 of
2.6 nM and 78 nM, respectively (Figure 1). Contrary to the
report of Ohta et al29, however, we found that allyl
isothiocyanate has no effect on TRPV1-expressing cells, since it
did not evoke calcium influx applied at concentrations ranging
from 125 nM to 2.5 mM. Lack of AITC effect on TRPV1 and
selectivity of this ligand for TRPA1, has recently been shown by
others too11,16.
To dissect potential side effect(s) of molecular neurosurgery
in vivo, mice were treated with RTX either at birth or at adult age
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then changes in behavioral, cellular, and molecular biomarkers
(i.e. chemo-, and heat sensitivity, tissue specific expression/
distribution of TRPV1 and TRPA1) were systematically
compared.
As expected from previous studies5, mice treated with RTX
two days post-natal and tested at the age of two months
completely lost the sensitivity to vanilloids, since capsaicin-
induced eye wipe, a behavioral marker of TRPV1 conferred pain
signal, was completely abrogated. We have chosen an RTX dose
at which no mortality occurred. In our experimental conditions
applied in preliminary experiments, RTX-caused mortality was
detected from 75 μg/kg body weight, while the maximal dose
used in the paper was 50 μg/kg body weight. We also noted that
mice were unresponsive in AITC-induced eye wipe tests as well,
as the AITC-induced eye wipes were completely abrogated. In
accordance with that fact, these animals consumed AITC
containing drinking water in a significantly higher volume
overnight than untreated mice (2.7 ± 1.7 ml vs 5.5 ± 1.5 ml),
another signature of specific loss of this sensory modality.
Figure 1: 45Ca2+-influx induced by resiniferatoxin (RTX), capsaicin
(CAPS) and allyl isothiocyanate (AITC). HaCaT keratinocytes stably
expressing rat TRPV1 were seeded on 96-well plates, then ten-minute
agonist induced 45Ca2+-influx assays were performed. Cell-bound
radioactivity was measured in a liquid scintillation counter. Only RTX
and CAPS induced a Ca-influx, while AITC was totally ineffective. The
experiment was repeated two additional times with similar results.
Figure 2: Changes in the chemical- and heat sensitivity of mice treated
with resiniferatoxin at 50 μg/kg body weight on the second day after
birth. Mice were tested at second month of their life. Comparisons were
made using age-matched control animals treated with vehicle only. Bars
represent means of measured values plus standard deviations (n=7). The
experiments were repeated two additional times with similar results. A.)
Oral aversion to allyl isothiocyanate (AITC; mustard oil). Treated mice
consumed significantly more allyl isothiocyanate containing drinking
water than untreated mice in a 24 h test. *P < 0.05 vs. control B-C.) Eye-
wipe response to corneal application of 100 μM capsaicin and 10 mM
allyl isothiocyanate. Neonatal RTX administration significantly reduced
the eye-wipe response to corneal application of capsaicin and also to
allyl isothiocyanate. *P < 0.05 vs. control. D.) Cold plate test. Paw
withdrawal latency (left) or time to first shiver (right) were measured
following placement of mice on a plate maintained at 5°C. Responses
were not significantly different. E.) Response latency in the tail
immersion into 4ºC cold water. No significant differences were seen
between control and RTX treated animals. F) Licking latencies in the hot
plate assay at 53°C. The responses were not significantly different.
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Figure 3: Changes in the chemical- and heat sensitivity of mice treated
with 50 μg/kg resiniferatoxin at adult age. Mice were tested two weeks
later. Comparisons were made using age matched control animals
treated with vehicle only. Bars represent means plus standard deviations
(n=7). The experiments were repeated two additional times with similar
results. A.) Oral aversion to allyl isothiocyanate (AITC). Treated mice
consumed significantly more allyl isothiocyanate containing drinking
water than untreated mice in 24 h tests. *P < 0.05 vs. control B-C.) Eye-
wipe response to corneal application of 100 μM capsaicin and 10 mM
allyl isothiocyanate. RTX administration significantly reduced the eye-
wipe response to corneal application of capsaicin and allyl
isothiocyanate. *P < 0.05 vs. control. D.) Cold plate test. Paw
withdrawal latency (left) or time to first shiver (right) was measured
following placement of mice on a plate maintained at 5°C. Treated mice
showed more sensitivity to cold. *P < 0.0001 vs. control. E.) Response
latency in the tail immersion into 4°C cold water. Significant differences
were seen between control and RTX treated animals. *P < 0.05 vs.
control. F) Licking latencies in the hot plate assay at 53°C Responses
were significantly different. RTX treated animals had longer reaction
times. *p < 0.05 vs. control.
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Interestingly, they showed no change in temperature sensitivity
neither in cold plate, nor in hot plate assay (Figure 2).
Mice treated with one dose of RTX at adult age become
similarly unresponsive to chemical stimuli, i.e., they did not
respond either to CAPS or AITC in the eye wipe tests, and they
were also able to consume AITC containing drinking water in
high quantities. In addition, the animals that underwent RTX-
mediated neurosurgery at adult age exhibited changes of heat
sensitivity. As it was expected from previous observations5, loss
of TRPV1-expressing neurons resulted in decreased heat
sensitivity. Surprisingly, however, the RTX-treated animals also
become more sensitive to cold, showing a marked reduction of
reaction time (around 30%) on cold plate as measured in cold
plate tail flick and cold plate shivering tests (Figure 3).
In the case of chronic RTX treatment (3 x 20 μg/kg body
weight rather than 1 x 50 μg/kg body weight) mice become
similarly unresponsive to CAPS. However these mice lost heat
sensitivity to a higher extent compared to mice with acute
treatment, so chronic treatment seemed to be more effective than
a single treatment in this respect (Figure 4).
Immunohistological staining experiments performed on adult
mice treated with 1 x 50 μg/kg body weight RTX confirmed that
TRPV1 is indeed lost after the treatment. The staining was
performed with a new monoclonal antibody developed in our
laboratory. Our hybridoma cell line was established from a
normal BALB/c mouse immunized previously with a crude
plasma membrane fraction isolated from a BALB/c 3T3 cell line
permanently expressing the rat TRPV1. By employing indirect
fluorescent labeling technologies, the monoclonal antibody was
verified to react with an extracellular loop of both rat and mouse
TRPV1. Parallel to TRPV1, TRPA1 also disappeared from the
trigeminal ganglions of the RTX treated animals (Figure 5), but
the TRPM8-positive cells remained readily detectable. TRPA1
and TRPM8 were stained with commercially available
antibodies.
The correlation between TRPV1 and TRPA1 levels in the
dorsal root ganglion and trigeminal ganglion with the changes in
chemical and heat sensitivity in mice treated at adult age was
tested in Western blot experiments. In this case, TRPV1, TRPA1
and TRPM8 were immunostained with commercially available
polyclonal antibodies. Our Western blot experiments confirmed
that, parallel to TRPV1, TRPA1 also disappeared from the
trigeminal ganglions of the RTX treated animals; the decrease
was 83% in the case of TRPV1, while 86% in the case of TRPA1,
while the amount of TRPM8 barely, non-significantly changed
(Figure 6).
DISCUSSION
Recently one of us proposed a novel use of RTX as pain killer
drug5. Being at least a thousand fold more potent analogue of
CAPS, RTX applied either intrathecally or intraganglionicallly
can execute a highly specific TRPV1 targeted molecular
neurosurgery to eliminate cellular generator of inflammatory as
Figure 4: Comparison of acute and chronic RTX treatment. Chronic RTX
(3 x 20 μg/kg body weight) is more effective than acute treatment (1 x 50
μg/kg body weight) as measured in hot plate assay. Bars represent means
plus standard deviations. Statistics were made by LSD post hoc test
following one-way ANOVA, *P < 0.05 vs. control.
Figure 5: Microscopic images showing the effect of RTX on TRPV1-,
TRPA1- and TRPM8-positive trigeminal ganglion neurons. Unlike
TRPM8, both TRPV1 and TRPA1 immunoreactivity was lost in the
treated animals. Bar represents: 0.2 mm.
Figure 6: Western blot analysis. Western blot shows the level of TRPV1,
TRPA1 and TRPM8 proteins in the lysates of pooled trigeminal ganglions
obtained from control and RTX treated mice. Similarly to TRPV1, TRPA1
also disappears from the trigeminal ganglions of treated animals, while
TRPM8 does not change. Sigma beta-actin was used in the Western blot
as an internal control.
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well as cancer pain 4,5. According to literature data, 24 hours after
CAPS treatment a population of primary sensory neurons of
newborn30 and adult rats31 show TUNEL staining, indicating that
neurons are killed by apoptosis. Likewise CAPS, RTX, due to 3-
4 magnitudes more potent agonist activity on TRPV1 can induce
Ca2+-cytotoxicity and eventually ablates these neurons by rapid
necrosis, followed by removal of the cell debris4,5,21,24.
Resiniferatoxin has been shown to eliminate inflammatory
pain by specific Ca2+-cytotoxicity in newborn25 as well as in
adult rats5, and it had an anti-nociceptive effect in adult mice32,
monkeys27 and dogs26. A number of in vitro and vivo experiment
has already validated safety and efficacy of molecular
neurosurgery management of arthritic and cancer pain, even in
large animals such as dogs and monkeys, promoting human trials
and registration of RTX as an alternative drug in pain
inflammation and various neuropathy indications26,27. Contrary
to TRPV1 antagnists, also in development as painkillers,
intraganglional or intrathecal RTX treatment would provide a
permanent solution to incurable chronic pain.
Resiniferatoxin treatment manifests in mice, as in other
experimental animals, in drastic loss of sensitivity to noxious
chemicals and coincident drop out of TRPV1+ nociceptive
neuronal bodies in sensory ganglia. Results in mice not only give
another reassuring validation of the molecular neurosurgery
technology4,5,24, but prompted us to develop the first monoclonal
antibody for better diagnosis of cell type specific drop out4.
Convincing decrease in number of small and medium size
TRPV1+ neuron counts has been determined in RTX treated
mice also cross-validated specificity of our novel monoclonal
antibody. Moreover, we found that RTX-treated mice also
showed loss of TRPA1-dependent chemical sensitivity,
confirming previous obser-vations that TRPV1 indeed co-
expresses with TRPA1 in a number of nociceptive neurons in the
peripheral nervous system. The eventual effect of RTX on
TRPA1 is excluded by previous publications. For example,
cultured DRG neurons of TRPV-/- mice did not show stimulus-
evoked rise in intracellular free Ca in response to resiniferatoxin,
proving that none of the remaining TRP receptors is vanilloid-
sensitive33. In addition, iodo-resiniferatoxin did not interefere
with DRG neuron activation in response to TRPA1 agonists34,
confirming that TRPA1 does not bind vanilloids ligands. We can
conclude that RTX-mediated molecular neurosurgery eliminates
most or all TRPA1-containing neurons as well via TRPV1
activation, as it is indicated by and the almost complete loss
specific immunoreactivity in sensory nociceptors.
The RNA diagnostics with RT-PCR technology in DRG
samples from RTX-treated and untreated rats have shown
significant decrease of both receptors35. Observation in these
studies extends and corroborates results of Ruparel and co-
workers that allyl-isothiocyanate, a selective agonist of TRPA1,
can heterologously inactivate TRPV1, probably located in the
same nociceptor neurons36. However, Ruparel et al interpreted
their results as consequence of TRPV1 desensitization involving
signaling events. Although transient, functional desensitization
based on signalling events might also be induced by low dose
vanilloids in other models37,38, in our case RTX treatment
obviously induces the loss of both TRPV1+ and TRPA1+
neurons. As we have confirmed, the treated animals become
insensitive to vanilloids for a lifetime, indicating that the
mechanism is indeed deletion-, and not signaling-based. Since
RTX treated mice are also insensitive to allyl-isothiocyanate, that
only can happen if TRPA1 expression is coincident with TRPV1
expression in the vast majority of nociceptive neurons that
normally confer pain signal to endogenous substances produced
in pain and inflammation.
Co-ablation of TRPV1+ neurons with TRPA1/allyl-
isothiocyanate receptors by the RTX treatment have been
circumstantially verified in experiments carried out in TRPV1
knockouts. In concert with evidences here, TRPV1-/- genotyped
mice still express TRPA1 in their inflammatory pain sensor
neurons, thus preserve sensitivity to allyl-isothiocyanate39 and
behave like wild-types.
The neuron subtype specificity of TRPA1 was characterized
by Story and co-workers as well in cell cultures12 and they noted
that TRPM8 is expressed in a distinct cell population. Moreover,
vast majority of TRPA1-positive cells showed co-localization
with the CGRP neuropeptide, another prominent biomarker of
TRPV1+ inflammatory pain-sensing neurons. Based on these
data, two markedly distinct populations of cold-responsive
neurons can be distinguished: i) TRPM8-positive neurons that
lack of TRPV1 and TRPA1 expression and resistant to RTX
treatment and ii) TRPA1-positive neurons that express TRPV1 as
well and can be deleted either with allyl-isothiocyanate or RTX.
Adult mice, treated with RTX as newborn, had an impaired
response to both CAPS and AITC in eye-wipe tests and agonist-
laced water consumption assays. In hot-plate experiments,
reaction time of the treated animals was not significantly
different from that of normal controls. Similar to our results,
however, Gamse et al have found that mice treated with CAPS as
newborns had normal reaction times either on the hot plate or in
tail withdrawal latency tests. In contrast, mice treated at
adulthood had greatly prolonged latencies in both thermal
sensitivity. Thus, responses to noxious chemicals in adulthood
were only moderately inhibited in mice treated as newborn, but
almost completely abolished if the vanilloid was administered to
adults40.
Nociceptive thresholds reported in neonatal CAPS-treated
animals are apparently contradictory. Several groups have found
small increase in thermal nociceptive threshold28,41 but others
reported little if any effect in hot plate tests42,43. It was reported
that perineural resiniferatoxin selectively inhibits inflammatory
hyperalgesia44. We have determined in serial experiments that
the heat threshold increase depends on the efficacy of the RTX
treatment; heat insensitivity of the animal becomes more
pronounced if RTX ablates TRPV1+ nociceptors almost
completely. Chronic, repeated RTX gave the best results while
neonatal treatments were less effective.
Based on comparative data collected from TRPV1-null mice
(little33 or no effect45 in hot plate test), we can conclude that there
might be additional heat receptors. The complete lack of signal
transmitted by TRPV1 positive neurons leads to the most
complete heat insensitivity in mice lacking TRPV1+ neurons
rather than the TRPV1 receptor only.
Previously, Obata et al noted that inflammation and nerve
injury increases expression of TRPA1, but not TRPM8, in DRG
neurons. Occurrence of cold hyperalgesia coincided with nerve
growth factor (NGF)-induced up-regulation of TRPA1 in distinct
set of sensory neurons46. Moreover, Katsura et al with intrathecal
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administration of an anti-sense-oligo specific for TRPA1 could
suppress the nerve-ligation-induced cold hyperalgesia, but anti-
TRPM8 had little or any effect47. Contrary to these observations
we found that not TRPA1 but TRPM8 is the main cold sensor. To
explain this unexpected finding, at least two alternative
hypothesizes can be made.
First, following to RTX-mediated neuronal drop out the
intense arborization of resistant nerve endings can produce NGF,
a validated exocrine transducer of gene inducer in nerve injury
and might cause over-expression of TRPM8, a prominent cold
pain signal transducer, as verified by others48. In fact, upon
inflammations and nerve injuries, nociceptors’ and thermo-
ceptors’ NGF expression is known to induced that correlates with
sensitization to cold and allodynia49,50. Intraplantar injection of
CAPS produces a transient thermal and mechanical hyperalgesia
within three to six hrs, that disappears by 24 hours. Interestingly,
CAPS injection upregulates proinflammatory cytokines and
NGF within 1 hour, then cytokine levels return to control
levels51. However, we have not found upregulation of TRPM8
channel in RTX treated mice using Western blot and RT-PCR. In
accordance with that, DRG samples from RTX-treated and
untreated rats have not shown significant change on the TRPM8
level35.
On the other hand, sensory stimuli are known to “compete”
with each other for representation at the level of brain, for
example, blind individuals have better auditory ability than
sighted subjects, a mechanism that apparently compensates for
loss of vision52. Analogously, cold hypersensation might confer
an imbalance in the representation of sensory stimuli signaling
heat and cold at the levels of the CNS. Due to neuronal plasticity,
mice treated at neonatal age most likely can compensate for the
imbalance caused by that drop out of C-type afferents neurons,
while effect of RTX treatment in adulthood can not be
compensated by “fine-tuning”.
Importantly, experimental data in this paper predict a shift in
heat perception in humans following RTX injection, as
conceptualized in the clinical trial protocol to treat severe cancer
pain. Similar changes might be expected during application of
reversible, specific inhibitors of TRPV1, currently in
development by different pharmaceutical companies. Such
behavioral change, however, was not obvious in cancer/arthritis
patient dogs treated via the intrathecal rout of application26,
neither in monkeys, targeted with this molecular neurosurgery
agent at the trigeminus ganglion27. Nevertheless, clinical trial of
RTX in cancer pain patients may provide the answers to this
question via thorough monitoring of potential change in cold
sensation if it may happen in human at all.
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Abstract Transient receptor potential vanilloid 1 (TRPV1)
is a non-selective cation channel involved in pain sensation
and in a wide range of non-pain-related physiological and
pathological conditions. The aim of the present study was to
explore the effects of selected heavy metal cations on the
function of TRPV1. The cations ranked in the following
sequence of pore-blocking activity: Co2+ [half-maximal in-
hibitory concentration (IC50)013 μM]>Cd
2+ (IC500
38 μM)>Ni2+ (IC50062 μM)>Cu
2+(IC500200 μM). Zn
2+
proved to be a weak (IC50027 μM) and only partial inhib-
itor of the channel function, whereas Mg2+, Mn2+ and La3+
did not exhibit any substantial effect. Co2+, the most potent
channel blocker, was able not only to compete with Ca2+ but
also to pass with it through the open channel of TRPV1. In
response to heat activation or vanilloid treatment, Co2+
accumulation was verified in TRPV1-transfected cell lines
and in the TRPV1+ dorsal root ganglion neurons. The
inhibitory effect was also demonstrated in vivo. Co2+ ap-
plied together with vanilloid agonists attenuated the noci-
fensive eye wipe response in mice. Different rat TRPV1
pore point mutants (Y627W, N628W, D646N and E651W)
were created that can validate the binding site of previously
used channel blockers in agonist-evoked 45Ca2+ influx
assays in cells expressing TRPV1. The IC50 of Co
2+ on
these point mutants were determined to be reasonably com-
parable to those on the wild type, which suggests that
divalent cations passing through the TRPV1 channel use
the same negatively charged amino acids as Ca2+.
Keywords Heavymetals . Somatosensory system . Pain .
Calcium channel . TRPV1 . Cobalt
Introduction
Small-diameter sensory neurons in the peripheral nervous
system (PNS) express the transient receptor potential/vanil-
loid receptor subtype 1 (TRPV1). Four identical subunits of
this protein form a functional Ca2+ channel. Similarly to other
transient receptor potential channel members, the TRPV1
channel belongs in the large superfamily of cation channels
with six transmembrane (TM) segments. Following agonist-
induced channel opening, a pore loop between segments TM5
and TM6 serves as a cation filter and entry site [1].
When endovanilloids are produced under various inflam-
matory conditions around the C and Aδ afferents of these
PNS neurons, TRPV1 transmits a specific pain sensation to
the brain [2–4]. Besides endovanilloids such as anandamide
[5, 6], TRPV1 is activated by acids (pH<6.3) and chemo-
irritants such as the exovanilloid capsaicin (CAPS) or resin-
iferatoxin, a naturally occurring, ultrapotent CAPS analogue
with excellent specificity for TRPV1 [2, 7–9]. Moreover,
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TRPV1 can integrate the effects of heat and vanilloids. The
heat-sensing domain has been mapped to the C-terminal
intracellular region [3, 9, 10].
The vanilloid binding site is localized between segments
TM3 and TM4 of TRPV1 [5]. The pain signal, however, is
generated by opening of the Ca2+ channel situated between
domains TM5 and TM6 of four identical subunits [11, 12].
An acidic peptide motif in the pore loop region of TRPV1
(DXEXXEXXD) may serve as a docking site for positively
charged ions and channel blockers [13]. However, our
sequence comparison and previous in silico model-
building efforts have not revealed any obvious homology
to other divalent metal ion (M2+)-binding structures such as
the EF-hand (DXDXDGXXDXXE) or the Excalibur
(DXDXDXXXCE) [13].
Various studies have demonstrated that positively charged
molecules can act as TRPV1 receptor channel blockers by
plugging the pore. Ruthenium Red (RuRed) (a well-known,
but non-specific TRPV1 pore blocker) [11], R4W2 (a positive-
ly charged hexapeptide) [14] and anti-calmodulins/antipsy-
chotic tricyclics [13] have been shown to be able to bind to
the DXEXXEXXD domain of TRPV1, whereby they block
the movement of Ca2+ through the pore region.
We set out to assess the effects of various metal cations at
different concentrations on the vanilloid -or heat-induced
activity of the TRPV1 channel, focusing on the investiga-
tion of the most potent cations in vitro and in vivo. More-
over, in our experiments we aimed to shed light on the
characteristics of the gating of the TRPV1 channel in order
to improve the understanding of the structure and function
of the TRPV1 pore region, which may lead to the develop-
ment of potentially useful painkiller drugs that modulate the
activity of this receptor.
Materials and Methods
Reagents Stock solutions (200 mM) of CoCl2, NiCl2, ZnSO4,
CdCl2, CuSO4, CaCl2, CoCl2 and LaCl3 were dissolved in
water and diluted as required to the working concentrations.
To avoid the precipitation of insoluble La(OH)3 and La
(CO3)3, the formation of radiocolloids and the loss of La
3+
by adsorption to container surfaces, LaCl3 solution was pre-
pared fresh daily in polyethylene vials [15]. RuRed and cap-
sazepine (CapZ; Sigma-Aldrich, St. Louis, MO) were
dissolved in DMSO. CAPS was dissolved initially as a stock
solution of 3 mM in 95 % ethanol. The peptide R4W2 was
synthetized in our laboratories and then dissolved in water and
used as a 25 mM stock solution. Amitriptyline (AMI), pur-
chased from Sigma-Aldrich, was dissolved in water.
Plasmids The C-terminally epsilon-tagged rat TRPV1ε
plasmid construct was prepared in the metallothionein
(pMTH) plasmid vector as described earlier [9]. To avoid
cell loss through the Ca2+-excytotoxic mechanism that
occurs when TRPV1 is overexpressed at 37 °C, only the
basal activity of the pMTH promoter was used. The protein
kinase C ε epitope tag allowed immunological detection of
the TRPV1ε protein, as earlier described [16]. Mutants
Y627W, N628W, D646N and E651W were kindly given
by Dr. K. J. Swartz (National Institutes of Health, Bethesda,
MD 20892, USA) [17] and subcloned into an EF-promoter-
driven green fluorescent protein (EGFP)-tagging plasmid
vector. The EGFP tag was used for visual determination of
the transfection rate by flow cytofluorometry with a FACS-
Calibur instrument (Becton Dickinson, San Jose, CA, USA).
Cell Lines Expressing TRPV1 Ectopically The HaCaT ker-
atinocyte cell line was a kind gift of Prof. B. Farkas
(Department of Dermatology, University of Cologne, Fed-
eral Republic of Germany) [18]. The COS-7 (CRL-1651)
and BALB/c-3T3 (CCL-163) cell lines were obtained from
ATCC. The 3T3 and HaCaT cell lines permanently express-
ing the rat TRPV1 channel were prepared as described
earlier [19]. COS7 cells were transiently transfected with
plasmid containing the sequence of the Y627W, N628W,
D646N or E651W TRPV1 mutants or the wild-type TRPV1
channel, by using the Fugene transfection reagent (Roche,
Mannheim, Germany). The transfection efficacy was deter-
mined by flow cytofluorometry.
Primary Dorsal Root Ganglion Cultures Were prepared
from E16 embryonic rats as reported earlier [9]. Briefly,
dorsal root ganglions (DRGs) were dissected and then pro-
cessed in Hank’s balanced salt buffer until plated in Dul-
becco’s Modified Eagle Medium (DMEM). The DMEM
contained 20 mM HEPES, pH 7.4, 7.5 % foetal bovine
serum, 7.5 % horse serum, 5 mg/ml uridine supplemented
with 2 mg/ml 5-fluoro-2′-deoxyuridine and 40 ng/ml nerve
growth factor to inhibit cell division and to promote the
differentiation of long neuronal processes, respectively.
Cells were seeded on 25 mm glass coverslips.
Cobalt Histochemistry Rat DRG cells attached to the cover-
slips were washed in buffer A (in millimolars: NaCl, 57.5;
KCl, 5; MgCl2, 2; HEPES, 10; glucose, 12; sucrose, 139;
pH 7.4) for 2 min, and then incubated at 37 °C for 10 min in
Co2+-uptake solution (buffer A+5 mM CoCl2) containing
20 μM CAPS. High (20 μM) capsaicin concentration is
used in order to obtain a robust and easily detectable Co2+
signal. Following a brief wash in buffer A, the water-soluble
Co2+ taken up by the cells was precipitated with 0.12 %
ammonium polysulphide (Sigma-Aldrich) in buffer A,
which resulted in the formation of dark, water-insoluble
CoS in TRPV1+ cells. Cells were fixed in 4 % formalde-
hyde and mounted on glass slides, using Kaiser’s glycerol
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gelatine (Merck, Darmstadt, FRG). Cells were examined
under a Nikon light microscope (Melville, NY, USA) and
photographed with a SPOT RT-SE™ Digital Camera
(Diagnostic Instruments). Pictures of the cells were analysed
by means of ImageJ 1.45 s software (National Institutes of
Health, USA), and the subsequent statistical analyses were
performed with PRISM™ 3.01 software (GraphPad Software,
Inc. San Diego, CA, USA).
Vanilloid-Induced 45Ca2+ Uptake Vanilloid-induced 45Ca2+
transport was assayed in the HaCaT adherent cell lines ectop-
ically expressing the C-terminally ε-tagged rat TRPV1
(3×104 cells/well) and Cos7 cells transiently transfected with
rat TRPV1 mutants, seeded in poly-D lysine-coated 96-well
plates. Immediately before the transport assay, the cells were
washed three times with physiological saline solution at room
temperature (20–25 °C). We had previously found that
TRPV1-transformed cells functioned in the same manner at
room temperature as at 30 °C (data not shown). 45Ca2+ uptake
was performed for 10 min with 0.1 μCi 45Ca2+ as radioactive
tracer in a final volume of 100 μl (1.8 μM). CAPS was diluted
from a 3 mM ethanol stock solution to the indicated final
concentrations. For the termination of 45Ca2+ uptake, cells
were rapidly washed four additional times with 0.2 ml PBS
solution, and then lysed in 80 μl/well RIPA buffer (50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1 % Triton X-100, 0.5 %
deoxycholate, 0.1 % SDS and 5 mM EDTA) for 30 min [8, 9,
20, 21]. Aliquots of the solubilised cell extracts were mixed
with 120 μl SuperMiX and counted in a 96-well plate liquid
scintillation counter (TopCount-NXT, Packard). To measure
the effect of temperature on the TRPV1 function in the 45Ca2+-
uptake assay, TRPV1/HaCaT cells were plated on six-well
plates. 45Ca2+ uptake was evoked with 10 ml preheated buffer.
The procedure was followed as described above.
After the measurement, the data were corrected for the
basal activity of TRPV1 and normalized from zero to one,
where zero denotes the counts per minute in TRPV1/HaCaT
cells without CAPS and one denotes the counts per minute
in TRPV1/HaCaT cells with CAPS. The results of three
parallel measurements were averaged and evaluated with
PRISM™ 3.01 software (GraphPad Software, Inc. San
Diego, CA, USA). During curve fitting, the “Analyze/Non-
linear regression (curve fit)/Sigmoidal dose–response”
menu of PRISM™ software was applied. The curve-fitting
equation was: Y0Ymin+ (Ymax−Ymin)/(1+10(logEC50-X)),
where X0 logarithm of concentration and Y0the response.
Eye Wipe Tests Eye wipe tests were performed on CD1
mice. A 100 μM CAPS solution, or a solution containing
100 μM CAPS and 1 mM CoCl2, or a solution containing
100 μM CAPS and 5 μM CapZ was dropped into the eye,
and the number of defensive wiping movements was then
counted.
Statistical Analysis One-way ANOVA followed by Turkey’s
post-tests was performed with GraphPad Prism version 3.01
software (GraphPad Software, Inc. San Diego, CA, USA).
Results
In the 45Ca2+ uptake assay, the EC50 of CAPS for wild-type
TRPV1 was determined to be 0.0860 μM. Approximately
1 μM CAPS caused the full activation (EC100) of TRPV1 at
pH 7.5. Channel blocker-screening assays were therefore
carried out with 2 μM CAPS (an excess amount of agonist),
which does not cause Ca2+ cytotoxicity during the 10-min
incubation period. The interactions of the metal ions with
TRPV1 were studied by using a vanilloid-induced 45Ca2+-
uptake assay. Experiments were carried out on the TRPV1/
HaCaT permanent indicator cell line. Channel opening was
induced by CAPS in the presence of progressively increas-
ing M2+ concentrations in the uptake solution. Incubation of
the cells in uptake solutions containing both 45Ca2+ and
Mg2+, Mn2+ or La3+ (data not shown) resulted in little or
no effect, even at the highest concentration (4 mM), whereas
Zn2+ proved to be a weak [half-maximal inhibitory concen-
trations (IC50)027 μM] and only partial inhibitor of the
2 μM CAPS-induced 45Ca2+ uptake. The other cations ef-
fectively blocked the vanilloid-induced Ca2+ entry into
TRPV1/HaCaT cells, with the following sequence of
potency: Co2+ (IC50013 μM)>Cd
2+ (IC50038 μM)>
Ni2+(IC50062 μM)>Cu
2+ (IC500200 μM; Fig. 1a).
To assess the effect of Co2+, the most potent TRPV1
inhibitor, on the heat-activated TRPV1 channels, the activity
of TRPV1 was investigated in the presence either of 2 μM
CAPS alone or of 2 μMCAPS+250 μMCo2+, at both 37 and
42 °C. The negative control did not contain CAPS. In this
assay, high temperature activated the TRPV1 channels and
also increased the CAPS-evoked 45Ca2+ influx. Co2+ reduced
both the heat and CAPS-induced 45Ca2+ influx (Fig. 1b).
To compare the potency of Co2+ with those of the other
positively charged channel blockers, we measured the IC50
values of RuRed, AMI and R4W2, which are known to have
a docking site in the pore loop of TRPV1. The inhibitor
potentials of these pore blockers were measured via the
CAPS-induced 45Ca2+ uptake. All of them inhibited
CAPS-activated TRPV1, with the following IC50 values:
RuRed01 μM, AMI020 μM and R4W20100 μM (Fig. 1c).
For a better understanding of the inhibition kinetics of
Co2+ on TRPV1, increasing concentrations of both Co2+ and
CAPS were applied in the vanilloid-induced 45Ca2+-uptake
assays. The Ca2+ uptake of TRPV1/HaCaT cells was
inhibited by the simultaneous presence of Co2+ in a dose-
dependent manner. However, increasing concentrations of
Co2+ decreased only the maximal response of efficacy
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(Emax) of Ca
2+ entry; the affinity of CAPS for TRPV1 did
not change. The inflection point in the CAPS dose–response
curves in each of the Co2+ co-incubation studies was found
at ∼0.08 μM (i.e. EC50), independently of the Co2+ concen-
tration. The Co2+ inhibition patterns unequivocally indicat-
ed channel blocking kinetics (Fig. 2a).
By varying the concentrations of Co2+ and Ca2+ and
measuring the radioactive 45Ca2+ influx, we assessed
whether there was a competition between Co2+ and
Ca2+. The effect of dilution on the amount of accumu-
lated 45Ca2+ did not appear at extracellular cold Ca2+
concentrations below 1 mM (Fig. 1a), indicating that
TRPV1+ cells accumulate Ca2+ very effectively from
the extracellular space and collect them putatively into
ER or mitochondria. Increasing cold Ca2+ concentration
decreased the inhibitory effect of Co2+ (IC50 values in
the presence of 0, 15.625, 31.25, 62.5 and 125 μM cold
Ca2+: 7.944, 51.22, 72.69, 79.09 and 189.1 μM, respec-
tively), showing that the effect of Co2+ on Ca2+ entry
mainly depends on the competition for entry sites. These
results suggest that the Co2+ entry through the TRPV1
channel is slower, and the Co2+ displacing the Ca2+ from
the pore region of TRPV1 slows down or inhibits the
Ca2+ uptake (Fig. 2b).
The prolonged agonist stimulation of TRPV1 has been
reported to result in an increased permeability to larger
cations [22] or small molecules [23], due to conformational
changes in the open state of the TRPV1. Thus, we analysed
the kinetics of the channel-blocking activity of Co2+ by
employing different CAPS concentrations. An anticipated
shift in the IC50 of Co
2+ would be evidence supporting the
idea that Co2+ entry depends on the TRPV1 open stages. We
indeed observed a shift in the IC50 of Co
2+, which decreased
with increasing CAPS concentration (Fig. 2c). Consequent-
ly, increasing agonist concentration enhances the blocking
ability of Co2+. To investigate this phenomenon, we plotted
the IC50 values as a function of CAPS concentration. Curve-
fitting analysis confirmed a strong interrelationship between
IC50 and the CAPS dose applied (Fig. 2d), suggesting that
the increased efficiency of inhibition correlates with the
different open-state conformations of the TRPV1 channel.
We traced Co2+ upon vanilloid induction in sensory neu-
ron cultures prepared from DRGs of rat embryos. To test
Co2+-accumulation patterns, cells were co-incubated with
20 μM CAPS in Co2+-containing Ca2+-uptake medium,
and the Co2+ was then localized by means of NH4S histo-
chemistry. These experiments revealed that Co2+ not only
competes with Ca2+ but also enters into the cytosol of
specific PNS sensory neurons. Functionally responsive
vanilloid-sensitive neurons (i.e. TRPV1+) exhibited dark-
brown Co2+ precipitates inside the rounded neuronal bodies
(Fig. 3e). As expected from previous studies, TRPV1 is
endogenously expressed in approximately one third of the
cultured neurons [24–27]. Without CAPS, no intracellular
Co2+ accumulation was observed (data not shown). Similar
experiments were carried out on rTRPV1/HaCaT and
rTRPV1/3T3 cell lines. The accumulation of Co2+ was
blocked by RuRed, a channel blocker of heat and vanilloid
pain signalling. Moreover, the dose-dependent inhibition of
the cellular entry of Co2+ was determined by the co-
application of 5 μM CapZ, a long-known competitive
Fig. 1 Ranking divalent cations as channel blockers in cell-based
assays. a Efficacy of M2+ inhibitors of TRPV1 ranked by vanilloid-
induced 45Ca2+ uptake. b Co2+ inhibits heat-induced Ca2+ uptake at
37 °C and at 42 °C. c RuRed, R4W2 and AMI, previously validated
selective channel blockers of TRPV1, were also tested for better
comparison of inhibitors. Data are mean values±standard deviation
(SD) of the results of three independent experiments. Statistical signif-
icance was assessed by post hoc LSD t tests after significant one-way
analysis of variance (ANOVA). P<0.05
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antagonist of pungent vanilloids. After analysis of the pho-
tographs of the cells with the ImageJ program, statistical
analysis of the data further confirmed our findings: the mean
gray values of CAPS-exposed, CAPS-free and CapZ-
exposed cells proved to be significantly different (CAPS
without Co2+, 72.05±12.38 (S.D.), n0146; CAPS+Co2+,
124.4±21.51 (S.D.), n0111; CAPS+Co2+ + CapZ, 76.92±
22.21 (S.D.), n0100; P values of the t tests: CAPS without
Co2+ vs. CAPS+Co2+, P<0.0001; CAPS+Co2+ vs. CAPS+
Co2++CapZ, P<0.0001; CAPS without Co2+ vs. CAPS+
Co2++CapZ, P00.0290; Fig. 3). The gray values were
measured on the negatives of the images: the darker the
cells, the higher the gray values. Analysis of the pictures
in Fig. 4, showing TRPV1-expressing HaCaT cells, resulted
in the same outcome. Following ANOVA, the groups were
compared by using t tests. Each t test except that involving
CAPS without Co2+ vs. CAPS+Co2++100 μM CapZ indi-
cated a significant difference between the pairs of groups
(P<0.05; Fig. 4). No substantial staining could be observed
on 3T3 cells (Fig. 5a–e). Statistical analysis of the gray
values of the cells indicated no significant darkening in the
absence of TRPV1 in the cell membrane.
In order to rule out the possibility that Co2+ can enter the
cells through VGCCs, 3T3 cells were challenged with
50 mM extracellular KCl. These cells did not show any
VGCC activity: the high extracellular KCl concentration-
induced depolarization that opens the VGCC channels did
not cause 45Ca2+ accumulation in the 45Ca2+ -uptake assay.
Moreover, the VGCC blocker nisoldipine did not de-
crease the CAPS-induced TRPV1-mediated 45Ca2+ accumu-
lation (data not shown). No Co2+ staining was observed in
the presence of 50 mM extracellular KCl (Fig. 5f–j).
ANOVA indicated no significant differences among the
groups (P00.9150). These results confirm that the CAPS-
induced Ca2+ and Co2+ influx in TRPV1/3T3 cells is due
exclusively to the TRPV1 channel activity.
Besides the in vitro demonstration of Co2+ antagonism,
we further validated this Co2+ inhibition phenomenon in
tests of eye wiping in response to pungent vanilloids [28].
Co2+ again decreased the frequency of vanilloid-evoked
defending movements. Inhibition experiments with CapZ
cross-validated and confirmed our earlier findings (Fig. 6a).
To validate that Co2+ inhibition is a consequence of com-
petition with Ca2+ for M2+-chelating sites in the pore loop
domain, we prepared several point mutants in this region of
TRPV1, and determined the channel kinetics through 45Ca2+-
uptake experiments in 3T3 cells expressing the mutant chan-
nels. Some of these mutants had been partially characterized
earlier in the context of spider venom channel inhibitors [17],
and these residues proved to have an important role in the
binding of various previously tested channel blockers (RuRed,
etc.). Mutated sites are illustrated schematically in Fig. 6b.
The EC50 and EC100 values of mutant channels for CAPS
were different from those of the wild type (D646N EC500
270 nM, E651W EC500540 nM, N628W EC500720 nM and
Y627W EC500820 nM), and the blocking effects of Co
2+ and
Fig. 2 Co2+ inhibits Ca2+ entry through the TRPV1 channel. a Kinet-
ics of inhibition of Ca2+ transport by Co2+ in TRPV1+ cells. Data are
mean values±SD of the results of three independent experiments. b
Kinetics of competition between Co2+ and cold Ca2+ in TRPV1+ cells.
c Co2+ blockage at different CAPS concentrations. Representative data
are shown from independent experiments repeated at least three times.
d IC50 values as a function of CAPS concentrations. IC50 values of Co
2+
in the presence of 0.0625, 0.125, 0.25, 0.5, 1, 2 or 4 μMCAPS are 94.81,
57.97, 73.17, 32.6, 19.22, 22.55 and 15.62 μM, respectively
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Fig. 3 Co2+ histochemistry on the 3T3 cell line expressing TRPV1
ectopically. Cells were incubated for 10 min in buffer A containing a
20 μM CAPS+5 mM Co2+; b 20 μM CAPS+5 mM Co2++5 μM
CapZ; c 5 mM Co2+ without CAPS. The dark CoS precipitate indicates
the presence of intracellular Co2+ that is blockable with CapZ, a
competitive antagonist of pungent vanilloids. d Gray values of the
3T3 cell line expressing TRPV1 measured by means of ImageJ soft-
ware. e Co2+ histochemistry in CAPS-sensitive rat DRG neurons. Scale
bar00.05 mm. These results confirm that Co2+ not only acts as a
blocker but also enters the cell with Ca2+ through the TRPV1 channel
Fig. 4 Co2+ histochemistry on the HaCaT cell line expressing TRPV1
ectopically. Cells were incubated for 10 min in buffer A containing a
20μMCAPS+5mMCo2+; b 5mMCo2+ without CAPS; c 20 μMCAPS
+5mMCo2++300 nMCapZ; d 20μMCAPS+5mMCo2++5μMCapZ;
e 20 μM CAPS+5 mM Co2++100 μM CapZ; f 20 μM CAPS+5 mM
Co2++500 nM RuRed; g 20 μM CAPS+5 mM Co2++7 μM RuRed;
h 20 μM CAPS+5 mM Co2++100 μM RuRed. The dark precipitates
indicate the presence of intracellular CoS that is blockable with RuRed, a
channel blocker of heat and vanilloid pain signalling. Co-application of
CapZ, a competitive antagonist of pungent vanilloids, also inhibited the
cellular entry of Co2+ in a dose-dependent manner: this is a well-
characterized evidence-based method of localization of intracellular
Co2+. I: Gray values of the HaCaT cell line expressing TRPV1 measured
by means of ImageJ software
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RuRed on TRPV1 mutants were therefore analysed with
4 μM CAPS. The neutralization of D646 reduced the sensi-
tivity of TRPV1 to RuRed inhibition [11]. Our 45Ca2+-influx
studies on TRPV1 point mutants revealed the following IC50
data for RuRed: IC50 (D646N)012.8 μM>IC50 (N628W)0
1.33 μM>IC50 (E651W)00.94 μM>IC50 (wild type)0
0.87 μM>IC50 (Y627W)00.26 μM (Fig. 6c), which findings
correspond with published results [17]. Likewise, Co2+
inhibited the 4 μM CAPS-evoked 45Ca2+ influx in the
D646N and E651W point mutants similarly as determined in
the wild type. The neutralization of D646 caused no or only a
minimal change in IC50. As compared with the wild type in
this representative experiment, Co2+ sensitivity was slightly
reduced in the D646N mutant (IC50018.3 vs. 25.7 μM). The
Y627W, N628W and E651W mutants displayed little or no
difference relative to the wild type (IC50018.6, 16.4 and
15.3 μM, respectively vs. 18.3 μM; Fig. 6d). Based on these
findings, inhibition seems to be a consequence of competition
with Ca2+ for M2+-chelating sites in the pore loop domain.
Discussion
Testing the effects of various metal cations on the vanilloid-
induced activity of the TRPV1 channel, we demonstrated
that Mg2+, Mn2+ or La3+ caused little or no decrease in
Fig. 5 Co2+ histochemistry on
the 3 T3 cell line. Cells were
incubated for 10 min in
buffer A containing: a 20 μM
CAPS+5 mM Co2+; b 20 μM
CAPS+5 mM Co2++5 μM
CapZ; c 5 mM Co2+ without
CAPS. d 20 μM CAPS without
Co2+. No CoS precipitate could
be observed in the absence of
TRPV1 protein in the cell
membrane. e Gray values of the
3T3 cell line measured by
means of ImageJ software.
Cells were incubated for 10 min
in: f buffer A containing 5 mM
Co2+; g buffer A without Co2+;
h modified buffer A containing
50 mM KCl+2.5 mM
NaCl+5 mM Co2+; i modified
buffer A containing 50 mM
KCl+12.5 mM NaCl without
Co2+. j Gray values of the 3T3
cell line measured by means of
ImageJ software. These results
confirm that Co2+ does not
enter the 3T3 cells through
VGCCs
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channel activity, whereas Zn2+ proved to be a weak and only
partial inhibitor of the 2 μM CAPS-induced 45Ca2+ uptake.
The other cations effectively blocked the vanilloid-induced
Ca2+ entry into TRPV1/HaCaT cells, with the following
sequence of potency: Co2+>Cd2+>Ni2+>Cu2+.
It was reported by Nilius et al. [29] that Co2+ reduced the
inward Ca2+ current through ECaC1 (TRPV5), a close rel-
ative of TRPV1, sharing around 30 % homology with it.
Fast and reversible recovery of the current upon washout of
the inhibitor was detected during their experiments. Further-
more, they identified other M2+-s as effective inhibitors of
the Ca2+ influx. Their results indicated the following overall
blocking sequence: Pb2+0Cu2+0Gd3+>Cd2+>Zn2+>La3+>
Co2+>Fe2+>>Fe3+. Zeng et al. found Cu2+ to be a potent
inhibitor of the whole-cell current evoked by intracellular
ADP-ribose through TRPM2, another member of the TRP
group. The inhibitory effect of Cu2+ was irreversible, and
occurred only if Cu2+ was administered in outside-out
patches, suggesting that the action site is located extracellu-
larly. The TRPM2 current was also blocked by Hg2+, Pb2+,
Fe2+ and Se2+ [30].
In accord with the above-mentioned findings, we also
observed ion influx-inhibitory effects of M2+-s on TRP
channel. Depending on the TRP channel type, differences
of the orders of blocking potency could be detected. Fur-
thermore, the blocking effects of the individual cations
could be reversible or irreversible, depending on the channel
type. The three channels are close relatives and share high
degree of sequence and structural homology with one an-
other, which explains the similar responses to M2+-s. Hav-
ing diverged from a common ancestor, TRP channels
operate on uniform principles. However, during evolution
TRP superfamily has evolved for various specialized func-
tions. TRPV1 and TRPV5, for example, belong to different
subgroups of the TRPV family; TRPV1–4 are non-ion-
selective, whilst TRPV5–6 are highly Ca2+-selective.
Hence, this functional adaptation may cause the differences
in the M2+-evoked responses.
As concerns our own results, Co2+ reduced not only
CAPS-induced but also heat-induced 45Ca2+ influx. When
increasing concentrations of both Co2+ and CAPS were
applied, the Co2+ inhibition patterns indicated channel-
blocking kinetics. Our dose–response and Co2+ accumula-
tion experiments revealed a competition for binding sites
and a co-entry mechanism. We presume that Co2+ inhibits
TRPV1 through its ability to bind to the ion selectivity filter
of the channel: it passes through the ion channel much more
slowly than Ca2+. Ca2+ entry is also slowed down by the
binding of Co2+, which occupies the appropriate amino acid
residues of the ion selectivity filter. This hypothesis
seems to be further supported by the findings of Sajadi
[31], who determined the stability constants of the 1:1
complexes formed between M2+ and L-tryptophan and
other amino acids. The sequence obtained in the case of
tryptophan was Ca2+<Mg2+<Mn2+<Co2+<Ni2+<Cu2+>
Zn2+, which follows the Irving-Williams sequence [32].
The order of the stability constants was similar in the
cases of methionine, alanine, leucine, valine and glycine. The
amino acid sequence of the putative pore region is
STSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGD
(Q8NER1, UniProt), containing all the tested amino acids but
valine. The stability constants formed between M2+ and tryp-
tophan were Ca2+, 2.55±0.08; Mg2+, 2.84±0.08; Mn2+,
3.34±0.05; Co2+, 4.34±0.07; Ni2+, 5.31±0.06; Cu2+,
Fig. 6 Eye wipe test performed
on CD1 mice and cobalt uptake
experiments on TRPV1 point
mutants. a Eye wipe responses to
the corneal application of CAPS
alone or together with Co2+ or
CapZ. Statistical significance of
inhibition was assessed by means
of the paired t test (P<0.05). Data
are means±SD of the results of
eight independent experiments
(n08). b Schematic localizations
of the mutants used in the study.
c, d IC50 of RuRed and Co
2+
determined on TRPV1 point
mutants and wild type (WT).
Data are means±SD of the results
of three independent experi-
ments. TRPV1 point mutants
revealed that the binding regions
of Co2+ and RuRed are different
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8.05±0.05 and Zn2+, 5.00±0.08. The stability constants for
Mg2+ and Mn2+ are close to that of Ca2+, so these ions can
probably readily pass through the open channel of TRPV1.
Co2+, Ni2+ and Cu2+ can be characterized by much higher
complex-forming strength, elucidating the elevated TRPV1
blocking potency. Interestingly, for these three M2+-s, an
unexpected relationship can be observed between the stability
constant and the TRPV1 blocking potency. The stronger the
bond, the weaker the TRPV1 inhibition potency is. The ionic
radii (in picometres) of these cations are Ca2+, 100; Mg2+, 72;
Mn2+, 67; Co2+, 65; Ni2+, 69; Cu2+, 73 and Zn2+, 74 [33].
Ca2+ is likely to have the ideal ionic radius and stability
constant in its reactions with amino acids in order to be
effectively passed along the carbonyl groups of the peptide
backbone in the ion selectivity filter and the pore loop. Co2+
has a medium stability constant and the smallest ionic radius,
which is probably not adequate for efficient transport. These
two parameters seem to be equally involved in the proper ion
influx. The stronger the M2+-amino acid complex and the
smaller the ionic radius is, the more probable it is that M2+
will block the Ca2+ influx through the TRPV1 channel. As
another interesting finding, in our experiments, Zn2+seemed
to be only weak and partial inhibitor of the ion current. Its
stability constant is almost as high as that of Co2+, suggesting
a strong TRPV1-blocking ability, whereas its ionic radius is
much larger than that of Co2+. Interestingly, the IC50 of Zn
2+ is
the second lowest exceeding only that of Co2+, but Zn2+ can
achieve a decrease of merely 30 % of the maximal ion influx.
The TRPV1 channel is a non-selective cation channel, and
still shows preference for Ca2+. The sequence of permeability
is Ca2+>Mg2+>Na+0K+0Cs+ [3]. In addition to all these,
TRPV1 also conducts protons [34]. Following prolonged
exposure to agonists, TRPV1 becomes permeable even to
larger organic cations, including dyes such as YO-PRO1 and
FM1-43 [22] and a lidocaine derivative QX-314 [23]. Increas-
ing agonist concentration enhances the blocking ability of
Co2+, suggesting a correlation between the increased efficacy
of inhibition and the different open-state conformations of the
TRPV1 channel. Further experiments (involving patch-clamp
recordings) would be needed to clarify the inhibitory effect of
Co2+ on the fluxes of the other cations ormolecules mentioned
above. However, no channel blocker or antagonist of TRPV1
has been reported that is able to block the flux of only one
specific ion, and antagonists seem to block all these influxes.
For example, CapZ blocks the influxes of both Ca2+ and Na+
[35]. Overall, we presume that Co2+ can also block the ion
currents mentioned above.
Before the exploration of TRPV1 protein, Co2+ histo-
chemistry was a very useful tool for the identification of
vanilloid-sensitive primary afferent neurons with C-and Aδ
fibres after in vivo experiments. Co2+ uptake and the post-
mortem determination of Co2+ deposits quite accurately
identified C-and Aδ afferents, the neuronal subset that can
be activated by treatment with a vanilloid agonist, CAPS
[36, 37]. Likewise, as previously documented in a subpop-
ulation of pseudo-unipolar neurons [38], we have now dem-
onstrated selective vanilloid-induced Co2+ accumulation in
the cytosol of DRG primary cultures and TRPV1-transfected
HaCaT and 3T3 cells. The accumulation of Co2+ could be
blocked by RuRed or CapZ in a dose-dependent manner. The
CAPS-induced Ca2+ and Co2+ influxes in TRPV1/3T3 cells
proved to be due exclusively to the TRPV1 channel and not to
VGCC activity.
Co2+ inhibited the pain-evoked defensive movements in
eye wipe tests in response to pungent vanilloids. However,
not only TRPV1 but also some other calcium channels of
the sensory neurons, such as VGCCs, can be blocked by
Co2+ [39]. VGCCs share structural homology with TRPV1
channel. The α1 subunit of voltage-gated calcium channels
is organized in four homologous domains (I–IV), with six
transmembrane segments (S1–S6) in each [40]. There is an
additional region (H5) between S5 and S6, which forms a
part of the pore region of the channel [41]. Within each H5
region, there exist conserved glutamate residues, significant-
ly homologous to conventional EF-hand motifs [42], acting
as the selectivity filter [43]. Mn2+, Ni2+ and Cd2+ in contrast
with Co2+ are known to be stronger blockers of the VGCCs.
Cu2+, Mn2+ and Co2+ blocked high-voltage activated cur-
rents conducted by Ba2+ with IC50 of 920, 58, and 65 μM,
respectively [44, 45]. All of these ions exert their effects
through high-affinity docking to the cation-binding site at
the IIIS5–H5 pore region of the VACCs [46, 47]. Since Co2+
has higher IC50 for VGCCs (≈65 μM) than for TRPV1
(≈15 μM), we can conclude that decrease in the number of
eye wipes might be due, at least partially, to an inhibitory
effect of Co2+ on TRPV1.
Positively charged tricyclics, K/R-rich basic peptides and
RuRed dock to the DXEXXEXXD motif at the channel
orifice [13]. Although our point mutants overlap with the
RuRed docking site [11, 14, 45], our point mutant studies
suggest that Co2+ has a different binding site. Accordingly,
the D646N point mutant, which is crucial for RuRed bind-
ing, does not change the kinetic parameters of Co2+ inhibi-
tion in cells ectopically expressing the D646N mutant
TRPV1. We carried out vanilloid-induced 45Ca2+-uptake
experiments with channel point mutants of TRPV1 in which
the agonist binding site remained intact. Interestingly, no
significantly decreased efficacy of Co2+ inhibition was
found when 646aspartate was replaced by asparagine. Based
on these results, Co2+ is supposed to evoke its effect at a
different site on the pore loop region than RuRed, or to use
the same negatively charged amino acids passing through
the TRPV1 channel as Ca2+. This line of research on func-
tional point mutants should be continued to determine
whether Co2+ has a specific binding site on the channel
orifice or not.
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Most painkiller drugs are competitive agonists and target
the CAPS-binding domain [48]. As the 646DLEFTENYD
acidic tetrad sequence of the TRPV1 receptor is unique
among Ca2+-binding proteins, this permits the design of
painkillers targeting the channel orifice of TRPV1 and act-
ing as channel blockers. A better understanding of the
structural background and dynamics of the competition of
Ca2+ with other M2+ for entry may result in the discovery of
novel channel blocker painkillers. Furthermore, our data can
contribute to a better understanding of the structures and
functions of all TRP superfamily members. The specific
effect of the selected M2+-s on the given ion channel pore
region can serve as a valuable constraint during in silico
modelling of the pore region. By comparing the different
cation action profiles of pore regions, the model can be fine-
tuned. The mechanism of Co2+-mediated inhibition provides
screening for adjuvant therapeutics with higher selectivity
than that of AMI, an approved drug currently used in clin-
ical practice, but with only limited efficacy and with serious
side effects.
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This review aims to create an overview of the currently
available results of site-directed mutagenesis studies on
transient receptor potential vanilloid type 1 (TRPV1) re-
ceptor. Systematization of the vast number of data on
the functionally important amino acid mutations of
TRPV1 may provide a clearer picture of this field, and
may promote a better understanding of the relationship
between the structure and function of TRPV1.
The first few sections provide a brief introduction of
the transient receptor potential family and the TRPV1
ion channel. The following sections compile the posi-
tions crucial for the different channel functions and the* Correspondence: winter.zoltan@brc.mta.hu
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Szeged, Szeged, Hungary
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reproduction in any medium, provided the oramino acid changes of these 112 unique mutated sites of
TRPV1. The information collected in this form may
serve as a powerful tool for in silico molecular modelling
by facilitating the establishment of boundary conditions.
All mutations and positions discussed in this paper
generally refer to the rat ortholog (rTRPV1) of the
TRPV1. All results relating to other species will be
highlighted in the text.
Transient receptor potential channels
The first TRP channel was discovered in 1969 by Cosens
and Manning, who isolated a mutant photoreceptor from
Drosophila melanogaster, which caused the specimen to
become temporally blind upon exposure to bright light
[1,2]. TRP channels are one of the largest families of ion
channels. The mammalian TRP superfamily consisting of
28 TRP cation channels can be subdivided into sixLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TRPM (“Melastatin”), TRPP (“Polycystin”), TRPML
(“MucoLipin”) and the TRPA (“Ankyrin”) groups [3,4].
All TRP channels are tetramers assembled with four-
fold symmetry from the individual subunits containing
six putative transmembrane segments (TMs). The region
between the fifth and the sixth TMs, including a putative
pore loop, forms the ion permeation pathway [5]. The
amino and carboxyl (N- and C-) termini are located
intracellularly and vary vastly in length and amino acid
sequence. These cytoplasmic regions contain diverse well-
recognized domains and motifs that are likely to be involved
in channel assembly, activation and regulation through
protein-protein and/or protein-ligand interactions. Most
TRP channels are cation-selective, and some are highly se-
lective for Ca2+ or Mg2+ [4]. In accordance with their amino
acid sequence diversity, TRP channels exhibit various acti-
vation and modulatory mechanisms, such as those involv-
ing in the stimulation by G-protein-coupled receptors,
extracellular and intracellular ligands (including H+, Ca2+
and Mg2+), phosphatidylinositol-4,5-bisphosphate (PIP2),
temperature, and mechanical stretch [6].
The accumulating evidence that TRP channels are im-
portant components of several human diseases has cre-
ated a huge interest for these channels as novel potential
drug targets. Comprehensive reviews have been pub-
lished on the modulation and potential pharmaceutical
application of TRP channels [7-11].
TRPV subfamily
The TRPV family includes six mammalian ion channels,
TRPV1-TRPV6, with a large C- and an even larger N-
terminal cytoplasmatic domain containing ankyrin repeat
domains (ARD) [12,13]. Ankyrin repeats, the 33-residue
sequence motifs, are essential in channel function, ATP,
PIP2, and calmodulin (CaM) binding [14] and protein-
protein interactions [15,16]. They are present in many
proteins, with functions including signalling, cytoskeleton
integrity, transcription and cellular localization [17,18].
As polymodal thermo- and chemosensitive channels,
TRPV1-TRPV4 are non-selective for cations and modestly
permeable to Ca2+. In contrast, TRPV5 and TRPV6 are
the only highly Ca2+-selective channels in the TRP family,
and both channels are tightly regulated by the intracellular
Ca2+ concentration [10,19,20].
TRPV channels can be activated through a variety of
mechanisms. TRPV1-TRPV4 can act as thermosensors
at a molecular level. Interestingly, each of these channels
has a different thermal threshold for activation. When
expressed in transfected permanent cell lines (HEK293
and CHO cells) and in frog oocytes [4,21,22], TRPV2,
TRPV1, TRPV3 and TRPV4 are activated at 52°C , 43°C,
33°C, and below 33°C, respectively. The TRPV family
members, except for TRPV1, are insensitive to vanilloidcompounds [4]. TRPV3 can be activated by essential oils
from clove (eugenol), thyme (thymol) and oregano (car-
vacrol) [23]. Like TRPV1, TRPV3 is also activated by
camphor [24]. TRPV4 can be activated by cell swelling
caused by 5',6'-epoxyeicosatrienoic acid [25]. TRPV5 and
TRPV6, originally named ECaC [26] and CAT1 [27], are
Ca2+ entry channels responsible for Ca2+ absorption in
the kidney and intestine, respectively.
TRPV1
In 1997, the breakthrough work of Michael Caterina and
colleagues in the field of somatic sensory biology and pain
research led to the cloning of the vanilloid (capsaicin) re-
ceptor, TRPV1 [28]. The cloning of TRPV1 proved to be a
significant step in the understanding of molecular mecha-
nisms that underlie the transduction of noxious thermal
and chemical stimuli by sensory neurones [9].
Characteristics of TRPV1
As a TRPV subfamily member, TRPV1 can be character-
ized by some key properties that are common among the
members of the family. It is built from four individual sub-
units containing six TMs [29]. TRPV1 has a pore-forming
hydrophobic stretch between TM5 and TM6 and is be-
lieved to exist as a homo- or heteromeric complex form
[28-30] (Figure 1).
The TRPV1 receptor is a non-selective ligand-gated
cation channel with a ninefold higher permeability for
Ca2+ than for Na+. It is an integrator of a wide variety of
exogenous and endogenous physical and chemical stim-
uli, including capsaicin (CAPS), noxious heat (>43°C)
and protons (pH<5.2). Strictly speaking, CAPS and its
biological analogs isolated from plants and animals are
essentially sensitizers, because they act by lowering the
thermal “physiological” activation threshold of TRPV1.
Nevertheless, because these compounds bind directly to
TRPV1, they are conveniently considered as direct acti-
vators, in contrast to compounds that do not bind
TRPV1 and affect its functioning indirectly, which are
referred to as sensitizers [31]. Besides CAPS, many com-
plex amphiphilic molecules have been shown to activate
or inhibit TRPV1. These include polyring compounds
such as resiniferatoxin (RTX), a highly irritant diterpene
related to the phorbol esters [32] which is almost 20-
fold more potent than CAPS [33]. Species-specific differ-
ences in RTX potency have also been described, for ex-
ample, RTX is a more potent agonist on rTRPV1 than
its human ortholog (hTRPV1) [34,35]. Further molecules
with similar structures, such as quinazolinone [36],
evodiamine [37] and 17-β-estradiol [38], as well as mole-
cules with long acyl and amide chains, such as ananda-
mide [39-45], olvanil and omega-3 polyunsaturated fatty
acids can also activate the channel [46]. Other natural
TRPV1 agonists are 12-hydroperoxyeicosatetraenoic acid
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[42,47-49]. Piperine from black pepper, eugenol from
cloves and zingerone from ginger have also been shown to
activate TRPV1 [50,51]. Additionally, gingerols, present in
raw ginger, and shogaols, which are dehydration products
of gingerols present in steamed ginger, both of which pos-
sess a vanillyl moiety, also activate TRPV1 [35,45,52,53].
Since both CAPS and its analogues are lipophilic, they are
able to cross the cell membrane and act on binding sites
present on the intracellular surface of TRPV1 [54]. TRPV1
can also be activated by 2-aminoethoxydiphenyl borate
(2-APB). 2-APB inhibits both IP3 receptors and the ma-
jority of TRP channels, though at higher concentrations it
activates TRPV1, TRPV2 and TRPV3 [11,55]. There has
been debates about whether TRPV1 can [56-59] or can
not [60-63] be activated by AITC. Stimuli are detected
and transduced through opening of the ion channel,
which results in the entry of cations such as Ca2+ and Na+
to the neurone [28]. Due to its uniqueness in its diverse
operational features, which differ from the classical, more
restrained proteins of voltage-gated and ligand-gated
channels, as well as from the G-protein-coupled receptors,
TRPV1 was dubbed “multisteric nocisensor” in the recent
review paper by Szolcsányi and Sándor [64].
The inorganic dye Ruthenium Red (RuRed), is used in
histology to stain aldehyde fixed mucopolysaccharides.
Long before the cloning of TRPV1 RuRed was demon-
strated to be able to inhibit CAPS-induced responses in
sensory neurones [65]. Later it was shown that RuRed is
a non-competitive antagonist not only for TRPV1 but
for most other TRP channels functioning as a pore
blocker [31]. The first competitive antagonist identified
for TRPV1 was the CAPS analogue capsazepine (CapZ).
CapZ is a relative potent antagonist on hTRPV1 but
demonstrated much less potency on rTRPV1 [66,67], il-
lustrating the differences between species that is com-
mon for many TRPV1 antagonists. Since the discovery
of CapZ the number of TRPV1 patents has exceeded
1,000. Most of these antagonists show high affinity to
TRPV1 and are competitive antagonists binding to the
same site as CAPS and many of them have also demon-
strated in vivo effects in various pain models [68]. The
halogenated version of RTX, iodoresiniferatoxin (I-RTX)
has been identified as a high-affinity antagonist of the
TRPV1 channel and similarly to RTX, it also exert differ-
ent potency on the hTRPV1 and rTRPV1 [69]. R4W2, a
small positively charged peptide was identified to be
non-competitive antagonist blocker of recombinant
TRPV1 channels expressed in Xenopus oocytes [70],
blocking CAPS-operated ionic currents with micromolar
efficacy in a weakly voltage-dependent manner. R4W2
was later found to be competitive antagonist of TRPV1
also in primary cultures of adult rat dorsal root ganglion
neurons (DRGs) [71].Besides its involvement in pain sensation, TRPV1 dis-
plays a low level of activity at normal body temperature
[72,73]. Constitutive activity of TRPV1 is essential for
regulation of body temperature, evidenced by high fever as
a adverse side effect of many TRPV1 blockers during clin-
ical trials for their efficacy in management or prophylaxis
of pain [74,75]. Moreover, at room temperature (24°C) and
pH 7.3, TRPV1 behaves as a voltage-gated outwardly recti-
fying channel, since it can be activated, in the absence of
any agonist, by depolarizing voltages (> +60 mV) [76].
One striking feature of TRPV1 is that the receptor can
be sensitized and desensitized. This fact suggests that
the TRPV1 function is subject to extensive modulation,
which has significant implications for the involvement of
TRPV1 in physiological and pathophysiological condi-
tions. Some inflammatory mediators in damaged tissues
including growth factors, neurotransmitters, peptides or
small proteins, lipids, chemokines and cytokines sen-
sitize TRPV1 to its agonists [77]. Even in concentrations
that fail to activate a current, CAPS can sensitize TRPV1
channels to protons and heat. Similarly, protons can
sensitize TRPV1 channels to CAPS and heat [78,79]. The
elevation of temperature or local acidity can in principle
augment the efficacies of partial agonists, transforming
them from weakly or non-pain-producing ligands into nox-
ious chemicals [80,81]. Whereas protons sensitize TRPV1
directly, most of the mediators work through receptor
pathways, which include receptor tyrosine kinases and G-
protein-coupled receptors. It has been reported that phos-
phorylation by protein kinase A (PKA) [82-84] and protein
kinase C (PKC) can sensitize TRPV1 to CAPS, protons or
heat [47,78,85-88]. The phosphorylation of TRPV1 by PKC
acts to potentiate CAPS- or proton-evoked responses and
reduces the temperature threshold for TRPV1 activation.
Others have suggested that isoforms of PKCα [89] or
PKCμ [90] are responsible for the effects described above.
Protein kinase D/PKCμ is a member of the protein kinase
D serine/threonine kinase family that exhibits structural,
enzymological and regulatory features distinct from those
of the PKCs, with which they are related. TRPV1 can also
be phosphorylated by Ca2+ CaM-dependent kinase II
(CaMKII) [91], or Src kinase [92], whilst the phosphatase
calcineurin produces desensitization of the TRPV1 recep-
tor [93]. TRPV1 undergoes two types of desensitization on
activation by CAPS or protons: acute (short-term)
desensitization and tachyphylaxis or loss of sensitivity to
repeated stimulations [14,94]. Physiologically, TRPV1
desensitization can lead to the adaptation of peripheral
neurones to pain perception. The regulatory lipid PIP2 is a
putative intracellular modulator of TRPV1, although there
is some debate as to whether it sensitizes or desensitizes
the channel. Mutations in a C-terminal cytosolic region of
TRPV1 indicate an inhibitory role for PIP2 [95]. However,
others have found that PIP2 sensitizes TRPV1 and that
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portant membrane lipid in terms of TRPV1 activity is chol-
esterol. Cholesterol is a major component of plasma
membranes and is enriched in lipid rafts. It has been
shown to modify the function of many classes of ion chan-
nels [100]. Cholesterol can modify channel activity indir-
ectly by altering physical properties of the surrounding
lipid bilayer, and the highly ordered lipid rafts can serve as
organizing centres for many signalling processes [101].
In recent years compelling evidence has emerged of a
specific interaction between cholesterol and several chan-
nels [100-103]. A supporting role of sphingomyelin and
gangliosides was also demonstrated [104]. Sántha et al.
demonstrated that inhibition of neuronal ganglioside syn-
thesis by inhibition of glucosylceramide synthase reversibly
decreased the CAPS-induced activation and TRPV1 ex-
pression of cultured dorsal root ganglion neurons, appar-
ently leaving other markers of nociceptive neurons, such as
CGRP and IB4, unaffected [105]. Intracellular ATP can also
sensitize TRPV1.
TRPV1 binds and is modulated by Ca2+/CaM, a ubi-
quitous Ca2+ sensor [106,107]. An increase in intracellu-
lar Ca2+ concentration causes TRPV1 desensitization,
and CaM plays a role in mediating this effect [106-108].
CaM interacts in vitro with isolated peptides from the
TRPV1 N-terminal region in a Ca2+-dependent manner
[107], and also binds to the TRPV1 C-terminal region in
a Ca2+-independent manner [106]. The response of
TRPV1 to heat can be modified by tyrosine kinases or
G-protein-coupled receptors. Channel activation can
occur even at normal body temperatures [78,109,110].
Reducing agents such as dithiothreitol (DTT) strongly
increase the thermally induced activity of the TRPV1
channel [111]. Moreover, the oxidizing agents diamide
and chloramine-T also facilitate thermally induced
TRPV1-mediated currents [112]. Alkylating agents, such
as N-ethylmaleimide also strongly and irreversibly affect
heat-evoked responses from TRPV1, lowering the thermal
activation threshold in a DTT-dependent manner [112]. It
follows from these data that TRPV1 is targeted by redox-
active substances that directly modulate the channel activ-
ity, and that channel potentiation may occur under altered
redox states in a tissue, e.g., during ischaemia and/or in-
flammation, presumably leading to hyperalgesia.
Inflammatory agents such as bradykinin, serotonin,
histamine, or prostaglandins can further stimulate TRPV1
activity, either by PKC-dependent pathways [110,113,114],
by releasing the channel from PIP2-dependent inhibition
[99,115], by a PKA-mediated recovery from inactivation
[116,], or by the formation of 12-HPETE [78,117].
Vitally important functions of TRPV1
The role of the TRP channels in pain and neurogenic in-
flammation have been very well covered by previousauthors (e.g. [118-121]) reflecting the enormity of the
role that these channels play in sensory nerve function
at both a central and peripheral level [122]. Thus TRPV1
plays a key role in the development of the burning pain
sensation associated with acute exposure to heat or
CAPS, and with inflammation in peripheral tissues
[28,91]. The receptor seems to play important role in
certain chronic pain conditions, such as neuropathic
pain, osteoarthritis, bone cancer pain, inflammatory
bowel disease and migraine [9,123,124]. Its role in the
central nervous system (CNS) is known to involve pain
processing and modulation, neurogenesis [125] and
thermoregulation [126], amongst others, but is currently
less well understood.
Jancsó and Wollemann [127] have reported that CAPS
stimulates adenylate cyclase activity in the rat cerebral cor-
tex in vitro. Furthermore, direct injection of CAPS into the
preoptic area of the anterior hypothalamus [126] or i.c.v. re-
gion [128] of the rat brain causes hypothermia, suggesting a
role for this channel in thermoregulation. Similarly, sys-
temic administration of TRPV1 antagonists such as
AMG517 [73], AMG0347 [129] and A-425619 [130] causes
an increase in body temperature within approximately 1 h
of treatment [122]. However, antagonist-induced hyperther-
mia may not be mediated by hypothalamic TRPV1 as
peripherally-restricted antagonists still have the capacity to
cause an increase in body temperature [131].
Within the periphery, recent evidence has located
TRPV1 on a variety of non-neuronal tissues (for more
details see Table two in the paper of Fernandes et al.
[122]). Although TRPV1 channel expression has been
shown in a wide variety of tissues, evidence of function-
ality has not yet been demonstrated for all of these.
One of the first cell types in which functionality was
first identified is epidermal keratinocytes. Inoue et al.
[132] demonstrated that both CAPS and acidification
produced elevations in the intracellular calcium concen-
tration in cultured human epidermal keratinocytes that
could be inhibited by the TRPV1 antagonist, CapZ [122].
Similarly, treatment of human skin fibroblasts with
CAPS induced significant changes in the membrane
current and the intracellular calcium level that were an-
tagonized by CapZ [133]. It is therefore clear that TRPV1
is expressed and functional away from sensory nerves.
Physiological or pathophysiological effects of non-
neuronal TRPV1 have been implicated in inflammation,
infection and immunity, the cardiovascular system and
in conditions such as obesity [122].
A physiological/pathophysiological role for non-neuronal
TRPV1 is perhaps nowhere more apparent than in the case
of inflammation, infection and immunity. Although the
effects of these TRPV1 channels are non-neuronal, it is evi-
dent that they may well impact indirectly upon pain and/or
neurogenic inflammation [122]. Keratinocytes functionally
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maintaining the integrity of the immune response in skin
as well as stimulating cutaneous inflammation via pros-
tanoid and cytokine release [134]. TRPV1 activation by
CAPS causes an increase in COX2 expression in human
keratinocytes with a concomitant increase in PGE2 levels
in vitro [135]. An increase in IL-8 is also observed [135]
Stimulation of inflammatory mediator release by TRPV1
agonists from keratinocytes could well have a significant
effect upon sensory nerves that have a high density in
skin [122].
However, there is accumulating evidence that TRPV1
has functional roles away from sensory nerve activity
[122]. As well as keratinocytes, peripheral blood mono-
nuclear cells (PBMCs) are also directly affected by TRPV1
activation. For example, PBMCs undergo apoptosis when
stimulated with CAPS or RTX, an effect that is reversed
by the TRPV1 antagonist, AM630 [136]. There are various
other cells involved in immunity that respond to TRPV1
and TRPA1 activation including bone marrow-derived
dendritic cells, where CAPS leads to dendritic cell matur-
ation and an increase in antigen presentation [137].
TRPV1 is expressed, functional and active within cells
relevant to inflammation, infection and immunity. It is
clear from the studies that TRPV1 at least plays a para-
doxical role in inflammation in vivo, for example, ex-
acerbating inflammation in arthritis and yet in
experimentally induced sepsis, TRPV1 null mice demon-
strate elevated levels of pathological markers in compari-
son with wild type mice [123]. It cannot be ruled out
that this is due to differing effects of neuronal and non-
neuronal TRPV1 channels [122].
TRPV1 have been shown to control vascular responses
either by the well-established neurogenic response that
is mediated by sensory nerves [138] or via a direct effect
on vascular tissue [139,140]. However, the non-neuronal
mechanisms involved in mediating vasodilatation and
oedema formation following TRPV1 activation in vivo
are unclear. TRPV1 on endothelial cells has been shown
to regulate the expression and secretion of endothelial
cell-derived CGRP, which affords protective effects on
endothelial cells [141]. Furthermore, CGRP is a potent
vasodilator [142], and this CGRP may therefore impact
upon blood pressure. Indeed, TRPV1 activation on
sensory nerves also causes CGRP release, leading to a
profound decrease in vascular tone [143]. On the other
hand, TRPV1 expressed on vascular smooth muscle
appears to cause vasoconstriction [140,144,145]. It has
also been suggested that CAPS has biphasic effects on
the vasculature: at lower concentrations, CAPS (up to 10
nM) evokes vasodilation in skin due to sensory nerve ac-
tivation, whereas higher concentrations (0.1–1 mM)
elicit substantial constrictions in skeletal muscle arteri-
oles due to non-neuronal TRPV1 stimulation [140]. Itis unclear whether this difference is due to receptor
sensitivity or a difference in TRPV1 receptor density in
the two tissues. A similar biphasic effect of CAPS has
been demonstrated also in meningeal blood vessels
[146]. TRPV1 may also play a role in vascular responses
during chronic hypoxia where up-regulation of the
TRPV1 gene and protein is observed [147]. Chronic hyp-
oxia has been shown to enhance the ability of human
pulmonary artery smooth muscle cells to proliferate and
to increase resting levels of cytosolic calcium and capacita-
tive calcium entry with both effects being inhibited in a
dose-dependent manner by the TRPV1 antagonist, CapZ
[147]. These results suggest that TRPV1 on smooth
muscle may be a critical pathway or mediator in chronic
hypoxia-induced vascular changes [122].
Obesity is one of the most significant health issues in
western society due to the morbidity associated with this
condition that is increasing in prevalence. Obesity is in-
duced by the hypertrophy of adipocytes and the recruit-
ment of new adipocytes from precursor cells. These
processes are dependent on the regulation of adipocyte
differentiation. CAPS has been shown to inhibit adipocyte
differentiation in vitro by activation of AMP-activated pro-
tein kinase [148]. Furthermore, Hsu and Yen [149] have
shown that treatment of preadipocytes with CAPS de-
creases the number of normal adipocytes and increases
the number of early apoptotic and late apoptotic cells in a
dose-dependent manner. Thus the overall effect of TRPV1
modulation in obesity is stark. Both animal [150] and hu-
man [151] data have indicated that the consumption of
CAPS- or non-pungent capsiate-containing foods is corre-
lated with a reduced incidence of obesity. Similarly, oral
administration of CAPS alone also suppresses body fat ac-
cumulation in mice [151], and dietary CAPS can reduce
obesity-induced insulin resistance and hepatic steatosis in
mice fed a high fat diet [122,152].
In recent years, a role for TRPV1 in thermoregulation
has also been identified which may, at least in part, be due
to changes in thermogenesis (for review, see [72,153,154]).
For many years, CAPS has been known to cause a cen-
trally mediated hypothermia in mice [126]. In contrast, its
intragastric administration enhances thermogenesis and
heat diffusion [155]. Similarly, the jejunal administration
of non-pungent CAPS analogues was shown to increase
energy expenditure via direct activation of TRPV1 located
on intestinal extrinsic nerves [156]. Interestingly, some
TRPV1 antagonists cause hyperthermia, associated with in-
creased thermogenesis [130] through a peripheral mechan-
ism [131], whilst TRPV1 gene knock down does not affect
body temperature in mice [157] and TRPV1 knockout
mice exhibit a normal basal body temperature [122,129].
TRPV1 in the alimentary tract has also been impli-
cated in metabolism, hair growth regulation [158], and
the development of cancer [159].
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have the potential to provide exciting opportunities for
therapeutic interventions. Its known functions in both
health and disease have been continuously expanding
promoting a better understanding of TRPV1.
TRPV1 expression
TRPV1 channels are mainly expressed on primary sen-
sory neurones. They have been detected in key areas of
the pain transduction pathway: on terminals of small- to
medium-diameter nociceptors, such as peptidergic and
non-peptidergic C fibres, some Aδ fibres [28,79]; in skin
nerve endings, DRGs, nodose ganglia, trigeminal ganglia
of the peripheral nervous system, as well as laminae I
and II [79] of the dorsal horn of the spinal chord. Projec-
tions may also extend into laminae V and X [79]. More-
over TRPV1 has been found in different brain regions,
such as in dopaminergic neurones of the substantia nigra,
hippocampal pyramidal neurones, hypothalamic neurones,
neurones in the locus coeruleus, and in various layers of
the cortex [25,160,161]. The channel is present to a lesser
extent in the hippocampus, cortex, olfactory bulb and
cerebellum in the CNS [44,162]. However, more recently,
the use of TRPV1 reporter mice has revolutionized the
study of TRPV1 expression, and they would suggest that
the expression of this receptor is minimal within a few
discrete brain regions, most obviously in the vicinity of
the caudal hypothalamus [122,145].
TRPV1 is additionally expressed in discrete spots in the
plasma membrane and cytosol of different non-neuronal
cells such as the endothelium, immune cells (lymphocytes,
dendritic cells and mast cells), keratinocytes, smooth
muscle cells and urothelium, thymocytes and macro-
phages, some of which are known to be involved in
inflammation [159]. An increased level of TRPV1 expres-
sion has been demonstrated in the sensory fibres of
patients with an inflamed oesophagus (gastro-oesophageal
reflex disease) or an inflamed bowel (both ulcerative col-
itis and Crohn’s disease), or with chronic breast tender-
ness and pain [163]. There is likewise an increased TRPV1
expression in the sensory fibres of patients with rectal
hypersensitivity and faecal urgency, and this increase is
directly correlated with the degree of thermal and mech-
anical sensitivity [164].
Functionally important amino acid sites and their
mutations in the TRPV1
Emerging data of TRP channel research has elucidated
roles for TRP channels in diverse therapeutic areas, and
resulted in the identification of numerous potential drug
targets beyond TRPV1. Success in finding a viable ther-
apy targeting the TRPV1 channel depends on experi-
mental studies aimed at obtaining detailed knowledge of
the channel protein. TRPV1 pharmacology has reliedheavily upon information derived from studies of site-
directed mutants of the recombinant channel(s) by the
identification of the most appropriate acting sites for
potential drug candidates. Figure 1 indicates the mu-
tated residues and the functional changes evoked by
them, and also depicts the most important structural
properties of TRPV1 (For high resolution figure, see
Additional file 1). In order the easier comprehensibility
and the more effective usability of the data, a compre-
hensive table summarizes the information of the mu-
tants at the end of the article (see Table 1).
Mutations affecting agonist action and/or binding
CAPS and RTX
Jordt et al. provided molecular evidence that the muta-
tion of E600 caused enhanced sensitivity to CAPS [43].
In the experiments by Jordt et al., replacement of Glu by
Gln (E600Q) produced a greater than 10-fold leftward
shift in the CAPS dose–response curve, with EC50 values
of 520 and 40 nM for wild type and mutant receptors,
respectively (Figure 1). Moreover, channels bearing a Lys
at this position (E600K) exhibited even higher agonist
sensitivity, showing saturated current responses at 50
nM CAPS. Introduction of neutral or positive residues
at the E600 site potentiates responses to CAPS, whereas
introduction of a residue with lower pKa (E600D) de-
creases the channel sensitivity to this stimulus [43].
Welch et al. identified E636, D646 and E648 as specific
contributors to the CAPS response without affecting the
proton or thermal sensitivity. E636Q, D646N and E648Q
had a threefold greater sensitivity to CAPS than the wild
type TRPV1 channels [165].
A triple mutant (N676F/M677A/L678P) was reported
by Kuzhikandathil et al. to disrupt the ability of CAPS
and RTX to activate TRPV1, while retaining the ability
to respond to protons [166], suggesting that distinct
amino acids that are close to or in TM6 control the gat-
ing in response to several modes of TRPV1 activation.
Deletion of R114 and E761 in the N- and C-termini
can block CAPS-induced currents without affecting
TRPV1 activation by heat [16].
F489Y resulted in a rightward shift of the CAPS con-
centration of half-maximal activation (EC50) [167]. Jordt
et al. [168] conducted a search for residues involved in
the action of CAPS on the basis of the differences be-
tween avian TRPV1 and mammalian (rat and human)
orthologues [169], and found eight amino acids in the
vicinity of TM3 that differ between the two forms, which
may account for the species-specific sensitivity to CAPS
(F507, Q519, F522, M523, S532, K535, E536 and
T550 residues of rTRPV1 corresponding to I515, N527,
L530, L531, C540, E543, L544 and A558 of chicken
TRPV1, respectively). Exchange of any one of the Q519,
F522, M523, S532, K535 or E536 residues for the
Figure 1 (See legend on next page.)
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Figure 1 Summary of the mutated sites of rTRPV1 The figure summarizes the effect of 112 unique mutated sites along the rTRPV1 on
the function of the channel. Coloured circles indicate the involvement of the given residue in the corresponding process. Coloured boxes show
the putative location of some structural elements on the rTRPV1 sequence. Sequence and region information: TRPV1_RAT (O35433) (www.uniprot.org).
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sufficinet to ablate the vanilloid sensitivity of rTRPV1.
They investigated the TM2-4 regions for sites involved
in CAPS, RTX or proton action and observed that sub-
stitutions at two positions (R491G in TM2 and S512F
in TM3) led to dramatic reductions in both proton- and
CAPS-evoked currents. However, the introduction of
other mutations at these positions (S512A, S512T or
R491E) resulted in a greater preservation of functional-
ity, and in each case a greater reduction in CAPS sensi-
tivity was observed compared to extracellular protons.
The mutant S512Y displayed little response to CAPS up
to 100 μM, and no detectable specific binding of RTX.
Nevertheless, the proton sensitivity was retained, as were
the responses to noxious heat, albeit with a slightly
higher thermal threshold (>48°C) and smaller maximal
amplitudes compared to wild type receptors. An ex-
tended mutational analysis of the conserved residues ad-
jacent to S512 (D509, S510, Y511, E513 and I514)
revealed the most significant effects with the mutant
Y511A. Despite lacking any significant CAPS sensitivity,
this channel exhibited normal heat- and proton-evoked re-
sponses, with a thermal threshold and current amplitudes
that were indistinguishable from those of the wild type re-
ceptor. In tests of whether the aromatic nature of the
residue at position 511 is essential for ligand binding,
substitution with a Phe (Y511F) was found to have only
moderate effects, whereas substitution with a non-aromatic
Cys (Y511C) again eliminated the CAPS sensitivity [168].
Jung et al. [16] identified two regions near Arg114 and
Glu761 in the cytosolic tails of TRPV1 that determine
ligand binding. Because the Arg114 and Glu761 resi-
dues are charged, it is likely that these charges are ne-
cessary for vanilloid binding. When positively charged
Arg114 was replaced by a neutral amino acid, Ala, the
mutant (R114A) elicited a CAPS-induced current com-
parable with that of the wild type TRPV1. However,
when the Arg at 114 was replaced by negatively charged
glutamate (R114E), a significant reduction in CAPS-
induced current was observed with no apparent specific
[3H]RTX binding. Because the adjacent amino acid,
R115 is also positively charged, it was also replaced with
Asp (R115D). The R115D mutant also abolished the
CAPS-sensitive currents, indicating that charge at Arg-
115 contributes equally to activation by CAPS. When
the negatively charged Glu at 761 was changed to Gln, a
neutral amino acid retaining a similar structure, the mu-
tant (E761Q) elicited a great reduction in Icap (~98.0%
reduction), and had no specific binding for [3H]RTX.Furthermore, when the Glu at 761 was substituted with
positively charged Lys, the mutant (E761K) showed no
current response to CAPS or ability to bind [3H]RTX.
R114E and E761K elicited current responses to heat,
but not to acid (pH 5.5).
These results reflect the necessity of the negative
charge of Glu at 761 for ligand recognition and the fact
that the positive charge at R114 determines the ligand
binding to the channel, but to a lesser extent than the
charge at E761 [16].
Chou et al. [170] showed the residue in position 547
to be a key contributor to RTX binding of TRPV1 by ex-
changing a single amino acid between the human and
rat counterpart. Systematic replacement of the amino
acids in the TM1 to TM4 domain of hTRPV1 with the
corresponding rTRPV1 residues identified a single con-
servative substitution of Met for Leu (M547L) at pos-
ition 547 that accounted for the species difference in
RTX binding. The amino acid at this position also af-
fected the potency of the antagonists I-RTX and
capsazepine for inhibiting [3H]RTX binding and the
agonist response to RTX. The M547A mutation in
rTRPV1 reduced RTX affinity to the same degree as
M547L (≈30-fold). A more radical mutation, M547Q,
decreased potency to a smaller degree than either
M547A or M547L. In the case of L547A and L547Q
mutations in the hTRPV1 no [3H]RTX binding and little
channel activity were detected even though protein was
seen on western blots. The human L547M mutation has
a higher affinity for RTX than wild type rTRPV1, and
similarly the rat M547L displayed a lower affinity than
wild type hTRPV1 [170]. M547, W549 and T550 in the
S4 segment participate in ligand interactions [171,172].
F489 proved to take part in the CAPS activation of the
channel [167], probably because of its close proximity to
a domain containing mutations R491, Y511, and S512
shown to be implicated in CAPS sensitivity [168,173].
When associated with T704I, S502A was found to lose
the ability to be activated by CAPS and lose the ability
of vanilloid binding [85,91,174].
Rabbit oTRPV1 can be activated by heat (45°C) and pro-
tons (pH 5), but it is 100-fold less sensitive to vanilloid acti-
vation than hTRPV1 or rTRPV1, and oTRPV1-transfected
HEK293 cells did not exhibit any specific [3H]RTX binding.
Gavva et al. [171] constructed a rat-rabbit chimera of
TRPV1 by the transfer of TM3 through 4 (S505-T550)
from rTRPV1 to oTRPV1. The chimera displayed enhanced
sensitivity to vanilloids, similarly to rTRPV1. Additionally, a
human-rabbit chimera was created by transferring the
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lysis again showed that this chimera also gained sensitivity
to CAPS, further confirming that the TM3-4 region is
responsible for vanilloid sensitivity.
On the basis of the 10 differences found between
rTRPV1 and oTRPV1 and the six between hTRPV1 and
oTRPV1, Gavva et al. mutated the residues that in rabbit
differ from those in both rTRPV1 and hTRPV1 (A505S,
A520S, C534R, T540S and I550T). Changing the single
residue at 550 in rabbit to the corresponding residue
found in rTRPV1 and hTRPV1 (I550T) was sufficient to
confer a gain of function for activation by CAPS.
Changing the residues A505S, A520S, C534R and T540S
individually or in various combinations did not cause
any changes in the responses of oTRPV1 to vanilloids.
For a better understanding of the biophysical require-
ments at position 550, Gavva et al. explored several
polar and hydrophobic substitutions. A gain in CAPS
sensitivity was observed when Ser was introduced in-
stead of Thr (I550S), the small non-polar Ala (I550A)
resulted in only a partial gain of CAPS sensitivity, while
thiol group containing-residue Cys (I550C) resulted in a
very small gain in oTRPV1 CAPS sensitivity. Introduc-
tion of Tyr (I550Y) with its bulky phenolic side-chain at
this position resulted in a complete loss of TRPV1 re-
sponse to vanilloid, proton or heat activation, although
the expression level of this mutant remained comparable
to the others. To verify further that the T550 found in
native rTRPV1 hTRPV1 contributes to the vanilloid
sensitivity of TRPV1, the effects of substitution of the
natural Thr by the oTRPV1 Ile 550 (T550Y) residue
were examined. 45Ca2+-uptake experiments revealed a
10-fold loss in sensitivity to CAPS of rTRPV1-T550I,
and a 40-fold loss in sensitivity of hTRPV1-T550I.
Gavva et al. [171] confirmed the finding of Jordt and
Julius that T511 is critical for vanilloid sensitivity. Both
rTRPV1-Y511A and hTRPV1-Y511A had lower vanilloid
sensitivity. They tested the CAPS sensitivity of the
oTRPV1 double mutant containing I550T (gain of func-
tion) and Y511A (loss of function), i.e., oTRPV1-Y511A/
I550T. Compared with oTRPV1-I550T, the reduction in
CAPS sensitivity of oTRPV1-Y511A/I550T in the 45Ca2+
uptake assay was >100-fold. In fact, the magnitude of the
loss in CAPS sensitivity by Y511A was greater than the
gain seen in I550T. The T550I mutation resulted in the
CAPS dose-response curve shifting 10-fold to the right,
relative to the control, without reducing RTX sensitivity in
the 45Ca2+ uptake assay. However, [3H]RTX specific
binding was significantly reduced in rTRPV1-T550I-
transfected cells. A series of single point mutations were
introduced into oTRPV1 (M514I, A525V, T526S,
H533Q and L547M) to mimic the residues in rTRPV1,
which has been shown to display the highest RTX-binding
affinity. Replacement of the oTRPV1 residues at M514I,A525V, T526S and H533Q individually did not alter the
oTRPV1 response to CAPS or RTX. The single residue
change L547M in oTRPV1 resulted in a selective gain of
~30-fold higher sensitivity to RTX with no apparent
change in CAPS sensitivity in 45Ca2+-uptake assays.
oTRPV1-L547M demonstrated greater sensitivity to RTX,
but failed to show any measurable [3H]RTX binding, and
it was therefore hypothesized that L547M contributes to
RTX sensitivity, but requires additional residues such as
T550 to attain the affinity needed for measurable [3H]
RTX binding above the assay background. A reverse mu-
tation in rTRPV1 (M547L) displayed similar responses to
CAPS and RTX in the functional 45Ca2+-uptake assay. To
test whether oTRPV1 might require bothT550 andM547
to attain measurable [3H]RTX binding, the oTRPV1
L547M/I550T double mutant was constructed and its
vanilloid sensitivity was examined in functional 45Ca2+-up-
take and [3H]RTX binding assays. As predicted, oTRPV1-
L547M/I550T exhibited strong [3H]RTX binding together
with only a slight increase in functional sensitivity to
CAPS and a somewhat greater increase for RTX. This
demonstrates that Met547 and Thr550, as present in na-
tive rTRPV1, are required for measurable [3H]RTX bind-
ing in oTRPV1. oTRPV1-I550T and L547M/I550T
resulted in slight changes in sensitivity to pH 5.5. Gavva
et al. hypothesized that Y511, M547 and T550 may be
present in the binding pocket and are important molecu-
lar determinants for vanilloid sensitivity [171].
Johnson et al. [173] investigated the role of two resi-
dues (S512 and M547) identified earlier to be respon-
sible for major species-specific differences in vanilloid
activity in the response of the channel to a variety of li-
gands. Their initial studies confirmed the clear species-
specific differences in RTX potency described previously
by Chou et al. [170]. RTX activated wild type rTRPV1
with a fourfold higher potency than the wild type
hTRPV1. Johnson et al. switched the residues at position
547 between the two receptor homologs creating the
M547L rat mutant and the L547M human one. L547M
produced a significantly more RTX-sensitive channel with
the EC50 value comparable with that of the wild type rat
receptor. Conversely, when the reverse mutation was
made in the rat construct (M547L) a loss of function was
observed, although, the change was not significant.
The species-specific differences in CAPS sensitivity
were also investigated. CAPS was found to be signifi-
cantly more potent at the wild type hTRPV1 than at the
wild type rTRPV1 channel. When the 547 residue was
switched between the rat and the human constructs, the
sensitivity to the agonist was again altered. In this in-
stance, this mutation caused a significant decrease in po-
tency in the human mutant (L547M) compared with the
human wild type, with an EC50 value comparable with
that of the wild type rTRPV1. As for RTX, when the
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there was no significant difference [173].
Susankova et al. [175] Ala-scanned the residues Y666-
G683 containing the most conserved region of the TRP
protein family.
Three mutant channels (Y666A, I672A, N676A) showed
no CAPS-evoked activity at all. These mutants were also
pH insensitive, they were not activated in the absence of
extracellular Ca2+, and they gave very small and nonspecific
heat-induced membrane currents. Y666A and N676A
possessing no any potentiated currents in response to 47°C
and 30 μM CAPS applied together, proved to be non-
functional mutants, suggesting that these two residues
within the inner-pore region of rTRPV1 are critical for
channel functionality.
Co-application CAPS (30 μM) and heat stimuli (43°C)
caused efficient potentiation in mutants I672A, L673A,
L674A, L678A, and M682A which were functionally si-
lent or only barely responded to CAPS at base
temperature. Compared with wild type TRPV1 however,
the current densities of the CAPS-induced responses
measured at 47°C were significantly reduced in: I668A,
I672A, L673A, L674A, L675A, and M682A. These
mutations but L675, whose heat-activation was un-
affected, caused also significantly impaired heat- and
CAPS-activation.
Y671A dramatically lowered the CAPS EC50 value in
the experiments of Mohapatra et al. [176].
Susankova et al. [175] further studied this mutant and
reported that responses to CAPS were not potentiated
by heat, but in contrast to the other mutants and the
wild type channel, CAPS-evoked responses were consist-
ently inhibited by heating above 30°C. Susankova et al.
reasoned that the loss of potentiation in Y671A might
be attributable to changes in agonist sensitivity. When
the channels were desensitized by repeated applications
of CAPS (1μM and/or 30μM), the heat-induced potenti-
ation reappeared. Y761 might contribute to allosteric
coupling between temperature- and CAPS- dependent
activation mechanisms.
Susankova et al. evaluated the changes in CAPS re-
sponsiveness evoked by Ala mutations by comparing
their relative sensitivities at 1 and 30 μM CAPS at 47°C.
An alternating pattern was found with unaltered sensi-
tivity to CAPS in T670A, L675A, G683A, and wild type
channels and a reduced but not abolished CAPS sensi-
tivity in mutations I668A, Y671A, I672A, L673A,
L678A, and M682A. Interestingly, the mutation of Leu
673 to Ile (L673I) in the experiments of Myers et al.
[177] however caused a channel with elevated basal ac-
tivity and significant cytotoxicity.
To further assess the maximal CAPS-induced re-
sponses in the mutants, Susankova et al. compared the
inward currents measured at 47°C in the absence andpresence of a high concentration of CAPS. Except for
Y666A, N676A, and I679A, the inward currents were
significantly greater in the presence of 30 μM CAPS
than in its absence. The lack of mutual potentiation be-
tween the two stimuli in the former two mutants was
caused by their insensitivity to CAPS. Notably, the muta-
tion I679A retained normal sensitivities to both stimuli,
although it completely removed their mutual potenti-
ation at 47°C. In several residues (V667A, T670A,
I672A, L673A and L675A), the degree of the CAPS-
induced increase in the amplitude of the inward current
at 47°C was clearly reduced, although these changes did
not achieve statistical significance.
Changes induced by individual mutations in the 1 μM
versus 30 μM CAPS-induced current relationships mea-
sured at 47°C might reflect the changes either in CAPS
sensitivity or in the allosteric linkage between CAPS and
heat sensor movements and channel opening. Specific-
ally, mutation I679A appeared to cause a decrease in
the synergistic interaction of CAPS and heat with the
TRPV1 channel.
Susankova et al. denoted that the periodicity observed
in the relationships between the maximal activation cap-
acities obtained for 1 and 30 μM CAPS at 47°C supports
the hypothesis that there exists a structural explanation
for the gating of the TRPV1 channel by chemical stimuli.
The pattern of sensitivity to CAPS (every three to four
substitutions) is consistent with an α-helical structure
contributing to CAPS-induced channel gating. Similar
pattern of residues involved in the CAPS sensitivity can
be observed in TM3 and TM3-TM4 linker region identi-
fied by Jordt and Julius [168]. The repetitive patterns of
CAPS sensitive residues apparent in both papers how-
ever seem to fit better for a 3.4 residues per turn of the
helix than for a 3.6 one. This may further support the
finding of Salazar et al. [178] who reported that the TM6
of TRPV1 represent amphipathic helix with 3.4 residues
per turn and a P(φ) value of 107° rather than α-helix
with 3.6 residues per turn and a P(φ) value of 100°. Con-
sidering the above mentioned findings, all the TM heli-
ces of TRPV1 might be regarded to have the same
structure [175].
Boukalova et al. [179] found that the E570Q mutation
accelerated the rate of activation of the channel. In con-
trast, a significantly lower rate of activation was ob-
served in mutated rTRPV1 channels containing
mutations R557A, M581T, D576R, Q560H, R557K and
E570R, indicating contribution of the transduction of
the CAPS-binding signal to the opening of the pore. The
estimated deactivation time (the time taken for the
current to decrease to 50% of its level before removal of
the CAPS) was markedly longer in R557K as compared
with the wild type, but not in R557A or R557L, indicat-
ing that the specific side-chain properties of R557, and
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for the deactivation gating process. In R557A, R557K,
Q560H and M581T, the second response to 1 μM CAPS
reapplied after an apparent wash-out had a faster onset
than in the wild type, suggesting an incomplete deactiva-
tion process. The time courses of the CAPS-induced
whole-cell currents through R557A, R557L, E570R,
D576R, R579A and R576R/R579D closely resembled
those of wild type TRPV1. In contrast, R557E/E570R
exhibited slower activation and deactivation kinetics. A
significantly faster offset of CAPS-dependent responses
was detected in E570A and R576R/R579E. The muta-
tions causing similar defects in the voltage-dependence
affected the chemical sensitivity of TRPV1 very differ-
ently [179].
Mutation studies by Lee et al. [180] and other groups,
along with comparisons of TRPV1 variants from species
sensitive or insensitive to vanilloids, have identified im-
portant residues for ligand binding, such as Tyr511,
Met547 and Thr550 [168,170,171].
Lee et al. [180] generated a series of rTRPV1 mutants
within the TM3 (Y511A, Y511F) and TM4 (M547L,
T550A, T550I, T550S) regions, and performed docking
studies with the prototypical agonists, CAPS and RTX,
to assess their roles in ligand recognition. Their muta-
tional studies based on the foregoing in silico docking
experiments resulted in the discovery that the vanillyl
moiety of CAPS oriented towards Y511, while the tail
end extended towards M547. The vanillyl moiety formed
π-π stacking and hydrophobic interactions with Y511,
and H-bonding with S512. Moreover, the carbonyl
group participated in H-bonding interactions with Y511
and L571. Mutation of Tyr in position 511 to Phe
(Y511F) had only a slight effect on the activity of CAPS,
but its mutation to Ala (Y511A) caused loss of the π-π
stacking and H-bonding capabilities, leading to a sharp
decrease in CAPS activity. The mutation of T550I also
evoked a significant decrease in CAPS activity, but the
influence of the change of Thr to Ala (T550A) or Ser
(T550S) was much weaker. This may reflect the bulky
side-chain of Ile disturbing the binding of the nonenyl
tail of CAPS. Although the hydrophobic nonenyl tail
was oriented towards the upper hydrophobic region of
the binding site, it did not fully occupy the hydrophobic
region of the two shallow hydrophobic areas composed
of F543 and M547 because it is linear and too short to
reach both areas. These data indicate the relevance of
the overall size, shape and/or hydrophobicity of the lipo-
philic side chain region for binding.
In the case of RTX, the vanillyl moiety appeared to
form π-π stacking with Y511, as did that of CAPS. The
importance of Y511 in RTX binding was also confirmed
by their mutation study. When Tyr 511 was mutated to
Phe (Y511F), the binding affinity of RTX decreased lessthan fourfold, as the π-π stacking and hydrophobic in-
teractions of the vanillyl group of RTX were maintained.
As compared with the relatively short and linear tail of
CAPS, the C13-propenyl group of RTX contributed to
the hydrophobic interaction with M547, and its import-
ance in RTX binding was also justified by the mutation
studies. When Met was mutated to Ile (M547I), the
binding affinity of RTX decreased more than 11-fold.
This may be caused by the greater ability of M547 than
of Leu to extend to make the hydrophobic interaction
with RTX. In addition, the C4-OH group of RTX
seemed to fit well with the small side-chain of T550 in
addition to H-bonding with the residue. This docking re-
sult is in agreement with the mutation data that neither
mutated T550S nor T550A caused any binding loss
relative to the wild type, while T550I led to a drastic de-
crease (over 20-fold) in RTX-binding affinity. As with
CAPS binding, the bulky side-chain of Ile could cause
steric interference with the binding of RTX. It was no-
ticeable that the orthophenyl group of RTX underwent
hydrophobic interaction with L515. The ultrapotency of
RTX might be due to the fact that it could occupy the
binding site fully, taking maximum advantage of the
multiple possible binding interactions with TRPV1.
Since RTX has phenyl rings in both the 4-hydroxy-3-
methoxyphenyl and lipophilic side chain regions and
there are hydrophobic residues at both ends of the binding
site, RTX could flip over and achieve a minor binding
mode. In this case, the vanillyl moiety would point towards
M547 and participate in the hydrophobic interaction. Cor-
respondingly, the orthophenyl group would orient towards
Y511. The C20-ester seemed to take part in H-bonding in-
teractions with N551 and the C13-propenyl group formed
the hydrophobic interaction with L515 [180].APB
Boukalova et al. [179] reported that the inward currents
induced by 300 μM 2-APB were reduced in R557L,
R557K, Q560H, E570Q and E570R and most strongly
(>50-fold) in K571E, which was normal in all other as-
pects of TRPV1 activation (Figure 1).Allicin
The TRPA1 channel, which is co-expressed in many of
the same neurones as TRPV1, has been proposed to be
the sole target for the actions of allicin [56,181,182].
However, other groups have reported that TRPV1 is also
a target for the actions of this compound [57,183-185].
The agonist action of allicin was confirmed by Salazar
et al. [186], who further demonstrated that the allicin be-
haves as a TRPV1 agonist through the covalent modifi-
cation of a single Cys localized in the N-terminus of the
channel at position C157 [187] (Figure 1).
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The heat activation pathway is largely unknown, al-
though the outer pore region, including the turret and
the selectivity filter-to-S6 linker, is clearly part of the
protein structure participating in the heat-induced
conformational rearrangement. Intensive studies of
thermo TRP channels have so far indicated numerous
channel regions that contribute to temperature-
dependent activation. Exchanging the intracellular C-
termini between TRPV1 and the cold-activated
TRPM8 channel was found to switch their sensitivity
to heat [188]. This result is consistent with the earlier
observation that deletion of the last 72 amino acids of
the TRPV1 C-terminus influenced channel activation
(though in a modality-independent manner) [84]. Fur-
thermore, the intracellular segment between ANK and
TM1 was recently proposed to serve as the thermal
sensor for TRPV1 [189,190].
Introduction of neutral or positive residues at the
E600 site (E600Q and E600K) potentiated the responses
to heat, whereas the introduction of a residue with lower
pKa (E600D) decreased the channel sensitivity to it [43]
(Figure 1).
Susankova et al. [175] performed Ala-scanning of the
residues Y666-G683. The mutations I668A, L669A,
Y671A, I672A, L673A, L674A, M677A, L678A and
M682A blunted the heat-induced current responses. To
obtain a more complete picture of how the individual
mutations affect the heat sensitivity of the TRPV1 chan-
nel and to further characterize the specificity of their
temperature-induced responses, the temperature thresh-
old for activation and the temperature coefficient (Q10)
from the Arrhenius plots of individual current–temperature
relationships were quantified.
The most frequently observed phenotype was a left-
ward shift in the temperature threshold (V667A, I668A,
L669A, L673A, L674A, M677A, L678A and M682A).
Seven mutations (T670A, Y671A, I672A, L675A,
I679A, L681A and G683A) had thermal thresholds no
different from wild type TRPV1. Except for the T670A,
L681A, and G683A, the mutations strongly reduced Q10
in all mutants tested.
Susankova et al. claimed that average temperature-
dependent activation profile with the five peaks sepa-
rated by four troughs at residues I672-L674, N676,
L678, and M682 might correspond an α-helical struc-
ture, which most likely represents the inner-pore region
of the TRPV1 channel. The results of Susankova et al.
also provide functional support for the role of the puta-
tive inner-pore region in controlling the gating of the
vanilloid receptor TRPV1 channel.
L669A and M677A are significantly less sensitive to
heat without a significant change of CAPS- or heat-
potentiated CAPS currents suggesting that theseresidues are involved in heat activation of the channel,
but not in potentiation by heat. L678A displayed a re-
duced sensitivity to heat and CAPS with an unaffected
heat-potentiated current, suggesting a role of L678 in
the process of CAPS- and heat- activation, but not in
the potentiation mechanism. This finding somewhat
contradicts to the results of Kuzhikandathil et al.
[166] who demonstrated M677 to affect the ability of
CAPS and RTX to activate TRPV1 without changing
the channel's response to protons however working on
a triple mutant (N676F/M677A/L678P) containing
channel [175].
By generating a chimera between the TRPV1 and
TRPM8 channels, in which the region V686 to W752 of
TRPV1 was replaced by the same C-terminal region of
TRPM8 (V982 to W1055), Brauchi et al. [191] identified
TRPV1 C-terminal amino acids Q727 and W752 as be-
ing the minimum portion able to turn TRPM8 into a
heat receptor.
The mutations N628K, N652T and Y653T resulted
in TRPV1 channels responding normally to CAPS
and pH, but whose heat responses were reduced in
amplitude and shifted to higher temperatures. More-
over, the time course of activation of these single
point mutants was identical or very similar as com-
pared with wild type TRPV1, suggesting that the
desensitization was not strongly altered [167]. A
double mutant N652T/Y653T and a triple mutant
N628K/N652T/Y653T yielded receptors with CAPS,
2APB and pH EC50 values and maximal responses
that were indistinguishable from that of wild type
TRPV1, but with a further reduction in temperature
responses [167]. The triple mutant (N628K/N652T/
Y653T) exhibited altered heat-gating kinetics. Whilst
the unitary conductance of the wild type TRPV1 and
the triple mutant channel was identical, the triple
mutant possessed channel openings of only short (<1 ms)
durations, and the longer (~10 ms) ones proved to be
completely absent. The triple mutant, however, is nor-
mally gated by CAPS [167].
The T633A mutant exhibited a weaker response to
heat, reaching ~32% of the 1 μM CAPS current. In con-
trast with the change in peak activity, however, the ther-
mal activation threshold coincided with that of the wild
type (~42°C) [192]. A less severe perturbation to the tur-
ret region of the TRPV1 channel by deletion of its first
10 amino acids (ΔG603-S612) substantially and specific-
ally affected the heat activation but not CAPS activation
of the channel [190].
A significantly higher threshold for heat activation was
detected by Boukalova et al. [179] for E570A. The
Y554F, Y555F, Q561H, E570Q, E570R, K571E, R575A
and R579D mutations left the threshold for heat activa-
tion unchanged.
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Jordt et al. [43] demonstrated that E600 serves as a fun-
damental regulatory site for the proton potentiation of
vanilloid receptor activity over a physiologically relevant
range (pH 6–8), but not in proton or heat activation.
The E600Q mutants retained the ability to be activated
by acidic conditions or heat, but differed from the wild
type receptor in two significant ways (Figure 1). First,
upon heat activation the initial heat stimulus produced a
relatively large peak current response that was much
closer to the final plateau value than that typically ob-
served with wild type channels. Second, bath acidifica-
tion failed to potentiate peak currents beyond this
steady-state value. Similar results were obtained with oo-
cytes expressing the E600A and E600S mutants. The
pH dependence of thermal activation was related to the
side-chain charge of the residue at position 600: heat-
evoked currents in the E600D mutant were potentiated
only when the bath pH dropped below 6.5. The E600H
mutants, on the other hand, showed continuous potenti-
ation over the entire pH range tested (9.0 to 5.0), but
the extent of potentiation was significantly less than that
observed for wild type or E600D channels. For E600Q
or other mutants having non-titratable amino acids at
this position, the magnitude of the heat-evoked currents
was largely independent of the extracellular pH. The
D601N and E648Q mutants exhibited a phenotype
characterized by reduced proton-evoked responses, with
normal CAPS sensitivity. The E648A mutants demon-
strated an even greater decrease in proton-activated
current amplitudes, whereas the CAPS- or heat-evoked
currents did not differ significantly from those of wild
type or E648Q channels [43]. This finding is in direct
contradiction to the one made by Welch et al., who
identified E648 as specific contributor to the CAPS re-
sponse without affecting the proton or thermal sensitiv-
ity [165]. E458Q, D471N, E478Q, E536Q, H614Q,
E636Q, D646N, E651Q and D654N mutations were
also tested by Jordt et al. [43], but no phenotype was
reported in terms of acid activation or potentiation.)
E600V caused the complete and specific loss of pH sen-
sitivity [167].
Deletion of R114 was found by Jung et al. [16] to
abolish the sensitivity to acid. When the positively
charged Arg at 114 was replaced by a neutral amino
acid, Ala, the mutant (R114A) elicited an Icap compar-
able with that of the wild type TRPV1. However, when
the Arg at 114 was replaced by negatively charged Glu
(R114E), a significant reduction (~97% reduction) in
Icap was observed with no apparent specific [
3H]RTX
binding.
Sutton et al. reported that the S512Y mutant caused a
small but significant decrease in the ability of protons to
gate the TRPV1 channel [193].A mutation of hTRPV1-L547M by Johnson et al. [173]
caused a decrease in the potency of protons, but no in-
crease was seen when the reverse switch was made in
the rat receptor (M547L).
E651 was found to be important for pH activation [192].
Substitution of the residue T633 by Ala abrogated low
pH-activated currents, but the T633A mutant exhibited
normal CAPS responses, including rapid activation kinet-
ics and large steady-state currents. Furthermore, the po-
tentiation by low pH was also retained, despite the loss of
the low pH sensitivity for direct activation. Conserved resi-
dues on the N-terminal end of the pore helix were also
mutated by Ryu et al., i.e., Y627A and S629A. Both mu-
tants were functional and produced relatively normal re-
sponses to CAPS when applied either alone or in
combination with mildly acidic pH. The mutants were also
activated by low pH directly, albeit with a slightly smaller
maximal current than their wild type counterparts. The
data suggest that these residues may contribute to, but do
not play a pivotal role in the proton activation of TRPV1
as T633 does [192]. In the wild type counterpart, pH 5.5
evoked long bursts of activity, in which the openings were
separated by brief closures. The T633A mutant instead
showed rare spike-like openings. The mutation drastically
slowed the opening rate at low pH. The significant short-
ening of the open time suggests that the mutation destabi-
lizes the open conformation of the channel. T633 was
systematically mutated to others, including Y, R, Q, N, L,
K, E, D, V, S and A, which span both polarity and size.
Substitutions with polar residues such as Q, N and Y or
the charged residues R, K, E and D all resulted in non-
functional channels. The T633S mutation was functional,
but with a significant reduction in low pH current and a
slow activation by CAPS. However, the T633V mutation
preserved the wild type responses in all aspects. On substi-
tution with Leu, containing a larger hydrophobic side-
chain, the channel became non-functional. Together, these
results suggested that T633 is involved in functional inter-
actions in a compact hydrophobic environment. The size
of the side-chain at this position is crucial. Replacing Thr
by Ala, a smaller side-chain, was able to preserve the
CAPS response while abrogating the low pH activation; a
larger side-chain substitution at this position, on the other
hand, became deleterious [192]. The K535E, E536W,
V538L and A539P residues were clustered around the
centre of the loop, and the mutations appeared to impact
predominantly the proton responses. V538L resulted in
no detectable current at pH 5.5, while retaining >93% of
the wild type peak CAPS response. The CAPS response of
E536W was also reduced; however, this mutation, as with
K535E and A539P, involved substantial changes in the
side-chain property. Such substitutions could produce
non-local perturbations on the channel structure and con-
sequently non-specific phenotype changes. A common
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reduction of the low pH current, suggesting that the re-
gion plays an important role in proton activation. S532M,
Q533E, S540L and M541L exerted little effect on either
CAPS or low pH responses. The CAPS activation and its
potentiation by low pH were not altered by the V538L,
E536W, K535E or A539P mutations at the macroscopic
level. V538L displayed a marked (>90% suppression) re-
duction in the maximal activity elicited by pH 4.5. Also
unlike T633A, which exhibited no measurable pH current
over the entire pH range, V538L furnished a titration
curve with a consistently increasing trend as the pH was
lowered. It appears that the mutation weakened, but did
not disrupt the pH gating completely. The V538L mutant
also exhibited a robust heat response.
The function of the channel appeared to be quite sen-
sitive to perturbations at position 538 (V538L, V538A,
V538G, V538I, V538T). Even the relatively conservative
substitution with Ala abrogated the low pH currents and
also reduced the CAPS activity. Further reduction of the
size of the side-chain with a substitution by Gly resulted
in non-functional channels [192].
In the experiments by Myers et al. [177], wild type
TRPV1 responded strongly to CAPS but displayed negli-
gible current under basal conditions or in response to
pH 6.4, which is at the threshold concentration required
for proton-evoked activation at room temperature. In
contrast, eight mutants (H166R, I352N, I352T, Q560R,
M562D, E684G, E684V, L792P), displayed a significant
response to pH 6.4, although no basal current was
detected at pH 7.4 Mammalian cell patch-clamp experi-
ments by Myers et al. demonstrated that F640L
displayed a strong basal channel activity and substantial
toxicity when expressed in HEK293 cells. Whereas the
wild type channel was potentiated by exposure to pH
6.2, the F640L current was completely unaffected under
these conditions. Addition of CAPS to F640L-expressing
cells led to a marked increase in current, demonstrating
that F640L channels are not maximally open in the
basal state. Higher doses of protons could activate the
mutant channel illustrating that while the mutant has
lost the ability to be potentiated within a certain pH
range, its proton activation has not been completely ab-
lated. Weakly alkaline solution (pH 8.2) failed to reduce
the F640L-mediated basal current. N628D and V658A
showed a potentiation effect under moderately acidic
conditions. Furthermore T641S and T650S mutants
displayed large constitutive channel activation with rela-
tive insensitivity to pH 6.4 [177].
Wang et al. reported that the first four TMs (TM1-4)
of TRPV1 dictate whether the activity of a fully CAPS-
bound receptor can be further enhanced by protons, and
a glutamate residue (E536) in the linker between TM3
and TM4 of hTRPV1 is critical in the modulation byprotons and in the further stimulation of fully liganded
TRPV1 [75,194].
Aneiros et al. [195] replaced amino acid F660 in
hTRPV1 (corresponding to F659 in rTRPV1) with a var-
iety of different amino acids (A, C, E, H, I, K, L, S, T, V,
W, Y) to determine the side-chain contribution to the
proton activation of TRPV1. Proton activation was ab-
lated by all amino acid replacements with the exceptions
of F660Y and F660W, the two alternative non-basic aro-
matic amino acids besides Phe. Replacing Phe with His
(F660H), which contains a basic aromatic ring (imid-
azole), or non-aromatic amino acids caused complete
loss of proton activation. However, F660Y demonstrated
a reduced sensitivity to proton activation as compared
with wild type TRPV1. Although less pronounced, the
maximum effect values at 1 μM CAPS were also reduced
relative to the wild type, while the CAPS EC50 values at
pH 7.4 were comparable. Ca2+ flux and whole-cell
patch-clamp experiments using HEK293 cells transiently
expressing TRPV1 mutants or wild type TRPV1 demon-
strated a complete lack of activation of the mutant
F660S by protons. In contrast, F660S maintained re-
sponsiveness to CAPS. TRPV1 mutant F660S ablated
proton activation, but not CAPS or heat activation.
F660A neither significantly inhibited nor significantly
potentiated CAPS responses in the presence of protons.
F660W showed a reduction in sensitivity to proton acti-
vation as well as CAPS activation similarly to F660Y.
These data suggest that a non-basic aromatic amino acid
at position 660 is essential for proton activation. A non-
aromatic amino acid or His at position 660 seems to be
tolerated for the channel to be functional in the CAPS
activation mode; a non-basic aromatic side-chain, how-
ever, appears to be required to maintain activation by
protons. The loss of activation by protons when F660 is
replaced with a charged amino acid and the absence of a
titration phenotype suggest that Phe is critical for the
transduction of proton-mediated gating rather than volt-
age or proton sensing. Aneiros et al. concluded that the
proton activation and potentiation of TRPV1 are both
voltage-dependent and that amino acid 660 is the key
residue regulating the proton-mediated gating of
hTRPV1 [195].
Mutations affecting voltage sensing
Susankova et al. [175] also checked the Ala-scaned region
of Y666-G683 for mutants disturbing the voltage sensor
function of the channel. To compare the effects of muta-
tions on voltage-dependent activation, Susankova et al.
used a voltage step protocol from −140 to +140 mV (in-
crement, +20 mV) at 25°C and normalized the resulting
current–voltage relationships at +60 mV for each cell.
Except for the T670A, Y671A and M677A, the Ala
mutations led to a rightward shift of the activation curve
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reflecting a decrease in channel activity at more negative
holding potentials (Figure 1).
These data indicate that most of the Ala mutations
modulate the gating of the TRPV1 by shifting the voltage
dependence toward more positive membrane potentials.
Temperature- and voltage-dependent mechanisms under-
lying the TRPV1 channel activation do not need to be
strictly coupled [175].
Voets et al. demonstrated the roles of K571, R575 and
R579 in voltage sensing using charge-neutralizing muta-
tions in TM4 and the TM4-TM5 linker of human
TRPM8 [172,196].
In the experiments of Boukalova et al. [179], the half-
maximal activation voltage (V1/2) of wild type TRPV1 was
154 ± 4 mV, and V1/2 was shifted towards less depolarizing
voltages for R557K (97.1 ± 4 mV), G563S (78 ± 2 mV),
and M581T (122 ± 11 mV). Mutations Y554A, Y555S,
E570L, R557E and R579E led to a complete loss of func-
tion, but three charge-swapping double mutants (R557E/
E570R, D576R/R579E and D576R/R579D) exhibited
measurable voltage-dependent activity, indicating a partial
recovery of the functionality of the R557E and R579E
mutant channels. To reveal the voltage-independent
component of TRPV1 gating, Boukalova et al. [179]
quantified V1/2 and the percentage of the voltage-
independent component of gating from currents
obtained in the presence of 10 μM CAPS. Significant
changes in the apparent gating valence were detected
in E570R and D576R/R579D, indicating that the
S4-S5 linker may increase its contribution to voltage
sensing when CAPS is present. R557A, R557L,
D576N and D576R, which were only weakly voltage-
dependent under control conditions, became as
voltage-sensitive as wild type TRPV1 in the presence
of CAPS, suggesting a preserved or even increased
allosteric effect between these two stimuli. Relative to
wild type TRPV1, the percentage of the voltage-
independent component of CAPS-induced gating was
found to be strongly reduced in R557A, R557L,
E570A, R579A, R579D, R557E/E570R and D576R/
R579E. In contrast, this component was predominant
in E570Q and E570R. G563S possesses an enhanced
voltage-dependent activity; inward currents induced by
1 μM CAPS exhibited slow activation kinetics and an in-
complete deactivation that was fully blocked by 1 μM
RuRed. G563S was not responsive to a temperature
ramp (from 25°C to 48°C) and was only weakly sensitive
to 300 μM 2-APB. These data suggest that the mutation
G563S stabilizes the open conformation of the channel
and thus G563 in TRPV1 could play an analogous role
in channel gating as in TRPV3 [179].
The F660S mutant in hTRPV1 (corresponding to
F659S in rTRPV1) was shown by Aneiros et al. tolack both voltage-dependent proton activation and po-
tentiation, whereas activation by heat or CAPS was
preserved [194,195].Mutations affecting antagonist or channel blocker action/
binding
I-RTX
S512 and M547 were tested by Johnson et al. [173] for
their potential involvement in I-RTX action.
I-RTX shows species-specific activity on TRPV1, as
well. The effect of the 547 residue on the ability of I-
RTX to antagonize the response of TRPV1 to 500 nM
CAPS was also challenged. As for RTX, the antagonist
I-RTX was found to be significantly more potent at
the rat receptor versus human receptor. After substi-
tution of the rat-specific Met into the human con-
struct (L547M), I-RTX gained functional potency,
although the converse change (M547L) showed little
effect (Figure 1). Introduction of the Met residue thus
enables the human receptor to interact more effect-
ively with both agonist and antagonist alike in a man-
ner that is not matched by Leu.
S512Y was found to convert I-RTX from an antagonist
to an agonist with nanomolar potency, albeit with much
lower efficacy than its counterpart (RTX) for the wild
type channel. Other agonists such as CAPS or acidifica-
tion with pH 5.8 was shown to enhance the agonist po-
tency of I-RTX, producing a 20-fold decrease in the
EC50 value [173].RuRed
D646N was reported by Garcia-Martinez et al. to de-
crease the efficacy of RuRed to block the channel by 10-
fold [197] (Figure 1).Mutations affecting spider venoms action/binding
Venoms from spiders, snakes, scorpions and cone
snails can cause burning pain. Small peptides, named
vanillotoxins (VaTx) and “double-knot” toxin (DkTx)
were indentified as TRPV1 agonists from the venoms
of the spiders Psalmopeous cambridgei and
Ornithoctonus huwena, respectively. Alanin scanning
of the region S592-A665 revealed three sites (I599A,
F649A, and F659A) where alanin substitutions caused
reduced toxin responses (Figure 1). A657P and
A657W also showed loss of toxin sensitivity. Xenopus
laevis xTRPV1 also contains Pro at the extracellular
boundary of the S6 domain, corresponding to amino
acid A657 of rTRPV1, and is insensitive to VaTx or
DkTx, but responds to CAPS and low pH. The recip-
rocal mutant (P663A) conferred toxin responsiveness
of the frog TRPV1. The quadruple mutant (I599A/
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sensitivity [198,199].
The venom from the spider Agelenopsis aperta, a
North American funnel web spider, contains potent in-
hibitors of TRPV1. Two acylpolyamine toxins, AG489
and AG505, inhibit TRPV1 from the extracellular side of
the membrane [200]. To identify mutations that alter
these toxin affinity, Kitaguchi and Swartz [200] Trp
scanned the TM5-TM6 linker region from Y627 to E651,
mutating 25 consecutive residues to Trp. Of these mu-
tants, 15 resulted in channel expression that could read-
ily be studied by using electrophysiological techniques,
whereas 10 produced little or no CAPS-activated current
and were not studied further. One residue in this region
(D646) was also mutated to Asn. The D646W mutant
did not yield functional channel. N628W, E636W,
D646N and E651W dramatically decreased toxin affinity.
Mutations of Y627W , C634W and to a lesser extent
F638W, L647W and F649W enhanced the sensitivity to
the toxin [200]. According to these results and previous
studies on polyamine inhibitors of cation channels,
AG489 seemed to be a pore blocker.
Sites of action of negative or positive modulators
A number of studies have demonstrated that the cyto-
plasmic regions of TRP channels bind agonists and
regulatory molecules such as ATP, CaM and PIP2
[14,95,107,201-204].
ATP
Kwak et al. [205] found that D178N substitution abolished
the ATP-mediated upregulation of TRPV1. Mutations
generated by Lishko et al. [14], K155A and K160A, and
the double mutation Y199A/Q202A impaired the
TRPV1-ARD interaction with ATP. TRPV1 channels with
mutations in the ATP-binding site (K155A, K160A, or
Y199A/Q202A) showed little tachyphylaxis, even in the
absence of ATP, while the two negative control mutants
(R181A and K265A) had essentially wild type behaviour
(Figure 1). The lack of tachyphylaxis shown by the TRPV1
mutants was not due to an impaired CAPS sensitivity; in
fact, the mutant channels were slightly more sensitive to
CAPS than the wild type channel [14,46].
Ca2+/CAM
Ca2+/CaM has been reported to bind to peptides from
the N-terminal region of TRPV1, and that the residues
189-221 are crucial determinants for binding [107].
Grycova et al. [206] found that the CaM-binding site
overlapped with the PIP2-binding site in the C-terminal
distal region (L777-S820) and that PIP2 interacted with
the proximal region (I688-K718) of the TRPV1 C-
terminal (Figure 1).Lishko et al. [14] found that the TRPV1-ARD mutants
K155A and K160A, which no longer bind ATP, did not
interact with CaM in size exclusion chromatography,
emphasizing that the binding surface on TRPV1-ARD is
at least partially shared by both ligands.
The TRPV1-ARD Y199A/Q202A mutant, where resi-
dues important for interactions with the adenine moiety
of ATP were mutated, formed a weaker complex with
CaM that eluted earlier than the complex with wild type
TRPV1-ARD, still had a 1:1 stoichiometric ratio,
suggesting that the different elution properties may be
due to an altered conformation or binding constant, or
higher-order (e.g., 2:2) complex [14].
PIP2
PIP2 has been shown to physically interact with a C-
terminal fragment of TRPV1 [203]. In the experiments
of Brauchi et al. [191] the mutation of the positively
charged R701 and K710 to Ala strongly affected the
PIP2-dependent activation, shifting the dose–response
curves to the right along the concentration axis [191]
(Figure 1).
Grycova et al. [206] showed that two different PIP2-
binding sites on the C-terminus L777-S820 and the N-
terminus F189-V221 overlapped with the CaM-binding
sites, and the third PIP2-binding site K688-K718 occu-
pied the TRP domain on the C-terminus, a highly con-
served sequence among the members of the TRP ion
channel family. The presence of PIP2 was reported to
prevent the interaction of the distal region of the C-
terminus with CaM, which could play an important role
in the regulation of TRPV1. To identify the residues im-
portant for the binding of PIP2 to TRPV1-C-terminus, a
set of point mutations was generated by Grycova et al.,
involving the single substitutions R778A and R781A,
the double substitutions K770A/R785A, R771A/R781A
and R771A/R778A and the triple substitutions K770A/
R778A/R785A and K770A/R781A/R785A. The most
striking effect was the total loss of binding affinity ob-
served for the single mutant R778A, the double mutant
R771A/R778A and the triple mutant K770A/R778A/
R785A. Moreover, the K770A/R785A and R771A/
R781A mutations decreased the binding affinity. The
K694A/K698A/K710A triple mutant seemed to com-
pletely lose its ability to bind PIP2. Ala substitutions of
the additional candidate residues in the highly conserved
QRA region Q700A/R701A significantly attenuated its
binding affinity for PIP2. These data show that the
TRPV1 C-terminal proximal region (K688-K718) binds
PIP2 directly with a high affinity and suggest that basic
residues play a crucial role in the binding.
The steady-state anisotropy measurements by Grycova
et al. confirmed that the region denoted as a CaM inter-
action site F189-V221 binds PIP2 with high affinity. On
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acting with the TRPV1 C-terminal distal region, Grycova
et al. suggested that the phosphate head groups of PIP2
form polar interactions with positively charged Arg resi-
dues R778, R781, R785. PIP2 thus occupies the CaM
binding groove containing R771, R778, R781, R785 de-
scribed previously [201]. Residues R778 and R781 were
found to have key role in the binding of PIP2. Further
combinations of Ala substitutions revealed that the
TRPV1-CT distal region participates in PIP2 binding
through a cluster of basic residues: the double and triple
substitutions of R771A/R778A and K770A/R778A/
R785A avoided PIP2 binding totally, and the K770A/
R785A and R771A/R781A mutations suppressed this
interaction partially. Site-directed mutation of R701 Arg
reduced the binding affinity for PIP2. The triple substi-
tution at positions K694A/K698A/K710A had the most
pronounced effect, preventing PIP2 completely from
binding to this region. The regions F189-V221 within
the N-terminus and K688-K718 and L777-S820 within
the C-terminus are involved in PIP2 binding. Interest-
ingly, the F189-V221 and L777-S820 regions overlap
with the CaM-binding sites, suggesting that CaM and
PIP2 compete for the same binding site, which might
have implications for regulation of the channel function.
R778A was found to have the key role in the inter-
action. This single mutation leads to a total loss of bind-
ing affinity of the distal C-terminal region [206].Reducing agents
DTT, an agent that maintains the -SH groups of Cys in a
reduced state, has been reported to facilitate membrane
currents through TRPV1 when applied from the extra-
cellular face of the channel, by interacting with the resi-
dues at positions C616, C621 and C634 in the loop
between the fifth and sixth transmembranal domains
[207] (Figure 1).
Site-directed mutagenesis experiments in the pore loop
have identified C621 as the residue responsible for the
extracellular modulation of TRPV1 by reducing agents
[112]. Mutations C616G and C634G did not affect DDT
potentiation at 45°C, but C621G and the triple mutant
C616G/C621G/C634G significantly reduced DDT po-
tentiation without having any effect on the CAPS, heat or
voltage gating of the channel [78,112].Cholesterol
Using measurements of CAPS-activated currents in ex-
cised patches from TRPV1-expressing HEK293 cells,
Picazo-Juárez et al. [208] showed that enrichment with
cholesterol, but not its diastereoisomer epicholesterol,
markedly decreased wild type rTRPV1 currents in the
presence of CAPS, elevated temperature or voltage.Substitutions in the S5 helix by Picazo-Juárez et al.
[208], R579D and F582Q, decreased the cholesterol re-
sponse and L585I was insensitive to cholesterol addition
(Figure 1). Two hTRPV1 variants, with different amino
acids at position 585, displayed different responses to
cholesterol, with hTRPV1-I585 being insensitive to this
molecule. However, hTRPV1-L585 was inhibited by
cholesterol addition similarly to rTRPV1 with the same
S5 sequence (containing L585). In the absence of CAPS,
cholesterol enrichment also inhibited the TRPV1 cur-
rents induced by elevated temperature and voltage.
The amino acids in positions K571, R575 and R579
were confirmed to be involved in TRPV1-lipid interac-
tions [172,191].
Mutations of phosphorylation sites
Phosphorylation by PKC, which potentiates CAPS, acid,
and thermal responses in TRPV1 channels, occurs at
two target Ser residues (S502 and S800) [78,85,209]
(Figure 1). Residues located in the N-terminus of TRPV1
(S116 and T370) are phosphorylated by PKA and have
been implicated in desensitization [85,176,210] whereas
residues T144, T370 and S502 have been implicated in
the sensitization of heat-evoked TRPV1 responses when
phosphorylated by PKA [78,83]. Phorbol 12-myristate
13-acetate (PMA), a PKC-activating phorbol, was observed
to decrease the binding of [3H]RTX to TRPV1 [115]
through interaction withY704 in the C-terminus [46,85].
The site-directed mutation of residue S116A per-
formed by Wang et al. [90] was reported to block both
the phosphorylation of rTRPV1 by PKCμ and the
enhancement by PKCμ of the response of rTRPV1 to
CAPS. Ser116 is also a major phosphorylation site in
TRPV1 for PKA, and this site has been shown to be in-
volved in TRPV1 desensitization [116].
Numazaki et al. [174] observed that, when S502 and
S800 residues were replaced with Ala, the TRPV1 activ-
ity induced by CAPS, protons or heat was eliminated
[78]. S502A was found to significantly reduce PMA en-
hancement of CAPS-evoked currents, but had no effect
on direct activation by PMA [91].
CaMKII regulates TRPV1 activity through the phos-
phorylation of two residues: S502 and T704 [46,91].
Phe mutations of the hTRPV1 Y195, Y199, Y375, Y383
and Y402 did not diminish Src kinase dependent phos-
phorylation. But when Y200 (corresponding to Y199 in
rTRPV1) was mutated, Src-dependent, NGF-induced Tyr
phosphorylation was completely abolished [211].
A glycosylation site (N604) was identified by Wirkner
et al. [172,212].
Mutations affecting divalent cations
Site-specific analysis has shown that substitutions of D646
or Y671 in the pore domain can reduce the permeability
Winter et al. Molecular Pain 2013, 9:30 Page 18 of 29
http://www.molecularpain.com/content/9/1/30of divalent cations [176,197] (Figure 1). This cation select-
ivity is dynamic, not static, and can vary depending on the
stimulus duration or agonist concentration. Activation
can alter the Ca2+ permeability and pore diameter of
TRPV1 to allow influx of larger cations. This change in
permeability is mediated by amino acid residues in TM6.
Within this domain, L681 can regulate the permeability of
large cations, while Y671 gates the access of smaller cat-
ions [169,178]. Our group discovered a blocking effect of
divalent heavy metal cations and especially of Co2+ on
rTRPV1 [213]. The effects of the cations were evaluated
in rTRPV1 containing mutations reported earlier in con-
text of proton activation and tarantula toxin effect. The
Co2+ sensitivity was slightly reduced in the D646N mu-
tant. TheY627W, N628W and E651W mutants displayed
little or no difference as compared with the wild type
channel [213].
Mutations of structural involvement
Deletion studies have shown that the C-terminal TRP
domain (E684-R721) regulates the formation of func-
tional channel tetramers [214]. Removal of this region
prevents the oligomerization into stable TRPV1
heteromers [169].
Mutations causing heightened base activity
Constitutively active TRPV1 mutants might harbor
deficits in some aspect of channel activation, and a
comprehensive list of such mutations could provide
valuable information about the location of the chan-
nel gate.
Jordt et al. [43] showed that HEK293 cells expressing
E600Q TRPV1 channels showed markedly reduced via-
bility. Replacement of this Glu residue with Gln
(E600Q) or a positively charged amino acid (E600K)
resulted in a significant level of cell death in HEK293
cells expressing these mutant channels, over their
heightened activity under normal culture conditions,
whereas substitution with an acidic residue (E600D) was
not deleterious (Figure 1). This observation suggested
that a decrease in negative charge at the E600 site fa-
vours channel activation. The E600K mutant showed a
most dramatic sensitization phenotype. These channels
were already activated at temperature thresholds (30–32°
C) well below normal (43°C), resembling the heat sensi-
tivity of wild type channels at pH 6.3 [43].
By genetic screening of a randomly generated popula-
tion of TRPV1 mutants, Myers et al. [177] demonstrated
that mutations within the pore helix domain dramatic-
ally increased basal channel activity and responsiveness
to chemical and thermal stimuli. The screening for gain
of function mutations revealed a total of 30 unique mu-
tations at 25 amino acid positions: C73S, K160E,
S343R, A350T, Q561R, M581T, M609T, F640L,N652D, L673I, E684G, E684V, K710R, F742S, W787R
and L796P caused strong toxicity when expressed in
Saccharomyces cerevisiae, whereas other gain of function
mutations I75F, I76T, V78G, K155E, H166R, N310D,
S343G, I352N, I352T, Q560R, M609V, I689V, L792P
and L796V elicited weak toxicity to the cells.
Some mutants displayed large basal currents at pH
7.4, which could be blocked by RuRed. The authors clas-
sified mutants as constitutively active when the ratio of
the basal inward currents and the CAPS-elicited cur-
rents exceeded 0.15 (Ibasal/Icap ≥ 15%). The mutants
K155E, K160E, M581T and F640L achieved a rank con-
stitutively active.
F640L displayed the strongest basal channel activation,
and conferred substantial toxicity when expressed in
HEK293 cells, characterized by necrotic morphology
similar to that observed in cells expressing wild type
TRPV1 after prolonged exposure to CAPS. Inclusion of
RuRed (3 mM) in the culture medium significantly at-
tenuated the death of F640L-expressing cells.
Inside-out patches from the F640L mutant displayed
large basal currents with a substantial inward compo-
nent but CAPS at saturating concentrations elicited cur-
rents of similar magnitude to those evoked in patches
containing wild type channels.
Myers et al. found no significant difference in either
the single-channel conductance or the relative perme-
abilities for Na+, K+, and Ca2+ ions when comparing wild
type and F640L mutant channels, showing that the
F640L mutation affects gating rather than permeation
properties. Consistent with a hypersensitive gating
mechanism, F640L mutant displayed a 35-fold leftward
shift in the CAPS dose-response curve compared to the
wild type receptor, the basal current however, was
suppressed by CapZ demonstrating that the high consti-
tutive activity is not due to an inability of the channel to
close. Consequently, the gating machinery seems to re-
main intact in the F640L mutant, but the equilibrium
appears to be shifted to favor the open state. F640L mu-
tation enhances sensitivity to heat and CAPS by shifting
the stimulus- response relationships of the channel left-
ward while also decreasing apparent cooperativity of
gating.
To fully explore the structural requirements at pos-
ition F640 a codon randomization was performed. Most
substitutions at this position, particularly those of a
hydrophilic nature, weakened or abolished channel activ-
ity. F640K, F640Q, F640S, F640H, F640Y weakly,
whilst F640C, F640E, F640G, F640N, F640R, F640D,
F640P strongly decreased channel function. Further-
more, F640A and F640T represented an intermediate
phenotype between wild type and weak loss of function.
In contrast, several hydrophobic amino acids supported
wild type functionality (F640M, F640V, F640W), except
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channels (F640L, F640I). Thus this codon randomization
illustrated that most hydrophobic substitutions at F640
produced functional channels, whereas two small hydro-
phobic residues supported constitutive channel activity,
suggesting that F640 is buried in a non-polar environ-
ment. Myers et al. uncovered nine additional substitutions
conferring a toxic phenotype in yeast (N625D, N628D,
C634S, T641S, T650S, K656E, K656Q, V658A and
F659Y). These mutants were unable to grow on replica
plates containing CAPS but no RuRed. Of these, two
(T641S and T650S) showed high basal activity. Interest-
ingly, T641S (and, to a lesser extent, T650S) mutants
displayed large constitutive channel activation with rela-
tive insensitivity to pH 6.4 [177].
Mutations having deleterious effects on channel function
The E610Q mutants exhibited relatively small responses
to any stimuli (CAPS, heat or pH), suggesting that this
substitution had deleterious effects on the channel func-
tion at large [43]. The function of the channel appeared
quite sensitive to perturbations at the position V538
(Figure 1). Substitution with Gly (V538G) resulted in
non-functional channels [192]. Susankova et al. [175]
mutated and examined the residues Y666-G683 of
TRPV1. Y666A and N676A showed no CAPS-, pH- or
heat-evoked activity and exhibited no currents in re-
sponse to 47°C and 30 μM CAPS applied together. They
were determined to be non-functional mutants,
suggesting that these two residues within the inner-pore
region of rTRPV1 are critical for channel functionality.
Boukalova et al. [179] identified mutations Y554A,
Y555S and E570L and two charge-reversing mutations,
R557E and R579E, that led to a complete loss of func-
tion. In these mutants, 10 μM CAPS neither induced
measurable currents at a holding potential of −70 mV,
nor affected voltage-dependent (up to +200 mV) or
heat-dependent currents (up to 48°C). The Y554F and
Y555F mutations produced fully functional channels,
indicating that aromatic side-chains are required at
these positions.
Mutations providing structural information of the channel
without having phenotype
Ryu et al. investigated mutations of other residues
(D601-S611, Y627-F640 and D646-E651) that had
minimal consequences, leaving CAPS and low pH re-
sponses mostly intact. These included radical perturba-
tions such as the charge mutations N628R and S632D,
suggesting that these residues are probably exposed to
the aqueous phase. Such an arrangement would be con-
sistent with their positions in a helix, which renders
T633 facing away from the aqueous phase, making it ac-
cessible to interaction with other residues [192]. Thefunction of the channel appeared quite sensitive to per-
turbations at the position 538 (V538L, V538A, V538G,
V538I, V538T). Even the relatively conservative substi-
tution with Ala abrogated the low pH currents and also
reduced the CAPS activity. Further reduction of the size
of the side-chain with a substitution by Gly resulted in
non-functional channels. It appeared that the local struc-
ture of the channel lacks rigidity to tolerate a smaller
side-chain at this position. However, the size of the side-
chain was not the only factor determining the function
of the residue. Replacement by Ile, which has the same
volume as Leu, recovered a small, but significant portion
of the low pH activity. The data appeared to consist of
two populations, one similar to the wild type and the
other to V538L, as if the local structure of the channel
existed in some metastates. Finally, Thr substitution,
which preserved the side-chain size, did not confer the
wild type responses either. Together, these data indicate
that multiple aspects of the side-chain, including both
volume and steric hindrance are important for the func-
tion of the residue [192].
Deletion mutants
An N-terminus deletion mutant by Jung et al. [16], Δ1–109,
which elicited Icap, retained specific binding for [
3H]RTX.
In contrast, cells expressing Δ1–114, which failed to show
Icap, completely lost their specific binding to [
3H]RTX.
Similarly, deletion mutants at the C terminus, such as
Δ762–838 and Δ763–838, which displayed smaller Icap, bound
[3H]RTX similarly to the wild type. In contrast, Δ761–838,
which failed to elicit Icap, had no ability to specifically bind
[3H]RTX. Deletion mutants that lacked one of these two
regions lost current sensitivity to CAPS and the ability to
bind ligands. The two regions in the vicinity of R114 and
E761 are critical for ligand binding and that the loss of
these regions abrogates vanilloid activation. A deletion as
small as a single amino acid affects the ligand binding.
Δ114 and Δ761 failed to elicit CAPS-sensitive inward cur-
rents. Furthermore, the mutants did not show specific
binding to [3H]RTX. Both mutants elicited whole-cell cur-
rents when activated by heat at ~46°C, but both mutants
failed to respond to acid (pH 5.5) [16].
Deletion of a Thr residue in TM4 (ΔT550) reduced
CAPS sensitivity [171] (Figure 1).
To investigate the contribution of the pore turret to
the TRPV1 function, Cui et al. [190] generated a series
of turret deletion mutations by deleting the first 10
(ΔG603-S612), 17 (ΔG603-G619), or all 24 amino acids
(ΔG603- N626), and also deleted seven amino acids from
the C-terminal end of the turret (ΔS620-N626).
ΔG603-S612 mutant channel was found to be functional,
and exhibited nearly identical CAPS sensitivity to that of
the wild type. As CAPS exhibited very similar potency
and efficacy in activating wild type and ΔG603-S612
Table 1 Summary table of the mutants discussed in the article
Residue Mutated to Role in the channel function / Impact of the mutation on the channel function Refs
C73 S Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
I75 F Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
I76 T Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
V78 G Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
R114 A, E, Δ Its deletion or mutation abrogated vanilloid and proton activation and RTX binding,
without effecting heat activation.
[16]
R115 D Its mutation abrogated vanilloid activation and RTX binding, without effecting heat
activation.
[16]
S116 A The residue is phosphorylated by PKA and is involved in desensitization. It is also
functional target for PKCμ. Its mutation abolished phosphorylation by PKCμ and
enhanced the channel response to CAPS by PKCμ.
[85,90,176,210]
T144 Its phosphorylation by PKA causes sensitization of heat-evoked responses. [78,83]
K155 A, E Its mutation caused impaired TRPV1-ARD interaction with ATP, and impaired
tachyphylaxis, even in the absence of ATP. The mutant channel did not interact with
CaM, and was slightly more sensitive to CAPS than the wild type.
[14,177]
Its mutation resulted in a constitutively active channel, and caused gain of function
mutation and weaker toxicity when expressed in Saccharomyces cerevisiae.
C157 The residue is covalently modified by allicin causing allicin activation of the channel. [187]
K160 A, E Its mutation caused impaired TRPV1-ARD interaction with ATP, and impaired
tachyphylaxis, even in the absence of ATP. The mutant channel did not interact with
CaM, and was slightly more sensitive to CAPS than the wild type.
[14,177]
Its mutation resulted in a constitutively active channel, caused gain of function
mutation and strong toxicity when expressed in Saccharomyces cerevisiae.
H166 R Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae. Its mutation resulted in significant response to pH 6.4
(threshold concentration for proton-activation).
[177]
D178 N Its mutation abolished the ATP-mediated upregulation of TRPV1. [205]
Y199 A, F When both sites were mutated, Y199/Q202 impaired the TRPV1-ARD interaction with
ATP and ATP-mediated tachyphylaxis. The mutated channel was slightly more sensitive
to CAPS than the wild type. Mutant channels formed a weaker complex with CaM than
wild type but it still had a 1:1 stoichiometric ratio.
[14,211]
Phosphorylation of hTRPV1 Y200 (Y199 in rTRPV1) by Src kinase increases the surface
expression of TRPV1 and accounts for rapid sensitizing actions of NGF. When mutated,
Src-dependent, NGF-induced Tyr phosphorylation was completely abolished.
Q202 A When both sites were mutated, Y199/Q202 impaired the TRPV1-ARD interaction with
ATP and ATP-mediated tachyphylaxis. The mutated channel was slightly more sensitive
to CAPS than the wild type. Mutant channels formed a weaker complex with CaM than
wild type but it still had a 1:1 stoichiometric ratio.
[14]
N310 D Its mutation caused gain of function and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
S343 G, R, Its mutation caused gain of function and strong/weak toxicity when expressed in
Saccharomyces cerevisiae.
[177]
A350 T Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
I352 N, T Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae. Its mutation also caused significant response to pH 6.4
(threshold concentration for proton-activation).
[177]
T370 The residue is phosphorylated by PKA. It is involved in desensitization of the channel,
and in the sensitization of heat-evoked TRPV1 responses when phosphorylated by PKA.
[78,83,85,176,210]
F489 Y Mutation resulted in a rightward shift of the CAPS concentration of half-maximal
activation.
[167]
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R491 E, G, Mutation caused reduction in CAPS sensitivity. [168]
S502 A Its phosphorylation by PKC potentiates CAPS, proton, and thermal responses, and that
by PKA sensitizes the heat-evoked responses.
[78,83,85,91,174,209]
It is a CaMKII phosphorylation site.
When associated with T704I, S502A was found to lose the ability to be activated by
CAPS and to lose the ability of vanilloid binding.
Its mutation reduced PMA enhancement of CAPS-evoked currents, but had no effect
on direct activation by PMA.
Y511 A, C, F, Its mutation abolished CAPS responses, and RTX binding yet leave activation by heat
and protons intact.
[168-171,180]
S512 A, F, T, Y Its mutation abolished CAPS responses and RTX binding, yet left activation by heat and
protons intact. It is involved in I-RTX binding.
[168,169,173,193]
Q519 N Its mutation ablated the vanilloid sensitivity. [168]
F522 L Its mutation ablated the vanilloid sensitivity. [168]
M523 L Its mutation ablated the vanilloid sensitivity. [168]
S532 C Its mutation ablated the vanilloid sensitivity. [168]
K535 E Its mutation ablated the vanilloid sensitivity, and affected proton responses. [168,192]
E536 L, W Its mutation ablated the vanilloid sensitivity, and affected proton responses. [168,192]
V538 A, G, I, L, T Its mutation ablated proton activation, but not the proton potentiation. [192]
A539 P Its mutation affected proton responses. [192]
M547 A, I, L, Q The residue is involved in RTX binding, CAPS sensitivity, I-RTX sensitivity and proton
sensitivity.
[168,170,171,173,180]
W549 It is involved in vanilloid binding. [171,182]
T550 A, C, I, S, Y, Δ, It is an important molecular determinant in vanilloid sensitivity. Participates in Caps
and RTX binding.
[168,170,171,180]
Its deletion reduced CAPS sensitivity of the channel.
R557 A, E, K, L It is involved in CAPS potentiation of heat-induced currents and in the transduction of
the CAPS-binding signal to the opening of the pore.
[179]
It is also important in deactivation gating process, 2-APB activation and for voltage-
dependent gating.
It contributes to the voltage modulation of the CAPS-induced currents and the CAPS
potentiation of the heat-induced currents.
Q560 H, R It is involved in the transduction of the CAPS-binding signal to the opening of the pore. [177,179]
It is also important in deactivation gating process and for 2-APB activation.
Its mutation caused significant response to pH 6.4 (threshold concentration for proton-
activation).
Its mutation caused gain of function of the channel and weaker toxicity when
expressed in Saccharomyces cerevisiae.
Q561 H, R Its mutation caused gain of function of the channel and strong toxicity when
expressed in Saccharomyces cerevisiae.
[177]
M562 D Its mutation caused significant response to pH 6.4 (threshold concentration for proton-
activation).
[177]
G563 S The residue is involved in the voltage gating of the channel. [179]
E570 A, L, Q, R The residue contributes to the voltage modulation of the CAPS-induced currents and
the CAPS potentiation of the heat-induced currents.
[179]
It is involved in the transduction of the CAPS-binding signal to the opening of the
pore and in the 2-APB activation of the channel.
It is also a relevant heat-sensing factor.
K571 E The residue is a specific binding site for 2-APB. [172,179,191,196]
It is involved in voltage sensing and in TRPV1-lipid interactions.
R575 A The residue is involved in voltage sensing and in TRPV1-lipid interactions. [172,191,196]
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D576 N, R The residue is involved in the voltage-dependent gating of TRPV1, and contributes to
the voltage modulation of the CAPS-induced currents and the CAPS potentiation of
the heat-induced currents.
[179]
It contributes to the transduction of the CAPS-binding signal to the opening of the pore.
R579 A, D, E The residue contributes to the voltage modulation of the CAPS-induced currents and to the
CAPS potentiation of heat-induced currents. It is involved in the voltage sensing and in
TRPV1-lipid interactions. Its mutation decreased the cholesterol response of the channel.
[172,179,191,196,208]
M581 T The residue contributes to the transduction of the CAPS-binding signal to the opening
of the pore, and to the deactivation gating process. It is involved in voltage gating.
[177,179]
Its mutation caused gain of function of the channel and strong toxicity when
expressed in Saccharomyces cerevisiae.
F582 Q Its mutation decreased the cholesterol response of the channel. [208]
L585 I Its mutation abolished the cholesterol response of the channel. [208]
I599 A Its mutation caused reduced DkTx responses. [207]
E600 A, D, H, K, Q, S, V The residue is involved in the proton potentiation, but not in proton activation. [43,167]
Its mutation to neutral or positive residues potentiates responses to CAPS or heat, and
introduction of a residue with lower pKa decreased the channel sensitivity to CAPS or heat.
D601 N Its mutation reduced the proton-activated currents significantly, without altering the
heat- or CAPS-evoked responses, and without eliminating the ability of protons to
potentiate the responses to these stimuli.
[43]
M609 T, V Its mutation caused gain of function of the channel and strong/weak toxicity when
expressed in Saccharomyces cerevisiae.
[177]
C616 G The residue is involved in DTT interaction. [78,112,207]
C621 G The residue is responsible for the extracellular modulation of TRPV1 by reducing
agents. It is involved in DTT interaction. Its mutation and when associated with C616G
and C634G significantly reduced DDT potentiation without having any effect on the
CAPS, heat or voltage gating of the channel.
[78,112,207]
N625 D Its mutation caused toxicity when expressed in Saccharomyces cerevisiae. [177]
Y627 A, W The residue contributes to, but do not play a pivotal role in the proton activation. Its
mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505.
[192,200]
N628 D, K, R, W The residue plays essential roles in the heat response without affecting the CAPS
responses or the desensitization of the channel. It is involved in proton-induced
potentiation. Its mutation reduced the heat responses in amplitude and shifted them to
higher temperatures, dramatically decreased the sensitivity to the acylpolyamine toxins
AG489 and AG505 and caused toxicity when expressed in Saccharomyces cerevisiae.
[167,177,192,200,213]
S629 A The residue contributes to, but do not play a pivotal role in the proton activation. [192]
T633 A, S, V Its mutation eliminated the proton-activated currents while leaving normal responses
to CAPS and low pH potentiation. Its mutation exhibited a weaker response to heat in
amplitude, however, the thermal activation threshold was unchanged.
[192]
C634 G, S, W It is involved in DTT interaction, its mutation and when associated with C616G and
C621G significantly reduced DDT potentiation without having any effect on the CAPS,
heat or voltage gating of the channel. Its mutation also enhanced the sensitivity to the
acylpolyamine toxins AG489 and AG505, and caused toxicity when expressed in
Saccharomyces cerevisiae.
[78,112,177,200,207]
E636 Q, W The residue is a specific contributor to the CAPS response without affecting the proton
or thermal sensitivity. Its mutation dramatically decreased the sensitivity to the
acylpolyamine toxins AG489 and AG505.
[43,165,200]
F638 W Its mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505. [200]
F640 A, C, D, E, G, H, I, K, L, M, N,
P, Q, R, S, T, V, W, Y,
The residue is critical for heat activation. Its mutation was constitutively active, and
caused strong toxicity when expressed in Saccharomyces cerevisiae. Its mutation also
enhanced the sensitivity to heat and CAPS, and abolished the proton potentiation of
the channel. This mutation affected gating rather than permeation properties of the
channel.
[177]
T641 S The residue is involved in acid activation and potentiation. Its mutant displayed large
constitutive channel activation and caused toxicity when expressed in Saccharomyces
cerevisiae.
[177]
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D646 N, W The residue is a specific contributor to the CAPS response without affecting the proton
or thermal sensitivity, and it is engaged in inhibition by RuRed. Its mutation reduced
the permeability of divalent cations and dramatically decreased the sensitivity to the
acylpolyamine toxins AG489 and AG505.
[43,165,176,197,213]
L647 W Its mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505. [200]
E648 A, Q The residue is a specific contributor to the CAPS response without affecting the proton
or thermal sensitivity. Its mutation reduced the proton-activated currents significantly,
without altering the heat- or CAPS-evoked responses, and without eliminating the
ability of protons to potentiate the responses to these stimuli.
[43,165]
F649 A, W Its mutation caused reduced DkTx responses, and enhanced the sensitivity to the
acylpolyamine toxins AG489 and AG505.
[198,200]
T650 S The residue is involved in proton-induced potentiation. Its mutation caused large
constitutive channel activation with abolished pH sensitivity. Its mutation caused
toxicity when expressed in Saccharomyces cerevisiae.
[177]
E651 Q, W The residue is important in pH activation. Its mutation dramatically decreased the
sensitivity to the acylpolyamine toxins AG489 and AG505.
[43,192,200,213]
N652 D, T The residue plays essential roles in the heat response without affecting the CAPS
responses or the desensitization of the channel. Its mutation reduced the heat responses
in amplitude and shifted them to higher temperatures. Its mutation also caused gain of
function and strong toxicity when expressed in Saccharomyces cerevisiae.
[167,177]
Y653 T The residue plays essential roles in the heat response without affecting the CAPS
responses or the desensitization of the channel. Its mutation reduced the heat
responses in amplitude and shifted them to higher temperatures.
[167]
K656 E, Q Its mutation caused toxicity when expressed in Saccharomyces cerevisiae. [177]
A657 P, W The residue is critical for DkTx binding, its mutation showed loss of DkTx sensitivity. [197]
V658 A The residue is involved in acid potentiation. Its mutation showed a potentiation effect
under moderately acidic conditions. Its mutation also caused toxicity when expressed
in Saccharomyces cerevisiae.
[177]
F659 A, C, E, H, I, K, L, S, T, V,
W, Y
The residue is involved in proton activation, and is a key integrator of voltage sensing,
proton activation and potentiation. Its mutation caused lack of both voltage-
dependent proton activation and potentiation, whereas activation by heat or CAPS
was preserved. Its mutation caused reduced DkTx responses and caused toxicity when
expressed in Saccharomyces cerevisiae.
[177,194,195,198,199]
Y666 A Its mutation resulted in non-functional channel. [175]
I668 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-
potentiated CAPS currents.
[175]
L669 A The residue is involved in heat activation but not in CAPS activation, nor in the heat
potentiation of the CAPS currents.
[175]
Y671 A The residue might contribute to allosteric coupling between temperature- and CAPS-
dependent activation mechanisms. Its mutation affected the heat-induced current
responses, lowered the CAPS EC50 value of the channel. Responses to CAPS were not
potentiated by heat in the mutant containing channel, in fact CAPS-evoked responses
were inhibited by heat. The residue is involved in the regulation of permeability of
divalent cations, it gates the access of smaller cations.
[169,175,176,178,197]
I672 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-
potentiated CAPS currents.
[175]
L673 A, I Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae. Its mutation also reduced CAPS sensitivity, heat-induced
current responses and heat-potentiated CAPS currents.
[175,177]
L674 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-
potentiated CAPS currents.
[175]
L675 A Its mutation reduced CAPS sensitivity and heat-potentiated CAPS currents. [175]
N676 A, F Its mutation influenced the ability of CAPS and RTX to activate TRPV1 without
changing the response of the channel to protons. Its mutation to Ala resulted in non-
functional channel.
[166,175]
M677 A Its mutation in a triple mutant (N676F/M677A/L678P) influenced the ability of CAPS
and RTX to activate TRPV1 without changing the response of the channel to protons.
Its mutation alone blunted heat-induced current responses without a significant
change of CAPS- or heat-potentiated CAPS currents.
[166,175]
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L678 A, P Its mutation influenced the ability of CAPS and RTX to activate TRPV1 without
changing the response of the channel to protons. Its mutation also blunted heat-
induced current responses, with a leftward shift in the temperature threshold.
[166,175]
I679 A Its mutation retained normal sensitivities to CAPS and heat, although it completely
removed their mutual potentiation.
[175]
L681 A The residue is involved in the regulation of permeability of divalent cations, it regulates
the permeability of large cations.
[169,175,178]
M682 A Its mutation caused impaired CAPS- and heat- activation, and significantly reduced
their mutual potentiation.
[175]
E684 G, V Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae. Its mutation caused significant response to pH 6.4 (threshold
concentration for proton-activation).
[177]
I689 V Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
K694 A The residue participates in PIP2 binding. [206]
K698 A The residue participates in PIP2 binding. [206]
Q700 A The residue participates in PIP2 binding. [206]
R701 A The residue participates in PIP2 binding. [191,206]
T704 I The residue is a CaMKII phosphorylation site. PMA decreases the binding of [3H]RTX to
TRPV1 through interaction with this residue. When associated with S502A, its mutation
lost the ability to be activated by CAPS and lost the ability of vanilloid binding.
[46,85,91,115,174]
K710 A, R The residue participates in PIP2 binding. Its mutation caused gain of function and
strong toxicity when expressed in Saccharomyces cerevisiae.
[177,191,206]
Q727 The residue has key roles in heat activation. [191]
F742 S Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
W752 The residue has key roles in heat activation. [191]
E761 K, Q, Δ Its deletion or mutation blocks RTX binding and proton- and CAPS-induced currents
without affecting TRPV1 activation by heat.
[16,175,176]
K770 A The residue participates in PIP2 binding. [206]
R771 A The residue participates in PIP2 binding. [206]
R778 A The residue has key roles in PIP2 binding. [201,206]
R781 A The residue has key roles in PIP2 binding. [201,206]
R785 A The residue participates in PIP2 binding. [201,206]
W787 R Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
L792 P Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae. Its mutation caused significant response to pH 6.4 (threshold
concentration for proton-activation).
[177]
L796 P, V Its mutation caused gain of function and strong/weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
S800 A Its phosphorylation by PKC potentiates CAPS, acid, and thermal responses. [78,85,209]
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directly affect CAPS activation.
ΔG603-S612 reduced the heat response of the channel,
which was not a result of slow gating kinetics, as length-
ening the heat pulse did not yield any increase in the
current amplitude, heat becomes a less effective activator
for the ΔG603-S612 mutant channel.
Cui et al. found that, the turret deletion mutations
ΔG603-G619 and ΔG603-N626 completely disrupted channelfunction; no current could be detected from channel-
expressing cells challenged with either 10 μM CAPS or
high temperatures up to 50°C despite the normal cellular
distribution of the mutant channels similar to that of the
wild type TRPV1 [190].
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